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Don't Quit
When things go wrong as they sometimes will, 
When the road you’re trudging seems all up hill. 
When the funds are low and the debts are high 
And you want to smile, but you have to sigh, 
When care is pressing you down a bit,
Rest, if you must but don't you quit 
Life is queer with its twists and turns,
As everyone of us sometimes learns,
And many a failure turns about 
When he might have won had he stuck it out; 
Don’t give up though the pace seems slow- 
You may succeed with another blow. 
Success is failure turned inside out- 
The silver tint of the clouds of doubt,
And you never can tell how close you are,
It may be near when it seems so far,
So stick to the fight when you're hardest hit- 




The overall aim of this project is to produce high affinity human antibodies 
that can bind tightly and rapidly to their therapeutic targets. There are many 
problems associated with producing high affinity monoclonal human 
antibodies for therapy using established methods such as hybridoma 
technology, phage display and humanization, therefore another technique is 
desirable. It was intended to generate high affinity antibodies using a novel 
Saccharomyces cerevisiae antibody improvement strategy that was based 
upon the in vivo germinal centre reaction. Within the germinal centre, 
antibody improvement (Affinity Maturation) occurs through rounds of random 
mutation and antigen-selection. Hence, the overall intention of this project 
was to copy these processes within a yeast cell.
Firstly, to achieve this aim, antibody fragments were expressed in an 
intact form on the surface of S. cerevisiae. Surface expression was achieved 
by attaching the DNA of an anti-fluorescein-5-isothiocyanate (FITC) single 
chain Fv antibody fragment to the cell wall anchorage domain of the S. 
cerevisiae a-agglutinin gene. Functional expression of the anti-FITC single 
chain Fv antibody fragment was detected directly using epi-fluorescence 
microscopy.
The second part of this project describes the construction of an 
original antigen-selection strategy, which utilizes the mating characteristics of 
agglutinin mutants. To overcome variable surface expression, the relevant 
antibody or antigen DNA was integrated into the appropriate agglutinin loci 
using a novd Cre-/ox site-specific recombination system. The engineered a- 
and a-strains were individually analysed for functional expression of the a- 
agglutinin/antibody and a-agglutinin/antigen protein fusions, respectively. 
Finally, these engineered haploid cells were mated under conditions that 
were dependent on the antigen-antibody interaction for diploid formation. 
Unfortunately, this yeast antigen-selection system was unable to differentiate 
between a-cells expressing the appropriate antibody fragment and non­
expressors.
The experiments described in this project will form the basis of future 
work aimed at establishing an 'in-cell' affinity maturation system in yeast.
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1.1 THE IMMUNE RESPONSE
The environment contains a large variety of infectious microbial agents; 
viruses, bacteria, fungi and parasites, all of which can cause great 
pathological damage if they multiply undetected. The human immune 
system which combats these agents can be divided into two functional 
divisions; adaptive and innate immunity, but these do not act in isolation 
(Roitt et al., 1986). Innate immunity acts as the first line of defence against 
infectious agents and contains physical barriers such as skin, mucus 
membranes and circulating elements including complement and phagocytic 
cells.
If the innate system is not sufficient at preventing infection, the 
adaptive immune system is activated which produces a specific reaction to 
each infectious agent. A major element of the adaptive immune system is 
lymphocytes, which can be divided into two predominant classes, B- and T- 
cells, which carry out the humoral and cellular components, respectively. 
During their development, both T- and B-lymphocytes acquire specific 
receptors for antigen that commits them to a single antigenic specificity for 
the rest of their life span. The cells are activated when they bind to their 
specific antigen, proliferate and mature into effector cells (this is known as 
clonal selection).
The membrane-bound receptors on the surface of T-cells recognise 
antigens that have been endocytosed by antigen-presenting cells (APCs) 
such as B-cells and macrophages. Recognition triggers T-cell activation, 
which according to the class of T-cells causes immune responses such as 
cytokine release, cytotoxic T-cell activation or differentiation and 
proliferation of B-cells. Potentially auto-reactive T-cells are removed in the
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thymus and this therefore contributes to the discrimination between self and 
non-self antigens in the immune system (a process known as self­
tolerance).
B-cells produce specific antigen receptors known as antibodies that 
are distinct but structurally related to T-cell receptors. A large repertoire of 
antibodies is produced by B-cells, which recognise and bind to native 
antigen. Upon recognition of antigen, B-cells either differentiate into short­
lived (plasma) cells which produce soluble antibody or long-lived (memory) 
cells with membrane-bound antibody. Activation of antibody proliferation 
triggers a cascade of effects resulting in stimulation of complement and/or 
recruitment of specialised effector cells including macrophages, phagocytes 
and natural killer cells. The outcome of these interactions is complex but 
eventually the overall aim of removing the antigen is achieved.
1.1.1 Physiology of the immune system
The cells involved in the immune system are organized into tissues and 
organs in order to perform their functions most effectively (Figure 1.1). 
These structures are collectively referred to as the lymphoid system and 
comprise of primary and secondary lymphoid organs (Roitt et a/., 1986). The 
primary lymphoid organs are the major sites of lymphocyte differentiation. In 
humans, T-cells are produced in the thymus and B-cells in the bone marrow 
and foetal liver. The secondary lymphoid organs (spleen, lymph nodes and 
tonsils) contain mature T- and B-cells and create an environment in which 
the lymphocytes can interact with each other and antigen. The lymph nodes 
form part of the network (lymphatic system) which filters antigen from the 
tissue fluid during its passage through the body. These comprise of a B-cell 
area (cortex), a T-cell area (paracortex) and a central medulla. After antigen 
stimulation, the cortex of the lymph nodes contains aggregates of B-cells 
known as secondary follicles. The secondary follicles are areas of intense 
B-lymphocyte proliferation (Section 1.3.3) and can also be found in the 
periarteriolar lymphoid sheath of the spleen and the mucosal lymphoid 




Figure 1.1 - Major lymphoid organs and tissues.
The primary lymphoid tissues, bone marrow and thymus, are represented in the darker grey 
and produce B- and T-cells, respectively. Lymph nodes are present throughout the human 
body and only a few are depicted here. Peyer's patches are unencapsulated masses of 
lymphoid tissue in the small intestine.
1.2 ANTIBODIES
1.2.1 Antibody structure
The structure of an antibody combines two functions: antigen recognition 
and stimulation of effector function in a single multi-domain molecule (Roitt 
et al., 1986). In humans, there are five classes of antibody molecules 
[otherwise known as immunoglobulins (lg)], namely IgG, IgA, IgM, IgD and 
IgE. These differ from each other in size, charge, amino acid composition 
and carbohydrate content, but all have similar overall structures. The class 
of an immunoglobulin molecule (isotype) is determined by its heavy chain. 
This project concerns the engineering of the IgG molecule and therefore will 
concentrate on this major class of antibody.
The IgG molecule consists of two identical light (25kDa) and two 
identical heavy polypeptide chains (50kDa) linked together by covalent 
(disulphide) and non-covalent bonds within and between the chains to form 
an Y-shape (Figure 1.2). This Y-shaped molecule consists of two Fab
lymph
Waldeyer’s nodes.












(Fragment antigen binding) arms which bind antigen and an Fc (Fragment 
crystallisable) stalk which interacts with the Fc receptors on different cell 
types to initiate effector functions such as the complement cascade and 
general inflammatory responses. Each light chain consists of an N-terminal 
variable domain (VL) and a C-terminal constant domain (CL). The heavy 
chain comprises of one variable domain (VH) and three constant domains 
(CH1, CH2, and CH3). The principal sequence diversity is found in three 
short stretches within the variable region of the light and heavy chains. 
These stretches are called hypervariable regions (or complementarity 
determining regions: CDR1, CDR2, CDR3) and are held in place by four 










Figure 1.2 - An outline of a typical IgG molecule.
Each IgG molecule is composed of four chains, two heavy (H) and two light (L) chains. The 
heavy chain comprises of a variable heavy domain (VH) and three constant heavy domains 
(CH1, CH2 and CH3). The light chain consists of one variable light domain (VL) and one 
constant light domain (CL). The bivalent Y-shape is formed from specific disulphide bonds 
between the chains. The Fab region comprises of the Fv fragment (VL+VH) and part of the 
constant region (CL+CH1), while the Fc region consists of two pairs of constant domains (2 
x CH2+CH3).
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The three-dimensional (3D) structure of antibodies has been the 
subject of numerous investigations. The crystal structures for intact 
immunoglobulins and various antibody fragments are available in both the 
free state and bound to antigens (Poljak et at., 1973; reviewed in Alzari et 
al., 1988; Davies et al., 1990). All antibody domains are composed of a 
characteristic p-sheet sandwich known as an immunoglobulin fold (Figure
1.3). The variable domains consist of nine p-strands and the constant 
domains contain seven p-strands, all of which are folded in a similar way. 
The complementarity determining regions form the loops connecting the 
strands of the variable p-sheets. Non-covalent association of the VL and VH 
domains produces a p-barrel structure that places the six CDRs in close 
proximity to form the antigen-combining site. The major determinants in the 
formation of the antibody tertiary structure are the residues buried within and 
between the domains (Chothia and Lesk, 1987). Flexibility of the molecule is 
achieved by the hinge region between the CH1 and CH2 domains (Figure 
1.2). This region contains conserved cysteine residues, which are necessary 
for the formation of disulphide bridges between the various constant 
domains (Lesk and Chothia, 1982). The number of interchain disulphide 
bridges vary in different isotypes.
Figure 1.3 - The three-dimensional structure of an antibody molecule.
The heavy chains are shown in grey and the light chains are shown in white. Non-covalent 
association of the VL and VH domains produces a (3-barrel structure that places the CDRs in 
close proximity to form the antigen-combining site. Figure reproduced from Borrebaeck, 
1995.
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Generally, the variability and specificity of the antibody is 
determined by its CDRs and the framework regions conserve the 3D 
structure. Occasionally, the outer sequences of the framework regions can 
also affect specificity (Foote and Winter, 1992, Tomlinson et al., 1996). Five 
of the six complementarity determining regions can be classified into a small 
structural repertoire of main-chain conformations (otherwise known as 
canonical structures). These conformations are determined by a few key 
residues that influence the hydrogen bonding, packing and torsion angles of 
the canonical structures. Sequence changes at these conserved residues 
can convert one canonical structure to another (Chothia and Lesk, 1987; 
Chothia et al., 1989). Almost all of the VH gene segments which contain the 
first two hypervariable regions exist as one of seven canonical structures 
(Chothia et al., 1992). Only the conformation of the heavy chain CDR3 can 
not be predicted by this method due to the variety of size and sequence 
generated by various genetic mechanisms (Section 1.3.2). Recently, rules 
relating sequence to conformation of the heavy chain CDR3 have been 
stated, but to a less complete degree than the other five antigen-binding 
loops (Morea et al., 1998).
1.2.2 Antibody-antigen interactions
Numerous thermodynamic factors, both enthalpic and entropic affect the 
association between the antigen and antibody. Considerable configurational 
(translational and rotational) entropy is lost by each molecule when 
association occurs. To overcome these barriers van der Waals interactions, 
hydrogen bonds and salt bridges form between the antibody-antigen 
interface (Borrebaeck, 1995). These intermolecular attractive forces are 
optimised by complementary surfaces between the antigenic determinant 
and the binding site of the antibody. Depressions on one surface are filled 
by protuberances from the other, often with the total exclusion of water 
molecules from the interface (Davies et al., 1990). Sometimes, ordered 
water molecules are found at antigen-antibody interfaces and contribute to 
the stability and complementarity between the interacting surfaces (Bhat et
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al, 1994). Local conformational changes by the CDRs of the antibody also 
improve the efficiency of the association reaction and supports the ‘induced 
fit’ hypothesis (Herron et al., 1991; Bhat et al., 1994).
1.3 ANTIBODY IMPROVEMENT IN VIVO
To be effective the immune system must be continuously generating 
diversity to deal with the many potentially harmful infectious and toxic 
substances in the environment. The primary repertoire in humans comprises 
of more than 109 lymphocytes each displaying a single different antibody 
(Winter, 1998). This repertoire of antibodies is created by rearrangement of 
multiple gene segments during B cell development (Section 1.3.2). The 
affinity of antibodies in this naive population of B cells is normally low (Ka = 
105-107 M'1) but increases following secondary antigenic challenge [ ( K a  > 109 
M‘1) Winter and Milstein, 1991]. The increase in affinity over the course of 
an antibody response is due to a process known as affinity maturation 
(Berek and Milstein, 1987); the rearranged germline variable genes are 
mutated and antibodies with improved affinity are selected for (Section
1.3.3). Both the recombination and mutation genetic mechanisms greatly 
diversify the relatively small amount of genetic information encoded by the 
human genome.
1.3.1 Human immunoglobulin gene organization
The human immunoglobulin chains are encoded by three unlinked gene 
families; heavy, lambda (X) light and kappa (k )  light chains which reside on 
chromosomes 14 (Cook and Tomlinson, 1995), 22 (Frippiat et al., 1995) and 
2 (Schable and Zachau, 1993), respectively. These families are organised in 
different ways on their particular chromosomes and comprise of distinct 
gene segments that encode for the variable and constant domains of the 
antibody molecule.
The Ig heavy gene locus consists of a number of germline gene 
segments known as variable (V), constant (C), diversity (D) and joining (J).
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Each of these segments is separated by non-coding DNA (introns) and are 
spliced together by a process known as DNA rearrangement (Section 1.3.2) 
to produce a functional gene. The human heavy chain locus is 1100 
kilobases in length and is arranged (5' - 3') with multiple variable exons 
followed by numerous diversity, joining, and constant gene segments 
(Figure 1.4).
The human Ig light chain loci, lambda and kappa consist of variable, 
joining and constant gene segments. The kappa light chain locus is 
arranged similarly to the heavy chain locus, but each constant region 
segment is associated with a joining segment in the lambda light chain locus 
(Figure 1.4).
Conservation at the 5' and 3' ends of the variable germline 
sequences (i.e. the 5' leader-variable intron region and the 3' recombination 
signal sequence) has enabled researchers to amplify, clone and sequence 
the VH, V k  and VA, repertoires (Table 1.1). From this data the variable 
germline gene segments can be divided into different families due to 
sequence homology. The V k  and VH gene families are randomly distributed 
within their relevant loci but the VA, gene family is organised into three gene 
clusters (Schable and Zachau, 1993; Cox et al., 1994; Cook and Tomlinson, 
1995; Frippiat ef a/., 1995).
Table 1.1 - The number of germline gene segments present in the human genome.
Germline gene segments H A K
Variable® >87 >52 >76
Joining 6 7 5
Diversity >30 - 0 0
Constant 9 7b 1
a - These figures are most probably an underestimate, 
b - All seven constant lambda gene segments are identical.
Figure 1.4 - The genetic organization of the heavy, kappa and lambda loci in the human genome.
The letter L represents the leader sequence and symbols V, D, J and C depict the variable, diversity, joining and constant gene segments, respectively. 
Each CH gene is shown as a single box but in fact comprises of several exons. Asterisks indicate non-functional pseudogenes.
Heavy (H) chain locus (chromsome 14)
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1.3.2 Rearrangement of immunoglobulin genes
Every clone of B-cells expresses a unique combination of V, D and J genes 
(Roitt et al., 1986; Abbas et al., 1991). The non-coding DNA between these 
DNA segments is removed and the coding regions are spliced together by a 
genetic mechanism known as DNA rearrangement. This site-specific 
recombination mechanism is achieved by an array of enzymes collectively 
termed recombinases. Specific recombination recognition sequences are 
found after all germline V, D, and J segments and are complementary to 
those preceding J and D segments (Tonegawa, 1983). Recognition of these 
complementary sites by recombinases is thought to allow the formation of 
DNA loop structures where the intervening DNA is excised and the cut ends 
are joined together. Joining of the gene segments is imprecise and 
contributes to antibody diversity i.e. an identical set of gene segments can 
result in different amino acid sequences (junctional diversity). The imprecise 
joining of the V-D-J segments in the heavy chain is particular important and 
creates additional diversity of the CDR3 loop. Extra genetic diversity of the
heavy chain is also produced by insertion of nucleotides (N-sequences), not
present in the immunoglobulin loci, at the rearranged D-J and V-D junctions. 
The heavy chain contributes most of the structural diversity to the antibody- 
combining site because of these extra genetic mechanisms.
The VDJ variable regions are initially expressed with a Cp region 
(i.e. IgM) but during B-cell development the constant regions can be 
‘switched’. Upstream from each constant gene is a switch sequence (S) that 
allows the class (isotype) switching to occur via a 'DNA looping out' 
mechanism. This enables the B-cells to provide a variety of effector functions 
with the same antigen binding capacity.
1.3.3 The germinal centre reaction
T-cell dependent antibody responses initiate in the T-cell zones of the 
secondary lymphoid tissues. The majority of B-cells are activated in the T- 
cell zones migrate to local sites (the medulla cords and sinuses of the lymph 
nodes) where they differentiate into short lived plasma cells which produce 
fairly low affinity antibodies. Some of these B-cells bearing germline antigen
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receptors (antibodies) with relatively high affinity for antigen are selected by 
T-cells and migrate to secondary follicles which contain follicular dendritic 
cell networks. Once the B-cells have expanded to fill the follicular dendritic 
cell network, compartmentalisation takes place and a germinal centre is 
formed. This all occurs within the first three weeks after antigen challenge 
and on average three B-cell clones colonise each follicle (reviewed in 
Maclennan, 1994; Kelsoe, 1996; Camacho et al., 1998). There are a small 
number of antigens, which are capable of activating B-cells independently of 
T-cell help (T-independent antigens). These are large polymeric molecules 
and are unable to produce a secondary antibody response.
The germinal centre provides the location for both hypermutation 
and antigen selection of antibodies (a process known as affinity maturation) 
in a particular immune response. It involves the co-ordinated action of 
several different cell types: B-cells, T-cells, antigen-presenting cells, follicular 
dendritic cells and macrophages. The compartmentalisation of the germinal 
centre can be observed using a conventional light microscope and can be 








Figure 1.5 - Diagrammatic illustration of the germinal centre reaction.
The immunoglobulin DNA within the centroblasts is randomly mutated within the dark zone 
of the germinal centre. These centroblasts produce centrocytes, which express the mutated 
immunoglobulins on their cell surfaces. The centrocytes migrate to the light zone of the 
germinal centre and die by apoptosis unless they interact with the antigen. After a positive 
interaction with helper T-cells, the centrocytes differentiate into either memory or plasma B- 
cells. Additionally, the centrocytes can re-enter the dark zone (shown as a dashed line) and 
undergo further rounds of mutation and antigen-selection.
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The dark zone is found adjacent to the T-cell zone in the secondary 
follicle and contains B-cells that are rapidly dividing and not expressing 
surface immunoglobulins (known as centroblasts). The somatic 
hypermutation (Section 1.3.4) machinery acts upon the variable gene 
segments of the centroblasts to produce randomly mutated DNA (Jacob et 
al., 1991; Berek et al., 1991; Pascual et al., 1994). The centroblasts of the 
dark zone are continually giving rise to centrocytes which exit the cell cycle 
and display mutated immunoglobulins on their cell surfaces (Liu etal., 1989). 
These centrocytes migrate to the light zone of the germinal centre where 
they are separated by a dense network of follicular dendritic cells, which 
display antigen on their cell surfaces for extensive periods of time (Section
1.3.5). Centrocytes are predisposed to apoptosis and survival depends on 
the ability of their surface receptors (mutated antibodies) to bind antigen held 
by the follicular dendritic cells (Liu et al., 1989; Liu and Arpin, 1997). One of 
the characteristics of apoptosis is the rapid fragmentation of DNA by a pre­
existing endonuclease. Lindhout and colleagues (1985) showed that this 
DNA fragmentation in B-cells could be irreversibly blocked after interacting 
with follicular dendritic cells. The signals that prevent the B-cells from 
entering apoptosis are not fully characterised but the expression of 
oncogene, Bcl-2 has been shown to be important (Shokat and Goodnow, 
1995). Apoptosis also occurs in the dark zone, which might reflect the death 
of centoblasts that have deleterious mutations such as stop codons in the 
immunoglobulin variable genes. Phagocytosis by tingible body macrophages 
is believed to provide the mechanism for eliminating dead or dying cells 
(Szakal etal., 1989).
Once the specific interaction occurs between the antigen on the 
follicular dendritic cells and the antibody on the surface on the centrocytes, 
the antigen is internalised and processed by the centrocytes. These cells 
then re-express the antigen in a form that is recognised by the helper T-cells 
(Section 1.3.5). The specific interaction between the CD40 molecule on the 
surface of the B-cells (centrocytes) and the CD40-ligand on the surface of T- 
cells initiates isotype switching and differentiation of centrocytes into either 
plasma or memory cells. A positive CD40-mediated signal causes the B-cells 
to differentiate to memory cells whilst no signal produces plasma cells (Liu
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and Arpin, 1997). Recent evidence indicates that follicular dendritic cells 
and T-cells within the germinal centre may not only support the proliferation 
of B-cells by also provide the signals necessary for activation of the 
hypermutation mechanism (Camacho et al., 1998).
Three antigen-specific checkpoints in the germinal centre have been 
suggested to ensure no undesirable auto-reactive B-cells enter the memory 
B-cell pool (Lindhout et al., 1997). The first checkpoint occurs outside of the 
germinal centre in the secondary lymphoid follicle where only antigen- 
specific B-cells are activated by T-cells to produce germinal centres. 
Secondly only centrocytes, which bind to the antigen on follicular dendritic 
cells with high affinity, will escape apoptosis. Finally, B-cells which are 
expressing irrelevant or auto-reactive antibodies will display the incorrect 
antigen on their cell surfaces, thus will fail to initiate the T-cell help required 
to differentiate into plasma or memory cells.
Theoretical studies suggest that the optimal mutation schedule for a 
germinal centre reaction is one in which the antigen-selected centrocytes of 
the light zone are recycled back into the dark zone for further rounds of 
mutation and selection (Kepler and Perelson, 1993; Oprea and Perelson, 
1997). Recent experimental evidence shows the centroblasts of the dark 
zone are replenished from antigen-selected centrocytes of the light zone 
(Han et al., 1995). Hence, it would seem that the compartmentalisation of the 
germinal centre with its cycles of mutation and selection provides a near 
optimal mutation schedule.
1.3.4 Somatic hypermutation
The precise molecular mechanism which mutates the antibody DNA of the 
centroblasts in the germinal centre reaction is unknown, but numerous basic 
features of the hypermutation process have been deduced from the 
sequences of thousands of antibodies recovered from different stages of the 
immune response (Kabat et al., 1991).
The mutational process occurs in a non-random stepwise fashion 
and at an estimated rate of one mutation per thousand base pairs per 
generation (Berek and Milstein, 1988) which is a million times higher than 
the basal somatic mutation rate. The mutations are mainly nucleotide
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substitutions and there is clear evidence of a strand bias (Neuberger and 
Milstein, 1995). Mutations only extend about 1 to 1.5 kilobases from the 
variable region promoter to the joining segments in the rearranged antibody 
DNA loci and are rarely found in the constant region. Low doses of antigen 
have been shown to produce a more focused set of mutations due to the 
effects of antigen selection on the germinal centre reaction (Gonzalez- 
Fernandezand Milstein, 1998).
Surprisingly, mutational ‘hot-spots’ exist which owe nothing to the 
skewing effect of antigenic selection (Betz et al., 1993). In fact, the mutation 
machinery appears to intrinsically target sequence motifs in the CDRs of the 
variable gene which affect antigen binding compared to the framework 
regions which conserve the antibody structure (Tomlinson et al., 1996: 
Green etal., 1998).
Variable region genes have been replaced by numerous unrelated 
DNA sequences and hypermutation still occurs, hence showing the variable 
region genes themselves do not initiate the mutation process (Y6lamos et 
al., 1995). Numerous mechanisms for hypermutation have been suggested 
including an error-prone DNA polymerase or the lack of mismatch repair in 
DNA replication (Kocks and Rajewsky, 1989). Recent studies mostly support 
the idea that the transcriptional machinery plays an active role (Peters and 
Storb, 1996; Tumas-Brundage and Manser, 1997).
1.3.5 The 'alternative’ antigen pathway
After booster immunisation, immune complexes with antigen rapidly form 
and enter one of two pathways. The majority of complexes are endocytosed, 
degraded and eliminated from the lymph nodes by macrophages [The 
‘classical’ antigen pathway (Unanue, 1984)]
A second ‘alternative’ antigen pathway exists to preserve the 
immunogen (reviewed by Tew et al., 1989; Tew et al.,1997). Antigen 
transporting cells with dendritic morphology trap the immune complexes 
and migrates to the follicular dendritic cells present in the secondary 
lymphoid follicles. The antigen is then delivered to the follicular dendritic
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cells by an unknown mechanism (Tew et al., 1989). Scanning electron 
microscopy has revealed that the follicular dendritic cells retain the 
complexed antigen on the surfaces of their dendritic processes. Some of 
these dendritic processes mature and take on a ‘beaded’ morphology 
(Szakal et al., 1988). The ‘beaded’ dendrites are named immune complex 
coated bodies (iccosomes), and have been shown to disperse and interact 
with B cells approximately three days after antigen challenge. The antigen 
presented by iccosomes is processed by the B-cells into endocytic vesicles, 
becomes associated with the Golgi lamellae and is re-expressed in a form 
recognisable to the antigen-specific helper T-cells (Lanzavecchia, 1985; 
Kosco et al, 1988; Szakal et al., 1988). If helper T-cells recognise the 
antigen presented by the surface of B-cells they produce co-stimulatory 
signals such as lymphokines necessary for further B-cell differentiation. This 
alternative antigen pathway is described in figure 1.6 and follows the so- 
called antigen transport-follicular dendritic cell-iccosome-B cell axis.
Some of the antigen on the surface of the follicular dendritic cells 
does not take part in iccosome formation and is retained within the dendritic 
processes like ‘balls of yarn’ for long periods of time. This retained antigen is 
thought to play an important role in the regulation and long-term 
maintenance of humoral immunity. When antibody levels are high, newly 
produced antibody covers the antigen exposed on the surface of the 
follicular dendritic cells and consequently terminates the immunogenic 
stimulus. Cross-linking of the antigen by antibodies on neighbouring 
dendrites result in the formation of the ‘ball of yarn’ morphology. Antigen is 
then hidden in the convolutions of the dendrites until the antibody levels 
decline and the antigen becomes exposed to stimulate memory B-cells 
(Szakal et al., 1989). This cycle of events may explain how the levels of a 
particular antibody are maintained for months or sometimes years.
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1) A n t ig e n  t ra n s p o r t  (1 min- 
24hrs).
Immune complexes with 
antigen form rapidly in the 
subcapsular sinus and are 
delivered to FDCs at the 










2) Ic c o s o m e  fo rm a tio n  a n d  
d is p e rs io n  (Days 1-3). 
Iccosomes form on FDCs, 
disperse and interact with B- 
cells.
3) Ic c o s o m e  e n d o c y to s is  
(Day 5).
The antigen presented by 
iccosomes is endocytosed 
and re-expressed on the 
surface of B-cells in a form 
recognizable by helper T- 
cells.
4 ) A g  p ro c e s s in g  a n d  
p re s e n ta t io n  to  h e lp e r  T -c e lls  
(Days 3-7).
Co-stimulatory signals from 
helper T-cells stimulate 
further differentiation of B- 
cells into plasma or memory 
cells.
Note: Steps 2 - 4  occur within the germinal centre. After step 4, antigen is retained on the FDCs 
for long periods of time. Once antibody levels decline, the antigen is exposed and memory B-cells 
are stimulated. Abbreviations: Ag, Antigen; FDC, follicular dendritic cell; Ab, antibody; iccosomes, 
immune complex-coated bodies.
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1.4 ANTIBODY ENGINEERING
1.4.1 Production of polyclonal and monoclonal antibodies
Immunisation of a mouse with protein antigen A initially produces a variety of 
antibodies that are relatively low in affinity. Over the course of the response 
(repeat immunisation), the affinity of the antibodies to the protein antigen A 
increases due to affinity maturation (Section 1.3.3). The antiserum from the 
blood of this mouse will contain a variety of antibodies to different epitopes 
carried on the protein antigen A, all produced by different plasma cells 
(Polyclonal response). Additionally, this antiserum will comprise of a set of 
different antibodies with no affinity for protein antigen A. Once the serum 
from this mouse is used, it is impossible to produce the same set of 
antibodies by immunisation of a different mouse. These disadvantages of 
immunisation can be overcome by using monoclonal antibodies (an 
homogeneous population of antibodies with the same specificity).
Kohler and Milstein in 1975 first described the production of 
monoclonal antibodies using hybridoma technology. Hybridomas can be 
produced by fusing myeloma cells (cancerous B-cells) to antibody-producing 
spleen cells (or lymph node cells) in the presence of polyethylene glycol. 
Selective media can then be used to select for hybrid cells which have 
retained the immortal characteristic of the myeloma cells and the antibody- 
producing capacity of the spleen cells. Cell lines generating antibodies with 
single specificity for the desired antigen can then be isolated directly.
This powerful hybridoma technology has been applied successfully 
to a wide variety of biological problems, including many diagnostic 
applications. Unfortunately, the production of human monoclonal antibodies 
using this technology has not been so spectacular. This is mainly due to 
technical problems such as the instability of human heterohybrids, the loss 
of relevant structural/regulatory genes and imperfections in the secretory 
machinery of cells (James and Bell, 1987). Furthermore, the ethical 
problems associated with obtaining a good source of human B-cells from 
either the spleen or lymph nodes have hindered progression. The difficulty in
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making human monoclonal antibodies, especially against human self­
antigens, has prompted the development of human antibodies using genetic 
engineering techniques.
1.4.2 Humanisation of antibodies
Rodent monoclonal antibodies offer a plentiful and pure source of effective 
antibody reagents but if used in vivo they are recognised as foreign (i.e. 
produce a human anti-mouse immune response) and fail to recruit effector 
functions. Genetic and protein engineering techniques have provided the 
tools to overcome these problems by a process known as ‘humanisation’.
The first generation of humanised antibodies consisted of rodent 
variable domains being transplanted onto the constant domains of a human 
antibody (Morrison etal., 1984). These engineered fragments were shown to 
reduce immunogenicity but a residual immune response against the rodent 
variable domains decreased its effectiveness for clinical uses.
Due to the conservation of antibody structures across species, the 
humanisation process was further developed by transplanting the rodent 
CDRs onto a human p-sheet framework (Jones et al., 1986; Verhoeyen et 
al., 1988). If the framework-CDR antibody interface is accurately 
reconstructed during this grafting process, the antigen-combining site is 
conserved and affinities close to the parental rodent antibodies are 
achievable (Holmes and Foote, 1997). Often additional substitutions of 
individual amino-acid residues within the framework are necessary to 
conserve the rodent antigen-combining site (Foote and Winter, 1992). 
Computational methods have been developed to determine which human 
framework is suitably similar to the rodent framework to conserve CDR loop 
structures and minimise the number of foreign residues (Queen etal., 1989).
A novel technique known as resurfacing has also been developed to 
reduce the immunogenicity of the murine antibodies by humanising the 
surface accessible residues located at the conserved positions in the 
rodent’s framework (Roguska etal., 1996).
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1.4.3 Engineered antibody fragments
The domain structure of the IgG molecule makes it particularly accessible to 
protein engineering and can be separated into functional domains carrying 
either the antigen-binding (Fab) or effector (Fc) capacities by limited 
proteolysis. Digestion with the protease pepsin removes the second and 
third constant regions (CH2 and CH3) leaving the two Fab fragments joined 
together by at least one disulphide bond [Figure 1.7 (F(ab')2 )]• Using 
another protease known as papain can also produce individual Fab 
fragments (Figure 1.7).







F(ab’)2 (1 OOkDa) Fv (25kDa) scFv (27kDa)
VL VH VL / VH
Figure 1.7 - Engineered antibody fragments.
The various formats of antibody engineered fragments compared with the native 
immunoglobulin. The whole antibody molecule can be split into one F(ab' )2 fragment which 
consists of the heavy (VH + CH1) and the light chain variable and constant regions (VL + 
CL) held together by at least one disulphide bond. The F(ab' )2 molecule can be separated 
into two functional antigen-binding fragments (Fab). When the CL and CH1 regions are 
removed, the remaining variable regions make up the Fv fragment. Single-chain Fvs (scFvs) 
have the heavy and light chains linked by a short peptide linker. Diabodies are formed by 
shortening the linker of the scFv fragment to force dimerisation.
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The smallest antibody fragment which contains the entire antigen- 
binding site is the fragment variable (Fv). This Fv consists of the variable 
heavy and light antibody chains held together by non-covalent bonds which 
tend to dissociate at low concentrations (Glockshuber et al, 1990). The 
advent of the single chain Fv [scFv (Figure 1.7)] which joins these two 
variable regions by a peptide linker overcame this dissociation problem 
(Bird eta l, 1988; Huston eta l, 1988).
Comparisons of the scFv's affinities with the parental antibodies 
have shown the scFv affinities to be slightly lower but essentially the same 
(Bird and Walker, 1991). Normally, the orientation of the variable regions in 
the scFv (i.e. the linker running from the C-terminus of the VH to the N- 
terminus of the VL or vice versa) does not affect affinity, unless the C- 
terminus or N-terminus of either of the variable domains contribute to the 
antigen-binding site (Desplancq eta l, 1994).
The peptide sequence spanning the distance between the variable 
domains in the scFv must be sufficiently long and flexible enough to allow 
the formation of the antigen-combining site (Johnson and Bird, 1991). 
Molecular modelling based on structural data has been used to successfully 
select for natural linkers with the correct molecular dimensions and length to 
span the distance between the variable domains (Bird et al, 1988). In 
addition to length, amino acid composition plays a crucial role in linker 
design and minimal secondary structure is desirable to inhibit any 
interference with the amino acids of the variable domains (Huston et al, 
1988; Argos, 1990). Commonly, linkers between 14 and 25 residues in 
length and various amino acid sequences are used (Huston et al, 1991). 
The (Gly4Ser)3 linker used in this project is designed with glycine residues 
which provides the necessary flexibility and hydrophilic serine residues 
which promotes stability by the formation of hydrogen bonds with the 
surrounding solution (Huston et al, 1988). Often, the C- and N-termini of the 
variable domains are flexible enough to serve as part of the linker if the 
peptide is too short.
Antibody fragments have particular advantages in tumour therapy 
and imaging due to their small size (rapid pharmokinetics and tumour
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penetration in vivo) and the absence of the side reactions associated with 
the Fc effector function (reviewed in Chester and Hawkins, 1995). 
Therapeutic applications using antibody fragments to date include in vivo 
diagnosis of cancer using radiolabels (Schlom etal., 1992; King et al., 1994; 
Neri et al., 1997), antibody fusions with cytotoxic agents [immunotoxins 
(Ghetie and Vitetta, 1994)] and antibody-directed enzyme prodrug therapy 
(Bagshawe, 1989). Additionally, antibody fragments are ideal models for 
protein engineering studies and have been used extensively to investigate 
various antibody-antigen interactions.
ScFvs with short linkers have a tendency to form dimers and 
multimers (Desplancq et al., 1994; Alfthan et al., 1995). These dimers arise 
from a head-to-tail intermolecular association of the variable heavy and light 
domains due to the short linkers inhibiting the folding needed for the 
intramolecular event (Figure 1.7). This property can be used to produce 
‘diabodies’ where short linkers are designed to force pairing of 
complementary domains on opposite chains to create two antigen combining 
sites (Holliger etal., 1993). Fab and scFv antibody fragments lack the region 
of the antibody that recruits natural effector functions (Fc fragment), 
therefore diabodies have been developed to overcome this disadvantage. 
Directing one antigen-combining site towards the antigen and the other 
towards an effector receptor such as the first component of the complement 
system [Clq (Kontermann et al., 1997)] or a natural immunoglobulin 
molecule (Holliger et al., 1997) have been shown to be fruitful. The clinical 
data obtained from treatment of tumours with various diabodies is 
particularly promising (van de Winkel etal., 1997).
In 1993, a new class of antibodies was discovered in the camelid 
species that lacked light chains (Hamers-Casterman et al., 1993). This 
camelid variable heavy domain replaced the Fv as the ‘minimal antigen- 
binding fragment’ (Sheriff and Constantine, 1996) and are expected to 
become extremely useful in a number of biotechnological and medical 
applications (Muyldermans and Lauwereys, 1999).
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1.4.4 Expression of recombinant antibody fragments
Until the advent of the polymerase chain reaction (Saiki et al., 1985), the 
cloning of antibody genes was a laborious and time-consuming process 
involving the creation and screening of genomic or cDNA libraries. The 
polymerase chain reaction has made it possible to reproduce antibody gene 
repertoires present in vivo (Orlandi et al, 1989). ‘Universal’ primers can be 
designed to the conserved regions of the 5' and 3' ends of the variable 
heavy and light DNA sequences present in the Kabat database. To date, 
this strategy has been used to prepare antibody gene repertories from 
hybridomas (Orlandi et al., 1989), mouse spleens (Huse et al., 1989; Ward 
etal., 1989) and peripheral blood lymphocytes (Marks et al., 1991).
Most laboratories generally express their chosen antibody gene 
fragments in Escherichia coli because of the relatively simple, fast and well- 
established methods available (reviewed in Pluckthun, 1991; Ward, 1992). 
Initial attempts to express antibodies intracellularly in E. coli produced very 
low yields of functional antibody (Cabilly et al., 1984; Boss et al., 1984). The 
expressed protein was contained in ‘inclusion bodies’ and the generation of 
functional antibody required in vitro denaturation and refolding. A significant 
breakthrough was achieved when signal sequences were used to target 
antibody expression to the periplasmic space (Better et al., 1988; Skerra 
and Pluckthun, 1988). The oxidising environment of the periplasmic space 
promotes the formation of disulphide bonds, hence functional antibody can 
be isolated directly without any further manipulations.
E. coli production of antibody fragments is not always 
straightforward and unpredictable expression biases exist (Knappik and 
Pluckthun,1995). Eukaryotic systems such as plants (Owen etal., 1992) and 
mammalian cells (Jost et al., 1994), which have more sophisticated folding 
pathways, have also been developed for antibody fragment expression. One 
of the most successful technologies used in the development of specific 
antibody fragments is phage display.
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Phage display
Understanding the way antibodies are made in vivo has inspired the creation 
of an artificial immune system using phage display technology (reviewed in 
Winter et al., 1994; Winter, 1998). This technology has been successfully 
used to develop numerous antibody fragments with different binding 
specificities for both foreign and self-antigens, often with such efficiency that 
hydridoma technology and immunisation can be surpassed.
To mimic the immune system, firstly a repertoire of antibody genes 
must be created. ‘Natural’ repertories of rearranged human variable genes 
from peripheral blood lymphocytes of unimmunized donors (Marks et 
al., 1991) and ‘synthetic’ repertories of unrearranged variable gene segments 
with randomised CDR3 (Hoogenboom and Winter, 1992; Griffiths et al.,
1994) have been produced.
The ‘genetic display package’ of the B-cell is copied by displaying 
these antibody libraries on the surface of a filamentous bacteriophage using 
the molecular information of its coat proteins. Valencies of 3-5 or >24 copies 
of antibodies per phage are achieved by the fusion of the antibody DNA to 
the minor [pill (McCafferty et al., 1990) or the major [pVIII (Kang et al., 
1991)] coat proteins, respectively. Both Fab (Hoogenboom etal., 1991) and 
scFv (McCafferty et al., 1990) antibody fragments have been successfully 
displayed on the surface of phage.
The antigen-driven selection of the immune response is imitated by 
panning of the phage display libraries with different types of antigen coated 
surfaces. Several rounds of selection can isolate a single phage with high 
affinity for the pre-defined antigen. Additionally, it is possible to take 
advantage of the differing dissociation rates (off-rates) of the phage from the 
antigenic surface to isolate antibodies with closely related affinities but 
differing off-rates (Hawkins et al., 1992). Multivalent interactions also 
improve discrimination between phages i.e. small differences in affinity can 
give rise to larger differences in avidity.
It is also possible to copy the function of antibody-producing plasma 
cells by placing an amber stop codon in-between the antibody and coat
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protein DNA sequences. When phage is grown in a suppressor strain of E. 
coli (supE), the amber stop codon reads as a glutamine and the antibody 
fusion is displayed on the surface of phage (analogous to memory cells). 
When phage is grown in a non-supressor strain, the amber codon is read as 
a stop codon and soluble protein is secreted into the periplasm (analogous 
to plasma cells).
Previously, the size of a phage antibody library was limited to <109 
clones by the efficiency of the transfection of DNA into bacteria. Waterhouse 
and coworkers (1993) overcame this problem by a novel technique known 
as ‘combinational infection and in vivo recombination’ and a library of 6.5 x 
101° colonies was obtained (Griffiths et al., 1994). In this method, bacteria 
harbouring a ‘donor’ heavy chain repertoire (on a plasmid) was infected by 
an ‘acceptor’ light chain repertoire (on phage) and then Cre-catalysed site- 
specific recombination was used to combine the heavy and light chains. 
Theoretically the larger the library, the greater the chance of finding a higher 
affinity antibody for any given epitope (Perelson and Oster, 1979). Isolation 
of high affinity antibodies from very large antibody libraries (Griffiths et al., 
1994; Vaughan et al., 1996) supports this hypothesis and antibodies to any 
given antigen with affinities comparable with those from a secondary 
immune response have been isolated directly.
Additionally, antibody fragments have been expressed on the 
external surface of E. coli by using outer membrane proteins such as the 
major lipoprotein-outer membrane protein A hybrid [Lpp-OmpA (Francisco et 
al., 1993)] and peptidoglycan associated lipoprotein [PAL (Fuchs et al., 
1991)] display systems. These have been successfully used with 
fluorescence-activated cell sorting (FACS) to directly isolate single E. coli 
cells displaying specific antibodies.
An antigen-specific selection process has also been developed 
which utilizes both bacterial and phage display systems (Malmborg et al., 
1997). Phage infection is reliant on the minor coat protein (pill) on the 
bacteriophage interacting with the F pilus on the bacteria. Bacteriophages 
were designed to display peptide-specific antibody fragments using the pill
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coat protein and bacteria were engineered to express a particular antigenic 
peptide using a protein subunit of F pilus (traA). Specific interaction between 
the antibody fragment and peptide resulted in bacterial infection.
Expression using the yeast Saccharomyces cerevisiae 
Expression of antibodies in S. cerevisiae was first reported by Wood and co­
workers in 1985. Although functional Fab antibody fragments were formed, 
the efficiency of assembly was very low and the antibodies accumulated in 
the vacuoles. High intracellular levels of functional catalytic antibody 
fragments were achieved using an ultrahigh copy number plasmid and a 
galactose-inducible promoter (Bowdish etal., 1991). The expressed catalytic 
antibody possessed chorismate mutase activity and was shown to be active 
in an engineered S. cerevisiae strain which lacked this functional enzyme 
(Bowdish et al., 1991; Tang et al., 1991). Additionally, antibody fragments 
have been expressed intracellularly to eliminate the function of a single 
enzyme (Carlson, 1988).
The first secreted Fab antibody fragment in S. cerevisiae was 
achieved by simultaneous expression of the light and heavy chains fused to 
the yeast invertase signal sequence (Horwitz et al., 1988). Although fully 
functional antibody fragments were formed, the efficiency of assembly was 
low. Recently, secretion of single chain Fv antibody fragments in S. 
cerevisiae has reached levels up to 20mg/ml by using a combination of 
expression level tuning and overexpression of folding assistants (Shusta et 
al., 1998). This project is concerned with the expression of antibody 
fragments (Fab and scFv) on the surface of S. cerevisiae.
1.4.5 Antibody improvement in vitro
For clinical applications, antibodies with high affinities (Ka ~109 M'1) are 
required to bind tightly and specifically to a particular therapeutic target 
(Schlom et al., 1992). Antibodies with high affinities can be isolated directly 
from very large antibody repertoires (Section 1.4.3) but antibodies selected 
from medium size naive, synthetic or immune phage libraries normally reflect
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the affinities typical of primary immune responses (Ka ~105 -107 M'1) and 
require improvement (Hoogenboom, 1997).
In vivo, antibody affinities are improved in the germinal centre by a 
step-wise process of mutation and selection (Section 1.3.3). This process 
has been imitated in vitro by adding mutations to the antibody variable 
regions using either an E. coli mutator strain (Low et al., 1996) or error- 
prone PCR (Hawkins et al., 1993) and selecting for improvements using 
phage display. Antibodies with high affinities for a number of therapeutic 
targets have been isolated using these methods.
Although mutations in framework residues may contribute to 
improved affinity, many successful techniques have focused on changing 
the CDRs of the antibody, which have a major influence on antigen binding. 
CDRs have been targeted using numerous mutatgenic techniques including 
using specific oligonucleotides engineered to reduce the number of amino 
acids which do not retain parental structural features [parsimonious 
mutagenesis (Schier et al., 1996)] and an oligonucleotide-directed method 
that replaces entire codons rather than individual nucleotides [codon-based 
mutagenesis (Yelton et al., 1995)]. A combination of CDR mutagenesis and 
selection of antibodies with improved affinity (CDR walking) has been 
successfully used to generate antibodies with picomolar affinities, especially 
when individually selected variants are amalgamated (Barbas et al., 1994; 
Yang etal., 1995).
A successful alternative to random point mutagenesis is a process 
known as chain shuffling. Three hundred-fold antibody improvements have 
been achieved by pairing a combination of heavy and light chains with the 
appropriate single partners (Clackson etal., 1991; Marks etal., 1992).
Antibody fragments that have been improved in vitro are now in 
clinical trials in areas such as tumour imaging and targeting (Neri et al., 
1997).
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1.5 THE CHOSEN EXPRESSION HOST - Saccharomyces 
cerevisiae
Saccharomyces cerevisiae is a unicellular eukaryote that can exist in any of 
three different cell types- a, a  and a/a. Its life cycle can be divided into two 
parts: cellular proliferation and change in ploidy. All three cell-types can 
mitotically proliferate but only a- and a-haploids cells can mate to form the 
diploid, a/a. Upon nutritional starvation, diploids are capable of undergoing 
meiosis which gives rise to four haploid cells (Herskowitz, 1988).
The secretory system in S. cerevisae is very similar to higher 
eukaryotes, therefore it is very useful for studying many of the basic 
questions of eukaryotic biology including gene expression, DNA replication, 
secretion and the cell cycle. Properties such as a stable haploid and diploid 
state, availability of good genetic markers, quick growth, simple inexpensive 
media and a small haploid genome [1.4 x 107 b.p. (Sherman, 1991)] have 
made S. cerevisiae particularly suitable for genetic studies. Replicating 
plasmids are available with origins of replication and selectable markers for 
both E. coli and S. cerevisiae. Therefore, E. coli can be used as a 
workhorse for all the genetic manipulations and S. cerevisiae as the 
expression host. Additionally, homologous recombination is very efficient in 
S. cerevisiae and marker genes can be directly integrated into specific 
locations in the genome, thus permitting simple ways to study gene function.
With the completion of the total DNA sequence of the genome of S. 
cerevisiae in the spring of 1996 (Goffeau et al., 1997), new opportunities 
have developed to study gene function. Computer analysis of the genome 
sequence of the sixteen yeast chromosomes has identified more than six 
thousand potential open reading frames. Thirty-five percent of these 
potential genes have no known function and are the subject to substantial 
international efforts such as the European Functional Analysis Network 
(EUROFAN) which is a network of European laboratories studying the 
function of these genes by gene disruption. The total DNA sequence of S. 
cerevisiae, including the mitochondrial genome (Foury et al., 1998), is
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available in the S. cerevisiae genome database (SGD) on the World Wide 
Web.
As well as S. cerevisiae having very well established genetics, it is 
also an ideal host for the expression of eukaryotic proteins (Romanos et al., 
1992; Hammond and Helenius, 1995). Its secretory system is similar to 
mammalian cells; hence it is able to undertake all post-translational 
modifications such as glycolysation and disulphide bond formation. It 
expresses more protein per litre than mammalian systems (but less than E. 
coli) and is a food organism, therefore has 'generally regarded as safe' 
(GRAS) status.
All the above properties make S. cerevisiae highly acceptable for the 
production of pharmaceutical proteins and numerous commercial successes 
including insulin (Thim et al., 1986) and hepatitis-B surface antigen 
(Valenzuela et al., 1982) have been reported. S. cerevisiae is the chosen 
expression system for this project and factors which can affect expression 
levels are described in Part One. Additionally, the mating characteristics of 
S. cerevisiae were utilized in the second part of this project (Chapters 5 and 
6) and therefore are reviewed in the next Section.
1.6 THE MATING PROCESS IN Saccharomyces cerevisiae
1.6.1 Pheromone induction
The first stage in the mating process is communication between the two 
haploid cell types, a and a. This is achieved via the cell-type specific 
production of secreted mating factors (pheromones). The MATa cell-type 
secretes a 13-residue pheromone, a-factor and expresses a cell surface 
receptor that binds a-factor. a-factor (a 12-residue peptide) is secreted by 
the MATa cell type and it also expresses a cell surface receptor for 
recognition of a-factor (Herskowitz, 1988). Both a- and a-factor precursor 
are encoded by two functional genes MFa1/MFa2 and MFa1/MFc2, 
respectively (Michaelis and Herskowitz, 1988, Singh etal., 1983).
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Mutual stimulation of the mating pair by pheromones activates a 
common response pathway which causes arrest in cell division (G1 phase of 
the cell cycle), increased agglutinability and morphological changes which 
cause the cells to elongate towards each other to form pear-shaped cells 
[sometimes called shmoos (Bardwell et a/., 1994)]. These processes 
synchronise the mating partners for both cell and nuclear fusion. Haploid 
cells that do not mate successfully are able to recover from pheromone- 
imposed cell cycle arrest and resume vegetative growth.
1.6.2 Agglutination
Cellular aggregation (or agglutination) occurs through complementary 
binding of the mating type specific glycoproteins, a- and a-agglutinin. This 
interaction mediates adhesion between cells of the opposite mating types 
during the mating process. Agglutinins are constitutively expressed at a low 
level on the cell surface of haploid cells (< 1 x 103 agglutinin molecules per 
cell) but expression is strongly enhanced by mating pheromones from the 
opposite phenotype [3-5 x 104 agglutinin molecules per cell (Terrance and 
Lipke, 1987; Watzele et al., 1988; Wojciechowicz and Lipke, 1989). 
Initiation of agglutination takes approximately twenty minutes and the 
agglutinins are often found concentrated at the tips of shmoos (Watzele et 
al., 1988).
Agglutinins are essential for mating under conditions that do not 
promote cell to cell contact (liquid medium) but are not essential under 
conditions that promote cell to cell adhesion (solid medium). Hence, all 
agglutinin mutants have an unusual mating phenotype where the mating 
frequencies are only slightly affected on solid medium but when assayed on 
liquid medium the frequencies decrease by several orders of magnitude 
compared to the wild-type isogenic strains (Lipke et al., 1989; Roy et al.,
1991). This phenotypic characteristic has been utilised to identify the 
agglutinin structural genes via two different approaches:
1) A genetic approach - agglutination mutants which only affect one mating 
type are isolated and the agglutinin genes are cloned by complementation.
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2) A biochemical approach - the relevant agglutinin is purified, the amino 
acid sequence is obtained and degenerate oligonucleotides corresponding 
to these sequences are used to clone the agglutinin genes.
a-Agglutinin
The a-agglutinin gene sequence (SAG7; Doi et a!., 1989) was determined 
both biochemically (Hauser and Tanner, 1989) and genetically (Lipke et al., 
1989). The DNA sequence obtained (1950 b.p.) encodes for a 650 amino 
acid open-reading frame containing a nineteen amino acid leader sequence 
and twelve potential N-glycosylation sites. The mature a-agglutinin protein 
(Saglp) is highly N-glycosylated (-50% carbohydrate) and has a molecular 
weight of over 200 kDa but the total removal of these carbohydrates does 
not effect the biological activity of the protein (Hauser and Tanner, 1989).
Analysis of truncated versions of the a-agglutinin structural gene 
revealed it consists of two functional domains: an N-terminal half which 
binds the a-agglutinin and a C-terminal half which is important for cell 
surface attachment (Wojciechowicz et al., 1993). The C-terminal half (amino 
acids 350-650) comprises of approximately 50% serine and threonine 
residues and a signal sequence for the attachment of the glycosyl 
phosphatidylinositol (GPI) anchor (Figure 1.8). The N-terminal part of the a- 
agglutinin protein (residues 20-350) is composed of three immunoglobulin 
variable-like domains (Wojciechowicz et al., 1993; Chen et al., 1995) and 
shares similarities with many of the features of eukaryotic cell adhesion 
proteins. A histidine residue at position 292 is critical in the a-/a-agglutinin 
interaction (Cappellaro eta!., 1991). Further mutagenesis studies identified a 
putative binding site comprising of three discontinuous patches in domain III 
of the a-agglutinin protein (de Nobel eta!., 1996).
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Figure 1.8 - Diagrammatic representation of the a- and a-agglutinin structural features. 
a -a g g lu t in in
The a-agglutinin consists of an N-terminal binding domain (residues 20-350) and a C- 
terminal anchorage domain (residues 350-650). It is proposed that the N-terminal a- 
agglutinin binding domain consists of three immunoglobulin variable like domains called Dl, 






a -a g g lu t in in
The a-agglutinin consists of two subunits; an anchorage subunit (AGA1p) and a small 










All three agglutinins contain a signal sequence (s) that targets the protein to the secretory 
pathway. Both AGA1p and SAG1p contain a C-terminal signal sequence (g) for the 
attachment of the glycosyl phosphatidylinositol (GPI) anchor.
a-Agglutinin
Genetic analysis of a-agglutinin revealed it consists of two glycoprotein 
subunits which are encoded by genes AGA1 and AGA2. The AGA1 gene 
(2175 b.p.) was cloned by complementation (Roy et al., 1991) and analysis 
indicated the protein contains a large amount of serine/threonine residues 
and a C-terminal signal sequence for attachment of the GPI anchor (Figure 
1.8). Evaluation of agal mutants confirms that it is involved in cell surface 





Treatment of a-cells with reducing agents eliminates cellular 
agglutination due to the release of the a-agglutinin binding subunit. The 
open-reading frame of the a-agglutinin binding subunit (AGA2) was 
determined biochemically (Cappellaro et al., 1991) and it encodes a 69 
amino acid protein which contains an N-terminal signal sequence and is 
highly O-glycosylated (Figure 1.8). The a-agglutinin binding subunit (Aga2p) 
binds to the a-agglutinin cell anchorage subunit (Agalp) via two disulphide 
bridges. The binding activity of a-agglutinin is located in the last ten amino 
acids of the C-terminus of Aga2p (Cappellaro et al., 1994).
The a- and a-agglutinins interact on the cell surface in a monovalent 
form (Cappellaro et al., 1991). The interaction is heterogeneous and both 
weak (Ka<108M'1) and strong (Ka = 1 x 109 M'1) association constants have 
been reported (Lipke eta!., 1987). The strength of the agglutination reaction 
is more closely related to the number of agglutinin molecules on the surface 
of S. cerevisiae than the binding constant (Lipke et al., 1987).
The secretory pathway
All three agglutinin structural genes contain N-terminal hydrophobic regions. 
These are likely to act as signal sequences which direct the agglutinins 
through the secretory pathway of S. cerevisiae [Figure 1.9 (Tohoyama and 
Yanagishima, 1985; Lu eta i, 1994)].
After the agglutinins have been directed through the secretory 
pathway the anchorage domains (SAG1p and AGA1p) become covalently 
attached to the cell wall. The cell wall of S. cerevisiae consists of two major 
components: p-glucans (p-1,3/p-1,6-glucan) and mannoproteins. It is a 
layered structure and its composition varies considerably throughout the cell 
cycle. The outer surface of the cell wall consists predominantly of 
mannoproteins, has a brush-like structure and is often named the fibrillar 
layer. The inner layer mainly consists of p-glucans and these are 
responsible for the mechanical strength of the cell wall (Klis, 1994).
Both anchorage domains (SAG1p and AGAIpJ contain C-terminal 
hydrophobic signal sequences for the attachment of the GPI anchor that is
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essential for covalent linkage to the p-1,6-glucan component of the cell wall 
(Roy et al., 1991; Lipke et al., 1989). The mechanism of cell wall attachment 
is complex and relies on the prior addition of the GPI anchor (Lu et al.,
1995). A recent study has shown that only a short amino acid sequence (co­
minus) in the GPI anchor is important for localization to the cell wall 
(Hamada et al., 1998). It has been proposed that the periplasm form of the 
agglutinin is cross-linked to preformed p-1,6-glucan which becomes 
integrated into the growing cell wall (Lu et al., 1995). It is speculated the 
agglutinins interact within the cell wall’s outer fibrillar layer (Cappellaro et 
al., 1994).
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The signal sequence mediates translocation of the agglutinin molecules into the endoplasmic 
reticulum (ER). The signal peptide is removed by a signal peptidase in the ER and O- and 
core N-linked glycosylation occur [attachment of the GPI anchor also happens in the ER 
(Step 1-5)]. The agglutinins are then transported in vesicles to the Golgi where modifications 
of these glycosyl structures take place (not shown). From the Golgi, the agglutinins are 
packaged into secretory vesicles (Step 6) and delivered to the cell surface (Step 7). The 
agglutinins are then transferred from the GPI anchor to the cell wall glycan (Step 8-9). The 
mature agglutinins remain anchored to the cell wall with the binding domain exposed at the 
cell surface (Step 10). Reproduced from Lipke and Kurjan, 1992.
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Regulation of expression
Agglutinin expression in S. cerevisiae is specific to its haploid mating-type 
and is subject to a variety of types of regulation including the mating-type 
locus, induction by pheromones and growth conditions.
Genetically, a- and a-haploid cells only differ at the single mating- 
type locus, MAT. The expression of the agglutinins is regulated at the MAT 
locus by a mechanism similar to other a- and a-specific products. The MAT a  
locus encodes two DNA binding proteins: MATalp, which is a positive 
regulator of a-specific genes and MATa2p, which is a negative regulator of 
a-specific genes. a-Agglutinin expression is positively regulated by MATalp 
and the MATalp consensus sequence is found upstream of the SAG1 
coding region. In a-cells, the a-specific genes are constitutively expressed 
and MATa2p negatively regulates Aga2p expression in a-cells (Lipke and 
Kurjan, 1992). Surprisingly, the AGA1 transcript is expressed in both a- and 
a-cells at low levels and the mating-type control of the a-agglutinin binding 
subunit (Aga2p) ensures that the active protein is only expressed in a-cells 
(Roy et al., 1991).
Both the SAG1 and AGA2 transcripts are also induced by the 
opposite mating-type pheromone and contain pheromone induction 
consensus sequences upstream from their start codons (Lipke and Kurjan,
1992).
Sexual agglutination has been studied in several other species of 
budding yeast including Hansenula wingei, Pichia amethionina and 
Saccharomyces kluyveri. The structural features of the agglutinins, peptide 
pheromones and pheromone receptors have been conserved across the 
different yeast species, although the agglutinin interactions themselves are 
highly species-specific (Lipke and Kurjan, 1992).
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1.7 TARGETING THE CELL WALL IN S. cerevisiae
Display of heterologous proteins on the surface of S. cerevisiae is well 
suited for eukaryotic cell surface proteins that require endoplasmic reticulum 
specific post-translational processing such as glycosylation and disulphide 
bond formation (Boder and Wittrup, 1997). Eukaryotic expression systems 
are often able to overcome the unpredictable biases observed when 
expressing eukaryotic proteins in prokaryotic expression systems (Knappik 
and Pluckthun, 1995). The ability to display eukaryotic proteins on the 
surface of Saccharomyces cerevisiae has created new development 
opportunities such as immobilisation of enzymes (Klis et al., 1994; Murai et 
al., 1997a; Murai et al., 1997b), screening of polypeptide libraries (Boder 
and Wittrup, 1997) and the creation of live vaccines (Schreuder et al.,
1996).
The first heterologous protein to be targeted to the cell wall of S. 
cerevisiae was the enzyme a-galactosidase from Cyamoposis tetragoroloba 
(guar) seeds (Schreuder et al., 1993). This construct consisted of an 
invertase signal sequence, the a-galactosidase gene and the C-terminal half 
of the a-agglutinin (Figure 1.10).
Promoter Gene of interest
3' half of the 
a-agglutinin gene
Figure 1.10 - The general DNA construct for expression of a protein on the surface of S. 
c e re v is ia e .
All DNA constructs used to express various proteins on the surface of S. c e re v is ia e  (Table 
1.2) contain a promoter, a secretion signal sequence (S), the gene of the protein of interest, 
the 3' anchorage domain of the a-agglutinin gene and a terminator sequence (T).
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This fusion was expressed onto the surface of S. cerevisae under 
the control of a constitutive phosphoglycerokinase (PGK) promoter. Analysis 
of the cell wall-extracted material showed that 70% of the a-galactosidase/a- 
agglutinin protein fusion was covalently attached to the p-1,6-glucan 
component of the cell wall. Furthermore, immunofluorescence experiments 
confirmed the a-galactosidase protein was on the surface of S. cerevisiae. 
However, the detectable amount of expression varied greatly between 
different cells in the population due to changes in the copy number of the 
expression vector (Schreuder et al., 1996).
To date, seven proteins have been displayed on the surface of S. 
cerevisiae using the C-terminal half of the a-agglutinin gene (Table 1.2). In 
all cases, the N-terminal half of the constructs were detectable 
immunologically on the surface of the intact cells and the fusions were tightly 
linked to the p-glucan component of the cell wall.
Table 1.2 - Proteins displayed on the surface of S. cerevisiae using the C-terminal half of the 
a-agglutinin gene.
N-terminal gene Reference
a-galactosidase Schreuder et al., 1993
VH antibody fragment Hamers-Casterman e t a l 1993
Lipase Klis etal., 1994
Cutinase Klis etal., 1994
Hepatitis B surface antigen Schreuder et al., 1996
Cellulase Murai et al., 1997a
Glucoamylase Murai et al., 1997b
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Recently, the a-agglutinin gene has also been used to target the cell 
surface of S. cerevisiae (Boder and Wittrup, 1997; Kieke et al., 1997). In 
these cases, the heterologous protein was fused to the C-terminus of the a- 
agglutinin binding domain (Aga2p). In 1997, Boder and Wittrup displayed a 
mutated antibody fragment library on the yeast cell surface using this 
method and high affinity antibodies were selected directly using 
fluorescence-activated cell sorting (FACS). This a-agglutinin surface display 
system has also been used to express high levels of a T-cell receptor on the 
surface of yeast (Cho et al., 1998). These engineered yeast cells were 
shown to act as ’pseudo' antigen-presenting cells and induce T-cell 
activation.
Additionally, other cell wall proteins such as flocculin gene (FL01) 
have been shown to be effective in cell surface display, although large 
differences in immobilisation efficiency compared to the C-terminal half of 
the a-agglutinin were observed (van der Vaart et al., 1997).
1.8 RATIONALE OF THE PROJECT
Antibodies intended for diagnostic and therapeutic purposes must bind 
tightly and rapidly to the relevant antigen to avoid undesirable side reactions. 
High affinity monoclonal human antibodies demonstrate great therapeutic 
potential in the treatment of diseases such as cancer (Schlom et al., 1992). 
The fundamental reason behind the conception of this project was to 
eventually create an antibody improvement scheme that could generate high 
affinity monoclonal human antibodies faster and more efficiently than any 
other improvement system already established.
The improvement of antibodies in vivo occurs in the germinal centre 
by a process known as affinity maturation (Section 1.3.3). The germline 
antibody DNA is mutated inside a B-cell and then antibodies containing point 
mutations are expressed on the B-celPs surface. B-cells displaying 
advantageously mutated antibodies are selected due to their ability to 
interact with antigen-presenting follicular dendritic cells. Positively-selected 
B-cells often undergo further rounds of mutation and selection to generate
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the high affinity antibodies which are characteristic of a secondary immune 
response. Ultimately, this project aims to produce an antibody improvement 
system based on, and as effective as, the germinal centre reaction in the 
human body.
S. cerevisiae is the chosen organism for antibody expression in this 
project (Section 1.5). The main reasons for selecting the yeast S. cerevisiae 
are firstly its genetics are very well established and therefore its genome can 
be easily manipulated. The ability to manipulate the yeast genome was vital 
for success in the later stages of this project. Secondly unlike phage, single 
yeast cells can be isolated using fluorescence-activated cell sorting (FACS) 
which was an essential requirement in the design of Part I of this project. 
Finally, S. cerevisiae is eukaryotic and therefore is able to undertake post- 
translational modifications such as disulphide bond formation, which is 
extremely important for antibody production.
To mimic the antibody-displaying properties of B-cells, the C- 
terminal anchorage domain of the a-agglutinin gene was used to show that 
antibody fragments can be functionally expressed on the cell surface of the 
yeast, S. cerevisiae. Unfortunately, the yeast FACS system devised to 
imitate the positive-selection of B-cells in the germinal centre reaction was 
never demonstrated in this work. This was due to the fact that an S. 
cerevisiae FACS-selection system had already been successfully 
established (Boder and Wittrup, 1997). Therefore, the second part of this 
project was designed to create a new antibody selection system based on 
the mating characteristics of yeast agglutinin mutants (Section 1.6.2).
It was intended to mimic the germinal centre reaction by using the a- 
agglutinin gene to display antibodies on the surface of a-cells and the a- 
agglutinin gene to create the antigen-presenting system on the surface of a- 
cells (Figure 1.11). This would be done by integrating the antibody and 
antigen DNA at the relevant agglutinin loci in the appropriate haploid cell 
genomes (Schreuder et al., 1996) to generate surface-display systems that 
have constant expression levels throughout the cell populations. Mating of 
these engineered haploid strains will hopefully create a selection system that 
is able to choose cells which are expressing high affinity antibodies and will
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not be affected by ceils which are displaying moderate affinity antibodies at 
higher expression levels. In order to efficiently integrate a mutant antibody 
library into the a-agglutinin locus a novel site-specific recombination system 
was developed. A large surface display library ought to improve the chances 
of selecting for high affinity antibodies directly (Perelson and Oster, 1979; 
Griffiths etal., 1994).
The proposed selection process in Part II of this project will depend 
on the antigen-antibody interaction between the haploid mating-type display 
systems. An antibody-antigen interaction was chosen which has a similar 
affinity constant to the a-/a-agglutinin interaction (Ka = 109M'1) in order to 
reproduce the agglutination process as closely as possible. Engineered a- 
cells displaying low affinity antibodies should not be able to interact 
sufficiently to produce cell adhesion and die because their nutritional 
requirements will not be fulfilled on subsequent selection on nutritionally- 
deficient medium. The positively-selected diploids cells will then undergo 
meiosis (in nutritional starvation conditions) and a-cells expressing high 
affinity antibodies will be isolated to undergo further rounds of mutation and 
antigen-selection. Eventually, it was anticipated that an 'in-cell' mutational 
system would be developed to avoid the extensive DNA manipulations, 
which are required between antigen-selection steps. Producing an antibody 
improvement system that can occur totally within yeast cells would be a very 
attractive prospect.
Ideally this yeast 'germinal centre reaction' will produce high affinity 
human antibodies which can be used directly for therapeutic applications, 
thus by-passing the requirement for immunisation (Section 1.4.1) and 
humanisation (Section 1.4.2).
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Figure 1.11 A diagrammatic comparison between the antibody improvement system in vivo (left) and the proposed 
artificial yeast germinal centre strategy (right). The stars represent the point mutations which could occur throughout 
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1.9 AIMS OF THE PROJECT
The overall aim of this project is to demonstrate an 'in-cell' affinity maturation 
strategy using the yeast, S. cerevisiae. Ultimately, this strategy will mimic the 
human germinal centre reaction (Section 1.3.3) as closely as possible to 
produce high affinity human antibodies for therapy. If successful, this 
process will by-pass the requirement for immunisation (Section 1.4.1) and 
become the eukaryotic equivalent to phage display technology (Section 
1.4.4).
The first aim of this project is to show that antibody fragments (scFv 
and Fab) can be expressed on the surface of S. cerevisiae and are 
accessible to their targets (Part I). It is proposed that the C-terminal half of 
the a-agglutinin gene can be used for the desired antibody surface display 
system by covalent attachment of the antibody fragments to the p-glucan 
component of the cell wall (Section 1.6.2). This technology has already been 
used to display a number of heterologous proteins on the yeast cell surface 
(Section 1.7). The antibody fragment expression vectors will consist of the a- 
agglutinin leader sequence which will target the antibody fragments to the 
secretory pathway, the C-terminal half of the a-agglutinin gene (except in the 
case of the Fab light chain), a selectable marker and a strong yeast inducible 
promoter (Chapter 3). The antibody fragments will have affinity for the 
fluorescent antigen, Fluorescein-5-isothiocyanate (FITC), therefore 
functionality will be shown directly using immunofluorescence (Chapter 4). 
Part I of this project was designed with the intention of developing a 
fluorescence-activated cell sorting (FACS) selection system that could 
isolate yeast cells expressing high affinity antibodies from a mixed 
population. Unfortunately, this objective was never achieved due to the fact 
a FACS-based yeast selection system had already been established (Boder 
and Wittrup, 1997). Therefore, although the overall aim of this project 
remained the same, the goal of the second half of this project will be to 
develop an alternative selection strategy that utilizes the mating attributes of 
agglutinin mutants.
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Hence, th& second aim of this project is to show that the germinal 
centre reaction can be mimicked using opposite mating-type haploid cells 
has antigen and antibody surface display systems (Figure 1.11; Part II). For 
this selection process to succeed it was decided constant surface expression 
of the antibody (and antigen) agglutinin fusions was required to avoid 
problems distinguishing between cells expressing high affinity antibodies 
from cells displaying moderate affinity antibodies at higher levels. To achieve 
constant surface expression, the objective will be to integrate the antibody 
and antigen genes at the appropriate positions in the agglutinin loci. The 
Cre-/ox site-specific recombination system will be recruited to integrate the 
antibody DNA into the a-agglutinin locus at an efficiency required for mutant 
library construction (Chapter 5).
The antigen-antibody system used will be the well-characterised 
scFv D1.3-hen egg white lysozyme interaction. The a-/a-agglutinin and scFv 
D1.3/lysozyme interactions have similar affinity constants (Ka ~ 109M"1), 
therefore the germinal centre reaction will be copied by attempting to mate 
engineered a- and a-cells displaying the lysozyme and scFv D1.3, 
respectively (Figure 1.11). Engineered a-cells displaying low affinity 
antibodies ought not to bind the antigen presented on a-cells and die 
because their nutritional requirements will not be met. Only mated (diploid) 
cells will be able to grow on the selective media used (Chapter 6). This 
diploid selection strategy is intended to mimic the antigen-selection process 
in the germinal centre reaction. Additionally, once this selective mating 
process is established, the future direction of this project will be to develop 
an 'in-cell' mutational switch to avoid all the extensive DNA manipulations 
needed between antigen-selection steps. Ultimately, rounds of mutation and 
antigen-selection within yeast cells should lead to direct isolation of high 
affinity human antibodies.
CHAPTER 2
GENERAL MATERIALS AND METHODS
This chapter details the general experimental techniques used throughout 
this project. Any materials and methods specific to a particular chapter are 
described within that chapter.
2.1 MATERIALS
2.1.1 Chemical reagents
Chemical reagents (analytical grade) were obtained from Sigma, Fisons Ltd. 
or BDH Ltd. except when stated otherwise. Water used throughout this 
project was Millipore Q-Plus filtered water.
2.1.2 Molecular biological enzymes and reagents
All restriction endonucleases, VentR DNA polymerase, T4 DNA ligase, T4 
polynucleotide kinase and (3-agarase I were purchased from New England 
Biolabs Inc. Taq DNA polymerase was obtained as BIOTAQ™ polymerase 
from Bioline Ltd and TaqIPwo DNA polymerase mix was obtained as 
Expand™ High Fidelity PCR system from Boehringer Mannheim. Ultrapure 
2 - deoxynucleoside 5-triphosphates (dNTPs) were purchased from 
Pharmacia Biotech. Ultrapure™ agarose, Ultrapure™ low melting point 
agarose, 100 b.p. and 1 k.b.p. DNA ladders were supplied by Life 
Technologies. Mineral oil, salmon sperm DNA and pancreatic RNase were 
purchased from Sigma.
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2.1.3 Culture media and antibiotics
Bacto-yeast extract, Bacto-peptone, Bacto-tryptone, and Bacto-yeast 
nitrogen base without amino acids were all purchased from Difco 
Laboratories. Bactcnagar was either purchased from Difco Laboratories or 
BDH Ltd. All amino acids were obtained from Sigma and wherever 
applicable, HCI salts of amino acids were ordered Glucose  ^ raffinose, 
galactose (minimum 99% pure) and the antibiotics, ampicillin and geneticin 
(G418) were also purchased from Sigma.
2.1.4 Other materials
Nitrocellulose membrane was obtained as Hybond™-C from Amersham 
International and the 3MM paper from Whatman Scientific Ltd The standard 
protein markers were either purchased from Amersham International (High 
and low molecular weight Rainbow™ protein markers) or New England 
Biolabs Inc. (Broad range prestained protein marker). Protogel™ was 
supplied by National Diagnostics Ltd. (New Jersey, USA) and was a 
premade 37:5:1 acrylamide:bisacrylamide solution, supplied at a 30% (w/v) 
acrylamide concentration. The 96^well ELISA plates and lids were obtained 
as Falcon 3072 tissue culture plates from Becton Dickinson. Cycloheximide 
and 3, 3', 5, 5-tetramethyl benzidine (TMB) were purchased from Sigma.
2.2 MOLECULAR BIOLOGICAL METHODS
2.2.1 Bacterial strains and culture conditions
Escherichia coli strain TOP10P (P{laclq 77?10(TetR)} mcrk A(mrr-hsdRMS- 
mcrBC) <|>80/acZAM15 A/acX74 deoR recAl araD139A(ara-/eu)7697 galU 
galK rspL endkA nupG) was the standard strain used throughout this project 
and obtained as part of the Eukaryotic TA cloning kit (Version 1.0) from 
Invitrogen.
Plasmids, which were supplied in other strains, are described in the 
appropriate chapters.
E. coli strains were cultured at 37°C in Luria broth [(LB) 10g/I Bacto- 
tryptone, 5g/l Bacto-yeast extract, 10g/I sodium chloride] liquid media [250
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revolutions per minute (r.p.m.)], or on LB-agar plates (supplemented with 
15g/l Bacto-agar) overnight.
For E. coli strains carrying plasmids conferring ampicillin resistance, the 
medium was supplemented with ampicillin to a final concentration of 
100|ig/ml.
2.2.2 Saccharomyces cerevisiae strains and culture conditions
All Saccharomyces cerevisiae strains are described in the appropriate 
chapters and were cultured at 30°C in Yeast-extract peptone dextrose 
[(YPD) 10g/I Bacto-yeast extract, 20g/l Bacto-peptone, 20g/l glucose] liquid 
media (250r.p.m.) overnight, or on YPD-agar plates (supplemented with 
15g/l Bacto-agar) for 24-48 hours.
Plasmids carrying the HIS3, LEU2, or URA3 selectable markers were 
transformed into S. cerevisiae strains with the corresponding auxotrophic 
mutations. Positive transformants were cultured in Synthetic Complete (SC) 
liquid media without the relevant amino acids (6.7g/l Bacto-yeast nitrogen 
base without amino acids, 20g/l glucose, 2g/l "drop-out" mix) at 30°C for 
approximately 24 hours. The “drop-out” mix was a combination of the 
following ingredients without the amino acids* which complemented the 
relevant plasmid:
Adenine 0.5g Leucine* 10.0g
Alanine 2.0g Lysine 2.0g
Arginine 2.0g Methionine 2.0g
Asparagine 2.0g Phenylalanine 2.0g
Aspartic acid 2.0g Proline 2.0g
Cysteine 2.0g Serine 2.0g
Glutamine 2.0g Threonine 2.0g
Glutamic acid 2.0g Tryptophan 2.0g
Glycine 2.0g Tyrosine 2.0g
Histidine* 2.0g Uracil* 2.0g
Inositol 2.0g Valine 2.0g
Isoleucine 2.0g
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The S. cerevisiae strains were also grown on SC lacking amino acids* 
plates (supplemented with 20g/l Bacto-agar) at 30°C for 4  days. The amino 
acids absent in the SC plates were produced by the appropriate transformed 
plasmids and were essential for the nutritional requirements of the chosen 
yeast strain.
Any other culture conditions/media used are described in the relevant 
chapters.
2.2.3 Glycerol stocks
All E. coli/S. cerevisiae strains werestored at -70°C in 16% (v/v) glycerol.
2.2.4 Design of oligonucleotides
Oligonucleotide primers were designed to bind to the designated DNA 
template with the following factors taken into consideration (McPherson et 
a/., 1992):
i) The primers consisted of at least 18 bases of homology to the target DNA 
to ensure good hybridisation. If a choice was available in the exact DNA 
sequence, the region of the greatest base diversity was chosen.
ii) The primer (G+G) base content was at least 50% to ensure stability of the 
primer-template duplex.
iii) Their annealing temperatures were calculated using the Wallace 
equation: Tm = 4(G+C) + 2(A+T) [Applied Biosystems manual - Automated 
DNA sequencing chemistry guide] and was always above 45°C. If possible, 
a primer pair with similar annealing temperatures was used.
iv) The primer pairs were checked for regione of complementarity to each 
other to avoid ‘primer-dimer* formation; Primer-dimer formation can lead to a 
reduction of the amount of available primers within a reaction.
v) Individual primers were also checked for self-complementarity to prevent 
primers annealing to themselves.
If restriction sites were required at the ends of the PCR products, 6-10 
extra nucleotides were added after the enzyme recognition sites to increase 
the efficiency of cutting. The reference section in the latest New England 
Biolabs catalogue (‘Cleavage Close to the End of DNA Fragments’) was
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consulted to decide the number and sequence of bases to flank the 
recognition sites.
2.2.5 Synthesis of oligonucleotides
Oligonucleotides used in Chapters 3/4 were synthesized by Severn Biotech. 
Ltd. and were supplied HPLC purified as a lyophilised pellet. The pellet was 
reconstituted in distilled water to a final concentration of 1 nmol/pl, unless 
otherwise stated and stored at -20°C.
Oligonucleotides used in Chapters 5/6 were synthesized by Perkin- 
Elmer Applied Biosystems and were supplied in 20% (v/v) acetonitrile/water 
and stored at -20°C.
An aliquot of each primer was used throughout as a working stock to 
prevent contamination and repeated freeze-thawing.
2.2.6 Quantitation of oligonucleotides
The concentration of each oligonucleotide was confirmed by measuring the 
absorbance at 260nm on a Cecil Ce6600 Multimode Computis UV 
spectrophotometer using a matched pair of Hellma quartz curvettes 
(pathlength 10mm). The primer concentration was calculated using the 
following formula (provided by Perkin-Elmer):
Primer concentration = pmol/pl = 100 x A^n
(1.54nA+0.75nC+1.17nG+0.92nT)
(n = number of A’s, C’s, G,’s orT’s)
2.2.7 The Polymerase Chain Reaction (PCR)
The precise cycling parameters for polymerase chain reactions (PCRs) were 
optimised and are listed in the appropriate sections, but the following basic 
guidelines were always applied:
i) DNA denaturation was carried out at 94°C.
Chapter 2 -  General Materials and Methods
ii) The annealing temperature was calculated for the primers using the 
Wallace rule (Section 2.2.4). If a PCR product was not amplified, the 
annealing temperature was decreased, and if any non-specific products 
were observed, the annealing temperature was increased.
iii) For amplification to 3k.b.p., an elongation temperature of 72°C was 
used. For any amplification above 3k.b.p., the elongation temperature was 
lower to 68°C.
iv) The elongation time depended on the PCR product length and the 
following table was adhere to:
Elongation Time 45sec 1min 2min 4min 8min
PCR fragment length (k.b.p) >0.75 1.5 3 6 10
v) The number of cycles were kept to a minimal to reduce the opportunity 
for errors.
Note: These guidelines are based on the Expand™ High Fidelity PCR 
System information sheet supplied by Boehringer Mannheim.
PCRs were performed on a M.J. Research Inc. PTC-100 programmable 
thermal controller using either BIOTAQ™ Tag, VentR or Expand™ DNA 
polymerases. Both VentR and Expand™ DNA polymerases exhibit 3 -5 ’ 
exonuclease proofreading activity, therefore increasing the fidelity of DNA 
synthesis compared to Tag DNA polymerase. The following table shows the 
error rates of the various DNA polymerases [figures were obtained from the 
Boehringer Mannheim Expand ™ High Fidelity PCR System data sheet and 
the New England Biolabs catalogue 1998/99 (page 76)]:
DNA polymerase VentR Expand™ Tag
Error rate (10"° errors/b.p./duplication) 57 8.5 285
A) VentR polymerase chain reactions
For a VentR DNA polymerase reaction the conditions were: 100pmol of each 
primer, 5|il of 10x NEB VentR buffer [100mM KCI, 200mM Tris-HCI (pH8.8),
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100mM (NH4)2S04> 0.1% (v/v) Triton X-100], 5pl of 10x stock dNTPs (300pM 
dATP, 300jiM dCTP, 300jiM dGTP, 300jiM dTTP) and O.Spil of bovine serum 
albumin (10mg/ml). These reagents were mixed in a 0.2ml thin-walled tube 
and template DNA (50-250ng) was added. Finally, the mixture was made up 
to a volume of 49.5pl with water and 0.5jil of VentR polymerase (2units/pl) 
was added.
B) Taq polymerase chain reactions
For a Taq DNA polymerase reaction the conditions were: 25pmol of each 
primer and 10jj.I of 5x Taq buffer [80mM (NH4)2S 04, 335mM Tris-HCI 
(pH8.8), 0.05% (v/v) Tween 20, 100pM dATP, 100pM dCTP, 100pM dGTP, 
100pM dTTP, 7.5mM MgCh]. These reagents were mixed in a 0.2ml thin- 
walled tube and 50-250ng of template DNA was added. Finally, the mixture 
was made up to a volume of 49.5pl with water and 0.5pl of BIOLINE™ Taq 
polymerase (5 units/pl) was added.
C) Expand™ polymerase chain reactions
For an Expand™ DNA polymerase reaction the conditions were: 25pmol of 
each primer, 5jil of 10x Expand buffer [20mM Tris-HCI (pH7.5), 100mM KCI, 
1mM dithiothreitol, 0.1 mM EDTA, 0.5% (v/v) Tween 20, 0.5% (v/v) Nonidet 
P40, 15mM MgCy and 5pl of 10x stock dNTPs (200|iM dATP, 200pM 
dCTP, 200jiM dGTP, 200pM dTTP). These reagents were mixed in a 0.2ml 
thin-walled tube and 50-250ng of template DNA was added. Finally, the 
mixture was made up to a volume of 49.25pl with water and 0.75pl of 
Expand™ DNA polymerase (3.5 units/pl) was added.
All PCRs were run with a negative control (no DNA template) to check 
for contamination. If available a positive control on an existing template was 
also carried out to check various parameters such as buffers, enzymes and 
temperature cycles. If the programmable thermal controller without the 
insulated lid was used, the PCRs were overlaid with a drop of mineral oil to 
prevent evaporation. All PCRs were kept at 4°C until analysis and each PCR 
(5pl) was examined using agarose gel electrophoresis (Section 2.2.8),
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unless otherwise stated. If the PCR contained no non-specific bands when 
analysed, it was purified directly using the Wizard™ PCR Purification System 
(Promega) according to the manufacturer’s instructions.
2.2.8 Agarose Gel Electrophoresis
DNA fragments were visualised using agarose gel electrophoresis. The 
agarose concentration was adjusted from 0.8-3.0% (w/v) to resolve a wide 
range of DNA molecules (10k.b.p. - SOb.p., respectively). The DNA 
fragments were stained using ethidium bromide and visualised directly using 
long or short wavelength ultraviolet (UV) light.
Gels were prepared by dissolving the appropriate amount of Ultrapure™ 
agarose in 50ml of TBE buffer (90mM Tris-borate, 2mM EDTA) by boiling in 
a microwave oven. Ethidium bromide was added to a final concentration of
0.5pg/ml when the agarose had cooled to 50-60°C. The agarose was then 
poured into a Flowgen (10cm x 7cm) mini gel unit, which already contained 
spacers and a well-forming comb. Once set the comb and spacers were 
removed and the gel was submerged in TBE. The DNA samples were mixed 
with 6x loading buffer [0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene 
cyanol, 40% (w/v) sucrose] and loaded onto the gel. Appropriate DNA 
markers were loaded either side of the samples and a constant voltage of 
80V (8.0V/cm) was applied. The gel was run until the bromophenol blue had 
migrated sufficiently and then visualised with short wavelength UV light.
To purify a DNA fragment from an agarose gel, low-melting point (LMP) 
agarose was used. LMP agarose gels were prepared by dissolving the 
relevant amount of LMP agarose in 75ml of TAE buffer (40mM Tris-acetate, 
1mM EDTA) by heating in a microwave oven. Once cooled to 50-€0°C, 
ethidium bromide was added to a final concentration of 0.5|ig/ml and poured 
in the cold room (4°C). The solidified agarose was submerged in TAE buffer 
and the DNA samples were mixed with 6x LMP loading buffer [0.25% (w/v) 
bromophenol blue, 40% (w/v) sucrose]. The gel was ran at 40V (4V/cm) in 
the cold room (4°C), until the bromophenol blue had migrated sufficiently. 
The DNA fragments were briefly visualised with a long wavelength hand-held 
UV lamp to avoid DNA damage.
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2.2.9 Recovery of DNA from LMP agarose gels
Two techniques were used for purifying DNA from LMP agarose gels:
1) p-agarase digestion.
2) DNA extraction kits.
The relevant DNA fragment was cut out of a LMP agarose gel with a 
clean razor blade and melted at 80°C for 5 minutes.
If a small quantity of DNA was available or the DNA fragment was going 
to be sequenced, p-agarase was used.
A) p-agarase digestion of LMP agarose
P-agarase buffer [10x (100mM Tris-HCI (pH6.5), 10mM EDTA)] was added 
to the melted LMP agarose to a final concentration of 10% (w/v). This 
mixture was reheated for 5 minutes, mixed and then allowed to cool to 40°C. 
Two units of p-agarase were added to digest 200pl of 1 % LMP agarose gel 
and incubated at 40°C, overnight. Sodium acetate (pH 5.2) was added to a 
final concentration of 0.3M and the mixture was incubated on ice for 15 
minutes. The undigested agarose was removed by centrifugation at 
13000r.p.m. for 15 minutes in an MSE Micro-Centaur microfuge and the 
supernatant was transferred to a clean 1.5ml Eppendorf tube. The DNA was 
precipitated with two volumes of ice-cold isopropanol, mixed thoroughly and 
incubated at -20°C for 30 minutes. The supernatant was removed by re­
centrifugation and the pellet was washed with 1ml of 70% ethanol. The 
supernatant was then carefully aspirated off and the pellet was dried at room 
temperature. The DNA pellet was then resuspended in the appropriate 
amount of water for subsequent manipulations.
B) DNA extraction kits
If the DNA fragment was above 3k.b.p., the melted gel was purified using 
either the Qiaquick™ gel extraction kit (Qiagen) or the Wizard™ DNA Clean 
Up System (Promega) according the manufacturer’s instructions.
If the DNA fragment was less than 3k.b.p., the Wizard™ PCR Purification 
System (Promega) was used by following the supplied instructions.
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2.2.10 Alcohol precipitation of DNA
A 3M sodium acetate (pH 5.2) solution was added to the DNA to a final 
concentration of 300mM. Three volumes of absolute ethanol were added, 
the solution was vortexed and then incubated for one hour or overnight at - 
20°C. The precipitated DNA was collected at 13000r.p.m. for 5 minutes at 
4°C, using an MSE Micro-Centaur microfuge. The supernatant was removed 
and the DNA pellet was washed once in 1ml of 70% ethanol. The DNA pellet 
was then air-dried, resuspended in the required amount of water and stored 
at -20°C.
2.2.11 Quantitation of DNA
A DNA solution was diluted with a suitable amount of water and the 
absorbance was measured at 260nm on Cecil Ce6600 Multimode Computis 
UV spectrophotometer. One absorbance unit at 260nm is equivalent to 
50pg/ml of double stranded DNA (Sambrook et al., 1989).
In practice, the DNA concentration of samples was often estimated by 
comparison to a known concentration of DNA marker using agarose gel 
electrophoresis (Section 2.2.8).
2.2.12 Restriction endonuclease digestion of DNA
All restriction enzymes were obtained from New England Biolabs (NEB) and 
used according to the manufacturer’s instructions. If two enzymes had a 
compatible buffer, a double digest was performed in one step. A reaction 
mixture consisted of 5pl of the required 10x NEB buffer and 1pl of each of 
the restriction enzymes (3-20 units). Some NEB enzymes required the 
addition of bovine serum albumin to a concentration of 100pg/ml. The 
reaction mixtures were incubated at the required temperature for 16 hours 
and then heat inactivated at 65°C for 20 minutes. Digestions were performed 
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2.2.13 Ligations of sticky ended DNA
Ligation mixtures were prepared using 6 Weiss units (400NEBunits/pl) of T4 
DNA ligase, 1pl of 10x NEB ligase buffer [500mM Tris-HCI (pH7.5), 100mM 
MgCfe, 100mM dithiothreitol, 10mM ATP, 250pg/ml bovine serum albumin] 
and insert and vector DNA with compatible cohesive-ends, into a final 
reaction volume of 10pl. Normally the molar ratio of insert to vector was 3 to
1. To assess the degree of vector religation, a cut vector-only control was 
prepared each time. These mixtures were incubated at 16°C for 16 hours 
and then heat-inactivated at 65°C for 10 minutes. Half of each ligation 
mixture (5pl) was directly transformed into competent TOP10F’ E. coli cells 
and the remaining amount was stored at -20°C.
2.2.14 Preparation of competent E. coti cells (Sambrook et a/., 1989)
TOP10F E. coli cells (50pl) from a glycerol stock were plated onto a LB agar 
plate and incubated overnight at 37°C. A loopful of these cells was used to 
inoculate 3ml of LB medium and the resultant cell suspension was grown to 
saturation overnight at 37°C. A 500jil volume of this overnight culture was 
used to inoculate 50ml of LB medium and was grown at 37°C, until an 
absorbance (at 450nm) of 0.4 units was reached. The cells were then 
centrifuged at 3000r.p.m. (1500g) for 5 minutes using a GLC4 General 
Laboratory Centrifuge (Sorvall Instruments) and the pellet was resuspended 
in 25ml of ice-cold 50mM calcium chloride. This suspension was left on ice 
for 20 minutes and then re-centrifuged. The cell pellet was resuspended in 
5ml of 50mM calcium chloride/18% (v/v) glycerol, snap-frozen in 100pl 
aliquots and stored at -70°C.
2.2.15 Transformation of foreign DNA into competent E. coli cells
A ligation mixture (5pl) or plasmid DNA (1pl) was added to a 100pl aliquot of 
competent E. coli cells, which had been gently thawed on ice. The cells were 
incubated on ice for 1 hour, heatshocked at 42°C for 90 seconds and then 
placed on ice again for 2 minutes. A 400pl volume of SOC media (20g/l 
Bacto-tryptone, 5g/l Bacto-yeast extract, 0.5g/l NaCI, 2.5mM KCI, 10mM
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MgCfe, 20mM glucose) was added and the cells were left to shake (250 
r.p.m.) at 37°C for 1 hour. An aliquot of each transformation (200pl) was then 
plated onto an LB plate, supplemented with 100pg/ml ampicillin and allowed 
to dry. The plates were then inverted and incubated at 37°C, overnight (this 
method was adapted from Eukaryotic TA cloning kit instructions, Invitrogen).
2.2.16 PCR screening of positive transformants
In order to check that the transformants contained the correct plasmid or 
integrated construct, PCR screening was undertaken (McPherson et al.t 
1992).
A numbered E  coli/S. cerevisiae colony was selected using a sterile 
toothpick and then transferred into a PCR tube containing the relevant Taq 
polymerase PCR reaction [Section 2.2.7 (20pl)]. The toothpick was left in the 
PCR tube for 2 minutes and then transferred to a numbered culture tube 
containing the appropriate selective media.
The PCR cycling parameters were: [94°C, 5min; (94°C, 1min; 50°C, 
1 min; 72°C, 1 min) x 25; 72°C, 5min] unless otherwise stated and 5pl of each 
of the PCR products were analysed by agarose gel electrophoresis (Section 
2.2.8).
2.2.17 Small scale preparation of plasmid DNA^^inipreps1
Small quantities of plasmid DNA were prepared from an overnight culture of 
E. coli cells carrying the plasmid of interest, using the Wizard™ miniprep 
DNA purification system (Promega), according to the manufacturer’s 
instructions.
When plasmid DNA was required for DNA sequencing, the S.N.A.P 
miniprep kit (Invitrogen) was used and the manufacturer’s instructions were 
followed exactly.
2.2.18 Automated DNA sequencing and sequence analysis
For automated sequencing, 250-500ng of plasmid DNA or linear DNA was 
required. A sequencing primer (3.2pmol) was added to a 0.2ml thin-walled 
tube containing the DNA template and a total volume of 6 i^l was completed
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with water. The samples were sequenced on an ABI PRISM 377 DNA 
Sequencer, using the fluorescent dye terminator protocol that was based 
upon the chain-terminator sequencing method (Sanger et a/., 1977).
The resulting DNA sequence chromatographs were analysed and 
checked against the published DNA sequence for any base mutations, using 
the Sequence Editor (SeqEd™) program version 1.03 (Perkin-Elmer, Applied 
Biosystems Division).
2.2.19 Preparation of pancreatic RNase A
Pancreatic RNase A (100mg) was dissolved in 10ml of 10mM Tris-HCI 
(pH7.5), 15mM NaCI and heated at 100°C for 15 minutes. The mixture was 
cooled to room temperature, dispensed into 0.5ml aliquots and stored at - 
20°C.
2.2.20 Preparation of single stranded carrier DNA (Johnston, 1994)
Salmon sperm DNA (0.1g) was dissolved into 10ml TE buffer [10mM Tris- 
HCI (pH8.0), 1mM EDTA] and sonicated, using a 19mm titanium probe, for 
30 seconds at 300-500W (MSE Isowatt Ultrasonic Disintegrator, Fisons). 
Once sonicated sufficiently, the DNA was extracted with 
phenol:chloroform: isoamyl alcohol (25:24:1) and centrifuged at 2000g for 5 
minutes, using a Megafuge 1.0 centrifuge (Heraeus instruments). The top 
aqueous layer was removed and transferred to a clean 50ml-centrifuge tube. 
The DNA was precipitated by adding 1 ml 3M sodium acetate (pH 5.2) and 
25ml ice-cold 100% ethanol. This solution was vortexed and centrifuged at 
5000g for 10 minutes. The DNA pellet was washed twice with 25ml 70% 
ethanol and allowed to air-dry. The pellet was resuspended in 10ml TE 
buffer (10mg/ml DNA solution), aliquoted and stored at -20°C.
2.2.21 Preparation of yeast genomic DNA (Adams et a/., 1996)
A 10ml culture of the relevant strain of Saccharomyces cerevisiae was 
grown to saturation in YPD at 30°C, overnight. The cells were collected for 2 
minutes at 3000r.p.m. (1500g) using a Sorvall GLC-4 general laboratory 
centrifuge. The supernatant was removed and the cells were resuspended in
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0.5 ml of water. The cell suspension was transferred to a 1.5ml screw- 
capped Eppendorf tube and centrifuged at 13000r.p.m. for 30 seconds, 
using a MSE Micro-Centaur microfuge. The supernatant was removed and 
the pellet was resuspended in the residual liquid. Cell resuspension buffer 
[0.2ml; 2% (w/v) Triton X-100, 1% (w/v) SDS, 100mM NaCI, 10mM Tris-HCI 
(pH8.0)], 0.2ml of phenol:chloroform:isoamyl alcohol (25:24:1) and 0.3g of 
acid-washed glass beads (0.2 microns) were added and vortexed for 4 
minutes. Water (0.2ml) was added, the mixture was vortexed briefly and 
centrifuged for 5 minutes at 13000r.p.m. The top layer was transferred to a 
new 1.5ml Eppendorf tube and 1ml of 100% ethanol was added to 
precipitate the DNA. The DNA solution was then vortexed and centrifuged 
for 2 minutes at 13000r.p.m. The supernatant was discarded and the DNA 
pellet was resuspended in 0.4ml of water. Five microlitres of a 10mg/ml 
RNase A solution was added and incubated at 37°C for 30 minutes. 
Approximately 1 ml of 100% ethanol and 10pl of 4M ammonium acetate were 
added, mixed and centrifuged for 2 minutes at 13000r.p.m. The DNA pellet 
was washed with 70% ethanol and either air-dried, or dried under vacuum 
using a Stratech Scientific SpeedVac concentrator. The DNA pellet was then 
resuspended in the required volume of water for subsequent manipulations.
2.2.22 Transformation of S. cerevisiae cells with plasmid DNA 
(Johnston, 1994)
The relevant strain of S. cerevisiae was grown on a YPD plate at 30°C, 
overnight. Approximately 50pl of cells were scraped off the YPD plate and 
resuspended in 1 ml of water. The cell suspension was then centrifuged for 1 
minute at 13000r.p.m. and the supernatant was discarded. The cell pellet 
was washed with 1ml of water and re-centrifuged. The pellet was then 
washed with 0.5ml of 100mM lithium acetate, re-centrifuged and then 
resuspended in an equal volume of 10OmM lithium acetate. Five microlitres 
of freshly boiled single-stranded DNA (1 Omg/ml) and up to 5pg of plasmid 
DNA was added to 50pl of lithium-acetate treated cells and vortexed. A 40% 
(w/v) polyethylene glycol 3350/1 OOmM lithium acetate solution (300pl) was
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added and vortexed again. The mixture was then heatshocked at 42°C for 
20 minutes, centrifuged for 10 seconds at 13000r.p.m. and the cell pellet 
was resuspended in 1 ml of water. Aliquots of the transformed cells (250 i^l) 
were then plated onto the appropriate Selective Complete medium.
2.2.23 Super efficient transformation of S. cerevisiae cells with 
plasmid DNA (Adams et al., 1996)
A single colony of the appropriate strain of S. cerevisiae was used to 
inoculate 5ml of YPD and grown overnight at 30°C. The cell density of the 
pre-culture was estimated using a haemocytometer and diluted to 5 x 106 
cells/ml in 100ml of YPD. The cells were grown for two additional cell 
divisions (~3 hours) and collected by centrifugation at 3000r.p.m. (1500g) for 
5 minutes using a GLC4 general laboratory centrifuge. The cells were 
washed twice with 10ml of water and once with 10ml of 100mM lithium 
acetate. The cell pellet was then resuspended in 10OmM lithium acetate to 
give a final cell density of 2 X 109 cells/ml. The cell suspension was 
incubated at 30°C for 15 minutes and then dispensed into 50pl aliquots. Five 
microlitres of freshly boiled single-stranded DNA (10mg/ml) and up to 5jig of 
plasmid DNA were added to 50pl of lithium acetate treated cells. A 40% 
(w/v) polyethylene glycol/1 OOmM lithium acetate solution (300pl) was added 
and vortexed thoroughly. The transformation mixture was incubated at 30°C 
for 30 minutes and then heatshocked at 42°C for 20 minutes. The cells were 
then centrifuged at 13000rpm for 10 seconds and the pellet was 
resuspended in 1ml of water. Aliquots (250pl) were plated onto the 
appropriate selective plates, air-dried and incubated at 30°C for 3-4 days.
2.2.24 Integration of linear DNA into the S. cerevisiae genome 
(Wach etal., 1996)
A single colony of the appropriate strain of S. cerevisiae was used to 
inoculate 5ml of YPD and grown overnight at 30°C. The cell density of the 
pre-culture was estimated using a haemocytometer and diluted to 1 x 104 
cells/ml in 50ml of YPD. The yeast cells were then grown at 30°C for
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approximately 16 hours and then the cells were recounted (The cells were 
not used for the transformation if the cell density was higher than 1.7 x 107 
cells/ml). The cells were collected by centrifugation at 3000r.p.m. (1500g) for 
5 minutes using a GLC4 general laboratory centrifuge. The cells were 
washed once with 20ml of water and re-centifuged. The pellet was then 
resuspended in 1 ml of water and transferred to a 1.5ml Eppendorf tube. The 
suspension was centrifuged at 5000r.p.m. for 5 minutes, using a MSE Micro- 
Ceutaur microfuge and the pellet was resuspended in 100mM lithium 
acetate to a final cell density of 2 x 109 cells/ml. These cells were then 
incubated for 20 minutes at 30°C to make them fully competent. 
Approximately 2.5 jig of the relevant purified DNA and 5pl of freshly boiled 
single-stranded salmon sperm DNA (10mg/ml) was added to 50pl of 
competent cells. The mixture was vortexed and incubated at 30°C for 20 
minutes. A 40% (w/v) polyethylene glycol 3350/1 OOmM lithium acetate 
solution (300pl) was added to each transformation mixture, vortexed and 
incubated again for 20 minutes at 30°C. The transformation mixture was 
then heat-shocked at 42°C for exactly 20 minutes and the cells were 
collected at 5000r.p.m. for 1 minute. The cell pellet was resuspended in 4 ml 
of YPD and incubated for 2-3 hours at 30°C. Aliquots (1.5ml) of each 
transformation culture were transferred to 1.5ml Eppendorf tubes, 
centrifuged at 5000r.p.m. for 1 minute and the cell pellet was resuspended 
in approximately 250pl of the remaining supernatant. The transformed cells 
were then plated onto YPD plates [supplemented with 200mg/l Geneticin 
(G418)] and incubated at 30°C for 2-3 days. The large colonies were then 
picked off the transformation plate, re-streaked onto a new YPD/G418 plate 
and incubated for 1 -2 days.
Chapter 2 - General Materials and Methods
2.3 PROTEIN METHODS
2.3.1 Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE)
Polyacrylamide gel electrophoresis was carried out under denaturing 
conditions (Laemmli, 1970) using the Bio-Rad Mini-Protean II 
electrophoresis system.
All samples were boiled for 5 minutes in 4x SDS loading buffer [62.5mM 
Tris-HCI (pH 6.8), 10% (v/v) glycerol, 2% (w/v) SDS, 0.1% (w/v) 
bromophenol blue, 870mM p-mercaptoethanol] and loaded onto a 
discontinuous polyacrylamide gel [6% (w/v) acrylamide stacking gel/10% 
(w/v) acrylamide running gel]. The 10% (w/v) acrylamide running gel was 
prepared by mixing: 3.33ml 30% (w/v) bis-acrylamide solution (Protogel™), 
4.0ml water, 2.5 ml 1.5M Tris-HCI (pH8.8), 100pl 10% (w/v) SDS, 40^1 25% 
(w/v) ammonium peroxodisulphate and 4pl N, N, N\ N - 
tetramethylethylenediamine (TEMED). Approximately 3.5ml of the mixture 
was pipetted between the vertical glass plates of the Mini-Protean II system 
and 500pl of water was carefully added to ensure a smooth surface between 
the stacking and the running gel. Once set, the 6% (w/v) acrylamide stacking 
gel was prepared by mixing 1.7ml 30% (w/v) bis-acrylamide, 6.7ml water, 
1.25ml 1M Tris-HCI (pH6.8), 100pl 10% (w/v) SDS, 40pl 25% (w/v) 
ammonium peroxodisulphate and 10^ 1 TEMED. The water was removed 
from the top of the running gel, the stacking gel was added and a comb was 
inserted carefully to avoid any air bubbles. Once set, the SDS-PAGE gel was 
run at 200V for about 45 minutes in SDS running buffer [25mM Tris, 200mM 
glycine, 0.1% (w/v) SDS]. The gels were either fixed and stained 
simultaneously with 0.25% (w/v) Coomassie Brilliant Blue R250 [in 45% (v/v) 
methanol/10% (v/v) acetic add] overnight at room temperature or transferred 
to nitrocellulose for Western analysis (Section 2.3.2). The gels were then 
destained with 30% (v/v) methanol/10% (v/v) acetic add for approximately 
two hours at room temperature. After destaining, the gels were either stored 
in a sealed plastic bag in 5% (v/v) glycerol/5% (v/v) acetic acid or dried using 
a Bio-Rad 583 gel dryer.
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2.3.2 Transfer of proteins from SDS-PAGE gels to nitrocellulose
Six pieces of Whatman 3MM filter paper and one piece of nitrocellulose were 
cut to the exact size of the SDS-PAGE gel. These were all soaked in transfer 
buffer [39mM glycine, 48mM Tris, 0.037%(w/v) SDS, 20%(v/v) methanol] for 
20 minutes. Three pieces of pre-soaked filter paper were stacked onto the 
anode plate of the transfer apparatus (2117 Multiphore II electrophoresis 
unit, LKB Bromma) followed by the nitrocellulose, SDS-PAGE gel and finally 
another three pieces of the pre-soaked filter paper. The upper cathode plate 
was placed on top of the stack and a current of 0.8mA/cm2 of gel was 
applied for 1.5 to 2 hours.
2.3.3 Detection of target protein via Western analysis
The nitrocellulose membrane was blocked using 2% (w/v) Marvel in 
phosphate-buffered saline [(PBS) 137mM NaCI, 2.7mM KCI, 9.2mM 
Na2HP0 4 , 1.8mM KH2PO4] for two hours at room temperature. The 
membrane was then washed twice, for 3 minutes each time, with PBS. The 
relevant primary antibody (Table 2.1) diluted suitably in PBS/2% (w/v) Marvel 
was incubated with the nitrocellulose membrane overnight (4°C) at 15 
revolutions per minute on a 3D rocking platform (Stuart Scientific). The 
membrane was then washed twice, for 3 minutes each time, in PBS/0.05% 
(w/v) Tween 20 and then PBS. The relevant secondary antibody (Table 2.2), 
diluted appropriately in PBS/2% (w/v) Marvel, was then incubated with the 
membrane for 40 minutes at room temperature on the rocking platform. The 
PBS/0.05% (w/v) Tween 20 and PBS washes were repeated and the 
membrane was developed using the chromogenic substrate 4-chloro-1- 
naphthol [0.6% (w/v) 4-chloro-1-naphthol, 20% (w/v) methanol, 8mM Tris- 
HCI (pH7.5), 120mM NaCI, 0.015% (v/v) hydrogen peroxide]. After 
development, the membrane was fixed using water, dried and then stored in 
a sealed plastic bag.
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Sigma 19010 Goat human IgG Fab 
specific
1/1000 4
Sigma M0614 Mouse human lambda 
light chain
1/100 2.35
Dako A191 Rabbit human kappa 
light chain
1/800 0.75










Rabbit mouse IgG, 
F(ab’>2 specific
1/1000 2.3







Sigma A0545 Goat rabbit IgG, peroxidase conjugate 1/1000
Sigma A4416 Goat mouse IgG. peroxidase conjugate 1/1000
Sigma A5420 Goat goat IgG, peroxidase conjugate 1/1000
Jackson
111-095-
144 Goat rabbit IgG, FITC conjugate 1/100
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2.3.4 Enzyme- Linked Immunosorbent Assay (ELISA)
The wells of an ELISA plate were coated with 100^1 of the relevant antigen, 
diluted appropriately in PBS and were left overnight at room temperature. 
The wells were rinsed three times with PBS and then blocked for 2 hours at 
37°C, using 2% (w/v) Marvel/PBS. The wells were then washed three times 
with PBS and 25|il of 10% (w/v) Marvel/PBS was added to each well. The E. 
coli supernatant (100jil) from the appropriate culture was added to the 
designated well and left for 1.5 hours at room temperature. The wells were 
then rinsed three times with PBS/0.05% (w/v) Tween 20 and then three 
times with PBS. A hundred microlitres of the relevant primary antibody 
(Table 2.1), diluted in PBS/2% (w/v) Marvel, was added to each of the wells 
and left at room temperature for 1 hour. The PBS/0.05% (w/v) Tween 20 
and PBS washes were repeated. A hundred microlitres of the 
complementary secondary antibody (Table 2.2) diluted in PBS/2% (w/v) 
Marvel was added to each well and incubated at room temperature for 30 
minutes. The PBS/0.05% (w/v) Tween 20 and PBS washes were repeated 
and the chromogenic substrate 3, 3', 5, 5'-tetramethyl benzidine [TMB 
(50mM citrate buffer (pH6.0), 4mM TMB, 2 x 10-4 % (v/v) hydrogen
peroxide)] was used to develop the wells. The reaction was stopped using 
50pl of 1M sulphuric acid and the adsorbance (450nm) was read using a 
Multiskan® MCC Labsystems ELISA plate reader.
2.3.5 Enzyme ImmunoAssay (EIA)
Approximately 2 x 107 yeast cells were added to a 1.5ml Eppendorf tube and 
washed three times with PBS. Two hundred microlitres of the primary 
antibody (Table 2.1) diluted in PBS/2% (w/v) Marvel was added, vortexed 
and left for 1 hour at room temperature on a vertically rotating platform. The 
cells were collected via centrifugation at 13000r.p.m. for 30 seconds on a 
MSE Micro-Ceutaur microfuge. The cell pellet was washed three times with 
PBS/0.05% (w/v) Tween 20 and then three times with PBS. Two hundred 
microlitres of the complementary secondary antibody (Table 2.2) diluted in 
2% (w/v) Marvel/PBS was added, vortexed and left for 30 minutes at room 
temperature on the rotating platform. The washes were then repeated and a
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100^1 of the chromogenic substrate 3, 3', 5, 5-tetramethyl benzidine (TMB) 
[50mM citrate buffer (pH6.0), 4mM TMB, 2 x 10-4 % (v/v) hydrogen peroxide] 
was added to the cell pellet. The reaction was stopped using 50|il of 1M 
sulphuric acid and re-centrifuged. The reaction supernatant (100pl) was 
transferred to an ELISA plate and the absorbance (450nm) was read using a 
Multiskan® MCC Labsystems ELISA plate reader.
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MIMICKING ANTIBODY-DISPLAYING B-CELLS USING 
SACCHAROMYCES CEREVISIAE
Strategy
During the germinal centre reaction (Section 1.3.3), B-cells display mutated 
antibodies on their cell surfaces. This part of the project is concerned with 
copying the display system of B-cells by over-expressing antibody fragments 
on the surface of S. cerevisiae and determining if these antibody fragments 
are accessible to the relevant antigen. The expression constructs used in this 
project were designed with the intention of developing a fluorescence- 
activated cell sorting (FACS) selection system that could distinguish between 
yeast cells displaying low or high affinity antibodies for a particular antigen on 
their surfaces. The proposed FACS selection system was devised to imitate 
the antibody selection process of the germinal centre reaction.
Numerous heterologous proteins have been covalently attached to the 
p-glucan component of the cell wall of S. cerevisiae using the C-terminal 
anchorage domain of the a-agglutinin gene (Section 1.7). The a-agglutinin 
anchorage domain contains a glycosyl phosphatidyinositol (GPI) attachment 
sequence that is essential for linkage to the p-1,6 glucan component of the 
cell wall (Section 1.6.2). This a-agglutinin anchorage domain will be used to 
display antibody fragments (scFv and Fab molecules) on the cell surface of 
S. cerevisiae.
When designing the strategy for high level expression of antibody 
fragments on the surface of S. cerevisiae, the following factors were taken 
into consideration (Romanos et a/., 1992):
1. The copy number of the antibody gene.
2. The nature of the promoter.
3. The type of signal sequence.
4. The stability of the mRNA.
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5. The stability of the protein after synthesis.
Firstly, the expression vectors used in this part of the project contain a 
fragment from the multi-copy plasmid present in most laboratory strains 
known as the 2p circle (Beggs, 1978). This fragment gives the vectors the 
ability to replicate autonomously and be stably maintained at 25-100 copies 
per cell. Additionally, the vectors carry an E  coli selectable marker and origin 
of replication. These will facilitate the cloning of the antibody fragments into 
the expression vectors using standard DNA manipulation techniques.
High level expression of a foreign gene can place a significant burden 
on the host cell, reducing its growth rate and affecting the efficiency of gene 
expression (Romanos et al., 1992). In constitutive systems, where growth 
and expression are linked, strong selective pressure exists for cells with 
reduced levels of foreign gene expression. To overcome this problem, this 
strategy employs a strong yeast inducible promoter (GAL1\ Section 3.1.1) 
which can largely separate the growth and expression phases.
To target foreign proteins through the yeast secretory pathway, a signal 
sequence must be used which normally consists of a charged N-terminus, a 
central hydrophobic core and a consensus sequence for cleavage in the 
endoplasmic reticulum. In this case, the native a-agglutinin signal sequence 
was fused to the 5' terminus of the antibody fragments to direct their 
expression to the secretory pathway (Section 1.6.2). Additionally, a yeast 
transcriptional termination sequence was placed at the 3' terminus of each 
construct to aid efficient 3' formation of the messenger RNA (Romanos et al., 
1992).
Finally, all expression vectors were transformed into a protease- 
deficient S. cerevisiae strain to overcome the severe protease problem in 
yeast (Jones, 1991). The lumenal vacuolar aspartyl (prA) and serine (prB) 
proteases are thought to be the major source of this problem, therefore the S. 
cerevisiae strain used in this part of the project was chosen to be deficient in 
these. This should decrease the amount of protein degradation that can 
occur after cell breakage.
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The single chain Fv and Fab antibody fragments expression constructs 
consist of an a-agglutinin signal sequence, the C-terminal anchorage domain 
of the a-agglutinin gene (except for the case of the light chain Fab construct) 
and a transciptional termination signal. Each construct was placed under the 
control of the inducible GAL1 promoter (Figure 3.3).
The light and heavy chains of the Fab antibody fragment were cloned 
into separate expression vectors which comprised of the same promoter and 
signal sequence but different yeast auxotrophic markers for individual 
selection. Hence, it is intended that the light and heavy chains will be 
expressed simultaneously through the secretory pathway and the Fab 
fragment will form in the endoplasmic reticulum where disulphide bond 
formation takes place. The a-agglutinin anchorage domain fused to the 
heavy chain will hopefully attach the assembled Fab fragment to the cell wall. 
Functional Fab fragments have been successfully assembled from separate 
expression vectors under the control of the same promoter and secreted into 
the culture supernatant (Horwitz et al., 1988).
A Factor Xa cleavage site (lle-Glu-Gly-Arg; Nagai and Thogersen, 
1984) was placed in-between the antibody fragment and the a-agglutinin 
anchorage domain in both the scFv and heavy chain surface display 
constructs. Therefore, antibody fragments could be detached from the cell 
wall with treatment with Factor Xa protease, which cuts at a single arginine 
residue at the cleavage site. This may aid in the characterisation of the 
antibody fragment affinities using techniques such as fluorescence quench 
titration or surface plasmon resonance. This part of the strategy is intended 
to mimic the soluble antibody producing plasma cells of the human immune 
system.
Once surface expression of the antibody fragments is established, it is 
proposed that yeast cells displaying antibodies with high affinity for a 
particular antigen could be selected from a mixed population of cells using 
fluorescence-activated cell sorting (FACS). The antibody fragments used in 
this part of the project bind to the fluorescent antigen, fluorescein 5- 




CONSTRUCTION OF A YEAST SURFACE DISPLAY 
SYSTEM FOR ANTIBODY FRAGMENTS
3.1 INTRODUCTION
The first aim of this project is to show that antibody fragments (scFv and Fab 
molecules) can be functionally expressed on the surface of Saccharomyces 
cerevisiae. This strategy is intended to mimic the antibody surface display 
system of B-cells in the germinal centre reaction (Section 1.3.3).
The C-terminal anchorage domain of the a-agglutinin gene has been 
used to display several heterologous proteins on the surface of S. cerevisiae 
(Section 1.7) and is the chosen expression system for this part of the project 
(Part 1). The a-agglutinin anchorage domain will be fused to the C-terminus 
of the antibody fragments. Therefore, when the antibodies are expressed 
they will hopefully become covalently attached to the p-glucan component of 
the cell wall and be displayed on the exterior surface of S. cerevisiae.
The human antibody fragments used in this section of the project 
(Chapter 3 and 4) bind to the fluorescent antigen, fluorescein 5- 
isothiocyanate (FITC; Griffiths et a/., 1994). It is proposed that by using anti- 
FITC antibody fragments, epi-fluorescence microscopy can be used directly 
to determine if functional antibodies have been expressed on the surface of
S. cerevisiae. Additionally, cells binding the fluorescent antigen could be 
individually selected using fluorescence-activated cell sorting (FACS). This 
selection method could be used to isolate high affinity antibodies from a 
expression library of mutated antibodies, analogous to the germinal centre 
reaction.
The background information concerning the inducible GAL1 promoter 
and the anti-FITC Fab fragments is reviewed below.
Chapter 3- Construction of surface display vectors 69
3.1.1 The inducible promoter, GAL1
The mechanism of regulation of the enzymes used in galactose utilization 
(GAL genes) is probably one of the most well characterised in yeast 
(Johnston, 1987). Galactose is converted to glucose-6-phosphate by the 
enzymes of the Leloir pathway (Figure 3.1). The genes: GAL2 (permease), 
GAL1 (kinase), GAL7 (transferase), GAL10 (epimerase) and GAL5 (mutase) 
encode the enzymes of this pathway.
Figure 3.1 -  The pathway of galactose utilization. Reproduced from Johnston, 1987.
Expression of these enzymes (except for GAL5) is tightly regulated and 
increases approximately one thousand fold after growth on galactose. 
Transcription of these genes is activated by a protein, GAL4, which binds to 
sequences located upstream from each of these genes [upstream activation 
sequences (UAS)]. Growth on galactose causes an inducer to bind to the 
GAL80 protein. This prevents the inhibition of the GAL4 protein function 
(Figure 3.2) and transcription is activated.
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Using glucose as a carbon source prevents GAL gene expression by an 
event termed catabolite repression. Little is known about the catabolite 
repression mechanism but even in the presence of galactose, expression of 
GAL genes is completely repressed at the level of transcription. Cells grown 
on a non-catabolite-repressing carbon source such as raffinose require only 
ten to twenty minutes after galactose addition to induce transcription of the 
GAL genes (Adams, 1972). Cells grown in glucose display a delayed 
induction time of approximately 3 to 5 hours, even after extensive washing to 
remove any excess glucose.
In this project, the GAL promoter consists of the divergent upstream 
activation sequence from the promoter region between the GAL1 and GAL10 
genes. Galactose induction, after growth in a non-catabolite repressing 
carbon source, should display a 1000-fold increase in expression levels.
3.1.2 The human anti-FITC antibody fragments
Numerous different anti-FITC Fab fragments with different human light and 
heavy gene segments (and randomised CDR3s) were isolated from a very 
large synthetic phage display library created by ‘combinatorial infection and 
in vivo recombination’ (Griffiths et al., 1994; Section 1.4.4). This part of the 
project utilizes two of these isolated human anti-FITC Fab fragments (A2 and 
B7), both of which have affinities comparable with antibodies from a 
secondary immune response (Table 3.1).
Table 3.1 -  The two human anti-FITC Fab antibody fragments used in this part of the project 
(Griffiths et al., 1994). The residues in the light chain CDR3 regions encoded by randomized 






FITC-A2 DP-47 YRFSAPPRD DPL-3 AAWDDSLPSGV 217(± 16)
FITC-B7 DP-67 AQRKYFDY DPK-12 MQSIQLRT 151(± 3)
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3.1.3 Experimental design for the construction of the surface display 
expression vectors
The first stage in the construction of the anti-FITC Fab expression vectors 
(pYES2-SAGf-Heavy A2 and pYX-Light A2; Figure 3.6 and 3.8) was to 
individually amplify the heavy and light Fab gene segments from the plasmid, 
pUC119His6mycXba-FITC A2. The 5' oligonucleotides used in both the 
amplifications were designed to encode for the a-agglutinin signal sequence. 
The a-agglutinin signal sequence was incorporated into all the expression 
constructs to target the antibody fragments through the yeast secretory 
pathway (Section 1.6.2). A restriction endonuclease recognition site (Msc I) 
was introduced at the 3' end of the a-agglutinin signal sequence to aid the 
cloning of other antibody gene fragments.
The second stage of construction consisted of amplifying the C-terminal 
anchorage domain of the a-agglutinin gene and fusing this fragment to the 3' 
end of the Fab heavy chain gene segment using a 'splicing by overlap 
extension' reaction (Horton et al., 1989). The complementary 
oligonucleotides used in this reaction also encoded for a Factor Xa cleavage 
site and a Not I recognition site. The Factor Xa cleavage site was present to 
detach the scFv or Fab molecules from the yeast cell wall (if desired) and the 
Not I recognition site was introduced to facilitate the cloning of other antibody 
gene fragments.
The yeast expression vectors chosen for this project, pYES2 and 
pYX243, comprised of a multiple cloning site flanked by a strong GAL1 
inducible promoter and a transcription termination sequence (Section 3.2.3b). 
Careful design of the oligonucleotides facilitated the cloning of the light chain 
gene and heavy chain-a-agglutinin gene fusion into the multiple cloning sites 
of the appropriate expression vectors using restriction endonucleases. The 
vectors used for the surface display of the anti-FITC Fab A2 molecules 
contained different yeast auxotrophic selectable markers. Hence, the 
individual heavy and light chain expression constructs were co-transformed 
into an appropriate protease-deficient yeast strain and simultaneously 
expressed due to the fact they were under the control of the same GAL1 
inducible promoter. It was reasoned that the separate heavy and light chains
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would form a functional Fab fragment in the endoplasmic reticulum and the 
a-agglutinin anchorage domain, which is fused to the C-terminus of the 
heavy chain, would covalently attach the Fab to the cell wall.
The construction of the anti-FITC scFv surface display vector (pYES2- 
S/\Gf-scFv B7) involved separately amplifying the heavy and light variable 
gene segments from the plasmid, pUC119His6mycXba-FITC B7 (Figure 
3.10). The variable heavy and light gene segments were then fused together 
by a 'splicing by overlap extension' reaction which also incorporated a 
(Gly4Ser)3 linker (Huston et al., 1988). Due to the careful design of the heavy 
chain expression vector, the construction of the scFv surface display vector 
was straightforward. Firstly, the heavy chain was removed from the pYES2- 
SAG1-Heavy A2 by using the two restriction endonuclease recognition sites 
(Msc I and Not I) placed at the 3' ends of the a-agglutinin signal sequence 
and heavy chain gene segment. The 5' and 3' ends of the scFv gene were 
designed to be compatible with these recognition sites, hence the scFv was 
digested and ligated into this expression vector. The created expression 
vector, pYES2-SACB1 -scFv B7, consisted of the scFv gene flanked by an a- 
agglutinin leader sequence and the a-agglutinin anchorage domain, all under 
the control of the GAL1 promoter.
This Chapter details the successful construction of anti-FITC Fab and 
scFv surface display expression vectors, pYES2-SAGf-Heavy A2, pYX-Light 
A2 and pYES2-SAGf-scFv B7 (Figure 3.3).
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Figure 3.3 - Diagrammatic representation of the constructed surface expression vectors. 
The letters L, G, T and Xa represents the a-agglutinin leader sequence, (Gly4Ser)3 linker, 
termination sequence and the Factor Xa recognition site, respectively.
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3.2 MATERIALS
3.2.1 Saccharomyces cerevisiae strain
The S. cerevisiae strain, YMTAB contained gene disruptions in the vacuolar 
proteases, pral and prb1 (Jones, 1991). The strain was galactose inducible 
and contained the relevant auxotrophic mutations required for plasmid 
selection.
Table 3.2 -  Saccharomyces cerevisiae strain used.
Strain Genotype Source Reference
YMTAB MAT a ieu2-3,112 ura3A5 
pra 1 ::HiS3 prb1 AAV GAL+
D. H. Wolf, University of 
Stuttgart
Sander et a!., 1994
3.2.2 E. coii strains and plasmids
The plasmids used in this chapter were either supplied in an aqueous DNA 
solution or as an E. coii slant culture (Table 3.3). When plasmids were 
provided in an aqueous solution, they were transformed into TOP10F E. coii 
cells (Section 2.2.15). For long term storage, glycerol stocks were made for 
all plasmids (Section 2.2.3).
3.2.3 Plasmid descriptions
A) The p(JC119His6mycXba-FITC A2/FITC-B7 plasmids (Griffiths et al., 
1994)
The pUC119His6mycXba expression vector contains the anti-FITC heavy 
and light Fab chains cloned into the plasmid as Xba VNot I fragments. The 
tags, c-myc and His6, are present after the Not I site for detection and 
purification of the anti-FITC Fab fragments, respectively. The Fab fragments 
are under the control of the inducible promoter, lac, and therefore expression 
can be induced by addition of isopropyl-p-D-thiogalactoside (IPTG).
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B) The yeast expression vectors, pYES2 and pYX243
The vectors, pYES2 and pYX243, contain selectable markers and origins of 
replication for S. cerevisiae and E. coii, therefore can be maintained in both 
(Figures 3.4 and 3.5). They are designed for high level expression of foreign 
proteins in S. cerevisiae and carry a strong inducible GAL1 promoter and 
transcription terminator sequence.
C) The pH27 vector (Lipke et al., 1989)
The E. coii cloning vector, pH27, carries a 6.1k.b.p. SAG1-complementing 
Hind III fragment which contains the complete a-agglutinin gene. A 
kanamycin marker and origin of replication are present for the selection and 
replication in E. coii, respectively.
Table 3.3 -  Plasmids used. NA, not applicable.
Plasmid Strain Genotype Source Reference
pUC119His6mycXba 
-FITCA2
TG1 supE hsdA5 
thiAflac proAB) F  
(traD36 proAB* 
lacf lacZAM15)
G. Winter, MRC, 
Cambridge





n  i« N  W i t  i t
pYES2 NA NA Invitrogen NA
pYX243 NA NA R + D systems NA
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M u lt ip le  c lo n in g  s ite  (M C S ) fo r  th e  e x p re s s io n  ve c to r, p Y E S 2 .
X b a  I S p h  I X h o  I N o t I B s fX  I EcoR I B s tX  I
T CT AG AT GC AT GCT CG AGCGGCCGCC AGT GT GAT GG AT AT CTGCAGAATT CCAGCACA
BamH I S a c  I K p n  I H in d  III 
CT GGCGGCCGTTACT AGT GGAT CCG AGCT CGGT ACC AAGCTT
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Figure 3.5 - Plasmid map of the yeast expression vector, pYX243.
MCS,







M u lt ip le  c lo n in g  s ite  fo r  e x p re s s io n  v e c to r, p Y X 2 4 3
B a m H  I A p a  I S a l I
EcoR I N c o  I Avrll Hindi III M lu  I S m a  I
G AATT CACCAT GGAT CCT AGGGCCCACAAGCTTACGCGT CG ACCCGGGTAT CCGTAT G
X h o  I
EcoR V S a c  I N h e  I
AT GTGCCT GACTACGCAT GATAT CT CG AGCT CGAGCT CAGCTAGCTAACT GA
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3.3 METHODS
3.3.1 Construction of the Fab heavy chain expression vector
A) Primer design
The fundamental design parameters for primers were followed as described 
in Section 2.2.4. Primer pairs, Agg(F1)/Agg(B) and Agg(L)/CH(F) were 
designed to amplify the C-terminal half of the a-agglutinin gene and the anti- 
FITC Fab A2 heavy chain (germline sequence DP-47 and the IgG constant 
domain 1), respectively (Figure 3.6).
Figure 3.6 -  Flow diagram summarising the construction of the Fab heavy chain expression 
vector, pYES2-S>4Gf-Heavy A2. The letters L and Xa depict the a-agglutinin leader 
sequence and Factor Xa recognition site, respectively. The symbols VH and CH1 represents 
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Oligonucleotides Agg(B) and CH(F) were synthesised with 
complementary 5' ends. Therefore, in a second PCR step, the heavy chain- 
a-agglutinin fusion can be assembled by a 'splicing by overlap extension' 
reaction (Horton et a/., 1989). These complementary primers also encoded 
for a Factor Xa cleavage site to aid the removal of antibody fragments from 
the yeast cell wall, if desired. To facilitate cloning Hind III and Xba I 
recognition sites were incorporated into the 5' ends of the oligonucleotides, 
Agg(L) and Agg(F1), respectively. Additionally, the primer Agg(L) was 
designed to encode for the a-agglutinin signal sequence.
In anticipation, the heavy chain surface display construct would be 
used to clone additional antibody fragments, primers Agg(L) and CH(F) were 
designed to incorporate a Msc I and a Not I site at the 3' end of the a- 
agglutinin leader sequence and 5' end of the a-agglutinin anchorage domain, 
respectively. This should lead to the easy removal and addition of antibody 
gene fragments in-between the a-agglutinin leader and anchorage domain. 
Figure 3.7 summarizes the heavy chain A2/a-agglutinin expression construct.
B) PCR amplification of the C-terminal a-agglutinin
The C-terminal anchorage domain of the a-agglutinin gene (nucleotides 982- 
1952) was amplified by a VentR PCR (Section 2.2.7a) using the vector, pH27 
as a DNA template and the primer pair, Agg(F1) and Agg(B) [Table 3.4]. The 
reaction was performed for 25 cycles using the following parameters: [(94°C, 
1min; 50°C, 2min; 72°C, 1min) x 25; 72°C, 10min]. The PCR product (986 
b.p.) was purified (Section 2.2.9b) and quantified by agarose gel 
electrophoresis (Section 2.2.8).
Note: M. Redfern optimised this PCR amplification.
Figure 3.7 - Schematic representation of the heavy chain A2/a-agglutinin gene expression construct including sequence details of the 5' and 3' ends. The 
DNA sequence encoding the heavy A2/a-agglutinin junction is also described. Restriction sites are represented in bold and the extra nucleotide is underlined.
Hind III Msc I Not I Xba I
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C) PCR amplification of the Fab heavy chain A2
The human heavy chain A2 consisting of the variable gene segment DP-47 
and first IgG heavy constant domain was amplified from vector, 
pUC119His6mycXba-FITC A2 using an Expand™ PCR (Section 2.2.7c) and 
primers Agg(L)/CH(F) [Table 3.4].The reaction conditions were: [(94°C, 1min; 
60°C, 1min; 72°C, 1min) x 25; 72°C, 10min] and the PCR product (749 b.p.) 
was purified using a DNA extraction kit (Section 2.2.9b).
Table 3.4 -  Sequences of the oligonucleotides used in the amplification of the 3' half of the a- 
agglutinin gene and the heavy chain A2 gene segment. Enzyme recognition sites are 
represented in bold and the Factor Xa site is underlined.
Primer Name Sequence (5-3') Description (5'-3')
Agg(B) ATCGAGGGAAGGGGTACCGCTAGCGCC
AAA
12 n.t. Factor Xa site; binds 982-999 b.p. 
downstream from the SAG1 start codon 
(Watson strand). The first six n.t. of 




2 n.t. overhang; a Xba  I site; one extra stop 
codon; 21 n.t. of homology to the 3' end of 
SAG1 (Crick strand).
Agg(L) CCCCCAAGCTTATGTTCAC1 1 1 ICTCAAA  
ATTATTCTGTGGC1 1 1 1 1 ICCTTGGCATT  
GGCCAGTGCTGAGGTGCAGCTGTTGGA  
G
5 n.t overhang; a Hind III site; 57 n.t. a- 
agglutinin signal sequence including an Msc 
I site; 18 n.t. of homology to the 5 ' end of 




24 n.t. which are complementary to Agg(B) 
and encompasses a  12 n.t. Factor Xa site; 
one extra guanine n.t.; 18 n.t. of homology 
to the 3' end of the first IgG constant 
domain including a Not I site (non-coding 
strand).
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D) Assembly of the heavy A2/a-agglutinin fusion
Approximately equal amounts (~50ng) of the amplified heavy chain A2 and 
the a-agglutinin anchorage domain were added together in a VentR PCR 
(Section 2.2.7a) with the primer pair Agg(L/SP)/Agg(F/SP) [Table 3.5]. The 
reaction conditions were: [(94°C, 1 min; 55°C, 2min; 72°C, 1 min) x 25; 72°C, 
10min]. The assembled product (1.7 k.b.p.) was separated from the other 
non-specific bands by low-melting point agarose gel electrophoresis (Section
2.2.8) and recovered using a DNA extraction kit (Section 2.2.9b).
E) Construction of the vector, pYES2-SAG 1-Heavy A2
The vector, pYES2 and the heavy A2-a-agglutinin gene fusion were digested 
with H//?d III (10units) and Xba I (20units) overnight, at 37°C (Section 2.2.12). 
The digested pYES2-H//7d WVXba I vector was separated from its multiple 
cloning site using low-melting point agarose gel electrophoresis (Section
2.2.8) and purified (Section 2.2.9b). Additionally, the restriction digestion 
buffers from the digested heavy A2/a-agglutinin fusion were removed 
(Section 2.2.9b). The heavy A2/a-agglutinin-/-//>?d III/Xba I insert was ligated 
into plasmid, pYES2-H//?d III/Xba I (Section 2.2.13) and transformed into E. 
coli (Section 2.2.15). Ampicillin-resistant colonies were PCR screened 
(Section 2.2.16) using conditions: [(94°C, 1min; 50°C, 1min; 72°C, 2min) x 
25; 72°C, 10min] and the primer pair pYES(FOR2)/pYX(FOR) [Table 3.5]. 
The PCR products were analysed by agarose gel electrophoresis (Section
2.2.8) and positive transformants were grown overnight in 3ml of LB (Section 
2.2.1). Glycerol stocks (Section 2.2.3) and plasmid DNA (Section 2.2.17) 
were prepared for some of the positive colonies. The construction of vector, 
pYES2-SAGf-Heavy A2 was verified by DNA sequencing (Section 2.2.18) 
using primers pYX(FOR), Agg(B), AggSeql and pYES(FOR2).
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Table 3.5 - Sequences of the oligonucleotides used in the construction and verification of the 
heavy chain expression vector, pYES2-SAGf-Heavy A2. Restriction enzyme recognition 
sites are shown in bold.
Primer Name Sequence (5'-3') Description (5'-3')
Agg(L/SP) CCCCCAAGCTTAT GTT CA 18 n.t. of homology to the 5* end of 
oligonucleotide Agg(L) including a Hind III 
site (coding strand).
Agg(F/SP) GCTCTAGATTATTAGAAT 18 n.t. of homology to the 5* end of primer 
Agg(F1) including a Xba  I site (non-coding 
strand).
PYES(FOR2) TTCGGTTAGAGCGGATGT Binds 51-69 n.t. downstream of the Xba  I 
site in pYES2 (coding strand).
PYX(FOR) TACTTTAACGTCAAGGAG Binds 57-75 n.t. upstream of the Hind III site 
on pYES2 (non-coding strand).
AggSeq! GCCT GTTT CTACT GT GGAAAT Binds 1068-1089 b.p. from the SAG1 start 
codon (crick strand).
3.3.2 Construction of the Fab light expression vector
A) Primer design
The oligonucleotide Agg(L/L) was designed to anneal to the 5' end of the 
human variable lambda light chain (DPL-3) and also encoded the a- 
agglutinin leader sequence (Figure 3.8). The oligonucleotide CL(FORX) was 
designed to bind to the 3' end of the human lambda constant region. To 
clone the amplified light chain A2 into the digested expression vector, 
pYX243-EcoR VNhe I, the primers Agg(l_/L) and CL(FORX) were designed 
with restriction sites, EcoR I and Xba I, respectively. The Nhe I recognition 
site could not be used because there was an unwanted Nhe I site in the 
lambda constant region. Therefore, the restriction site Xba I was recruited 
which produces compatible cohesive ends with Nhe I, when digested.
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Ligation of the Nhe I and Xba I cut sites removes both the recognition sites. 
Therefore to facilitate the removal and addition of the light chain gene 
segment, an Asc I recognition site was placed upstream from the Xba I site. 
Figure 3.9 details the design of the light A2 expression construct.
Figure 3.8 -  Flow diagram describing the construction of the Fab light expression vector, 
pYX-Light A2. The letters L, VL and CL depict the a-agglutinin leader sequence, variable 
















Figure 3.9 - Schematic representation of the light chain A2 construct including sequence details of the 5' and 3' ends. The restriction sites are 
represented in bold.
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B) PCR amplification of the Fab light chain A2
The Fab light chain gene segment was amplified by Expand™ PCR (Section 
2.2.7c) using the vector, pUC119His6mycXba FITC-A2 as a DNA template 
and the primer pair CL(FORX)/Agg(L/L) [Table 3.6]. The reaction conditions 
were: [(94°C, 1min; 55°C, 2min; 72°C, 1min) x25; 72°C, 10min] and the PCR 
product obtained was purified using the relevant DNA extraction kit (Section 
2.2.9b).
C) Construction of the vector, pYX-Light A2
The expression vector, pYX243 was digested with EcoR I (20units) and Nhe I 
(5units) overnight, at 37°C (Section 2.2.12). The digested pYX243-EcoR 
VNhe I vector (8.5k.b.p.) was resolved by low melting agarose gel 
electrophoresis (Section 2.2.8) and purified (Section 2.2.9b). The Fab light 
A2 PCR product was treated with restriction enzymes, EcoR I (20units) and 
Xba I (20units) overnight, at 37°C (Section 2.2.12) and the digestion buffers 
were removed (Section 2.2.9b).
The Fab light A2-EcoR I/Xba I insert was ligated into vector, pYX243- 
EcoR VNhe I (Section 2.2.13) and transformed in E. coli (Section 2.2.15). 
Ampicillin-resistant colonies were PCR screened (Section 2.2.16) using 
primers pYX(FOR2) and pYX(BACK2). Positive transformants were grown 
overnight in 3ml of LB (Section 2.2.1) and ‘minipreps’ were prepared (Section
2.2.17). Diagnostic restriction digestions with enzymes EcoR I (20units) and 
Asc I (10units) were performed on three positive colonies to check the light 
chain was present and glycerol stocks were made (Section 2.2.3). Primers 
pYX(FOR2), PYX(BACK2) and Cl.lib.seq were used to sequence the light 
chain (Table 3.6).
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Table 3.6 -  The sequences of primers used in the construction and verification of the light 
chain. Restriction endonuclease sites are in bold.
Primer Name Sequence (5-3') Description (5'-3')
CL(FORX) GCTCTAGAGGCGCGCCTTATTATGAACA
TTCTGT
2 n.t. overhang; a Xba  1 site; an Asc 1 site; 
18 n.t. of homology to the 3' end of human X 
constant region (non-coding strand).
Agg(LVL) CCGGAATTCATGTTCACI 1 1 1CTCAAAAT 
TATTCTGTGGCI I I I 1 1CCTTGGCATTGG  
CTAGCGCTCAGTCTGTGCTGACTCAG
3 n.t. overhang; an EcoR I site; 57 n.t. a - 
agglutinin signal sequence; 18 n.t. of 
homology to the 5' end of the human 
variable light chain, DPL-3 (coding strand).
PYX(FOR2) TGTATTACTTCTTATTCA Binds 76-94 b.p. upstream from the EcoR I 
site in pYX243 (coding strand).
PYX(BACK2) TTAATACTAGGAACAAGA Binds 35-53 b.p. downstream from Nhe I site 
in pYX243 (non-coding strand).
Cl.lib.seq GTGGCCTTGTTGGCTTGAAGC Binds to the lambda constant region 440- 
461 b.p. downstream from the start codon of 
construct Fab A2 light (non-coding strand).
3.3.3 Transformation of S. cerevisiae cells with pYES2-SAGf-Heavy A2 
and pYX-Light A2
Expression vectors, pYES2-SAG7-Heavy A2 (~2pg) and pYX-Light A2 (~2p 
g), were co-transformed (Section 2.2.22) into the S. cerevisiae strain, 
YMTAB. Leu+ Ura+ transformants were PCR screened (Section 2.2.16) for 
the presence of both plasmids in separate PCRs. The pYES2-SAG7-Heavy 
A2 expression vector was detected using primers pYX(FOR)/pYES(FOR2) 
and the pYX-Light A2 plasmid was identified using pYX(FOR2)/pYX(BACK2). 
Each PCR was analysed by agarose gel electrophoresis (Section 2.2.8) and 
positive transformants were grown in 1 ml of SC lacking uracil and leucine 
(supplemented with 2% raffinose) for 24 hours at 30°C (Section 2.2.2).
Chapter 3- Construction o f surface display vectors 88
Glycerol stocks were prepared (Section 2.2.3) and a 100pl aliquot of one 
culture was plated onto a SC agar plate containing 2% rafffinose but lacking 
uracil and leucine. This was used as a stock plate.
3.3.4 Construction of the scFv B7 expression vector
A) Primer design
The primer pairs, VH(B2)A/H(F) and VK(B)/VK(F/NT), were designed to 
amplify the human variable heavy (DP-67) and light (DPK-12) chains, 
respectively, from the vector pUC119His6mycXba-FITC B7 (Figure 3.10). 
The 5’ ends of oligonucleotides VH(F) and VK(B) were engineered to be 
complementary to each other and encoded for the 15 residue (Gly4Ser) 3  
linker. Hence, in a second PCR, the amplified variable regions can be joined 
together via a 'splicing by overlap extension’ reaction to create the single­
chain Fv B7. To facilitate cloning into the expression vector, pYES2-SAG1- 
Heavy A2, the primers VH(B2) and VK(F/NT) were designed to incorporate 
recognition sites, Msc I and Not I, respectively. The engineered Msc I site in 
the pYES2-S7\Gf-Heavy A2 expression vector is present four nucleotides 
upstream from the 5' Heavy chain/signal sequence junction. Therefore, 
primer VH(B2) was also synthesized to encode for the last two amino acids 
of the signal sequence. Using this cloning strategy allowed the removal of the 
heavy chain A2 gene segment and the in-frame replacement of the scFv B7 
gene. Figure 3.11 summarizes the scFv B7/a-agglutinin expression 
construct.
B) PCR amplification of the light and heavy variable regions of Fab FITC-B7. 
The human heavy (DP-67) and light (DPK-12) variable regions were 
amplified from vector pUC119His6mycXba- Fab FITC B7 in separate Expand 
PCRs (Section 2.2.7.C) using primer pairs VH(B2)/VH(F) and 
VK(B)/VK(F/NT), respectively (Table 3.7). The reaction conditions for the 
amplification of the heavy chain were: [(94°C, 1min; 55°C, 1min; 72°C, 1min) 
x 25; 65°C, 5min] and the cycling parameters for the light chain were the 
same, except the annealing temperature was 60°C.
Both amplified fragments were resolved by low-melting point agarose gel 
electrophoresis (Section 2.2.8) and purified (Section 2.2.9b).
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Figure 3.10 -  Flow diagram summarizing the construction of the scFv B7 expression vector, 
pYES2-S,AGf-scFv B7. The letters L, G, Xa and T represent the a-agglutinin leader 
sequence, (Gly4Ser)3 linker, the Factor Xa recognition site and a yeast terminator sequence, 
respectively. The symbols VL and VH depict the variable light gene segment (DPK-12) and 
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Figure 3.11 - Schematic representation of the single-chain Fv B7/a-agglutinin expression construct including sequence details of the 5' end. The 
DNA sequences encoding the (Gly4Ser)3linker and scFv B7/a-agglutinin junction are also described. Restriction sites are represented in bold.
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C) PCR assembly of the single-chain Fv B7
Approximately equal amounts (~50ng) of the light (DPK-12) and heavy (DP- 
67) variable regions were added together in a VentR PCR (Section 2.2.7a) 
with primer pair VH(B2)/VK(F/NT). The reaction was performed for 25 cycles 
using the following parameters: [(94°C, 1min; 65°C, 2min; 72°C, 1min) x 25; 
72°C, 10min]. The assembled product (767 b.p.) was separated from the 
other non-specific bands by low-melting point agarose gel electrophoresis 
(Section 2.2.8) and recovered using (3-agarase (Section 2.2.9a).
D) Construction of expression vector, pYES2-SAG1-scFv B7
The expression vector, pYES2-SAG7-Heavy A2 and the amplified scFv B7 
fragment were digested with Msc I (15units) and Not I (1 Ounits) overnight, at 
37°C (Section 2.2.12). The pYES2-SAG1-Msc VNot I was separated from the 
heavy A2 chain gene segment by low melting point agarose gel 
electrophoresis (Section 2.2.8) and purified (Section 2.2.9b). Additionally, the 
restriction buffers were removed from scFv B7-Msc VNot I using the 
appropriate DNA extraction kit (Section 2.2.9b). ScFv B7-Msc VNot I was 
ligated into pYE$2-SAG1-Msc VNot I (Section 2.2.13) and transformed into 
E. coli cells (Section 2.2.15). The ampicillin-resistant colonies were PCR 
screened (Section 2.2.16) using primers pYES(FOR2)/pYX(FOR) and 
conditions: [(94°C, 1min; 50°C, 1min; 72°C, 2min) x 25; 72°C, 10min]. 
Positive transformants were grown overnight in 3ml of LB (Section 2.2.1) and 
plasmid DNA was prepared from each culture (Section 2.2.17). Diagnostic 
restriction digests with Xba I (20units) and Hin6 III (1 Ounits) were performed 
and glycerol stocks were made (Section 2.2.3). DNA sequencing (Section
2.2.18) was performed using primers pYX(FOR) and AggSeql (Table 3.7).
3.3.5 Transformation of S. cerevisiae cells with pYES2-SAGf-scFv B7
The expression vector, pYES2-SAG7-scFv B7 was transformed into the 
protease-deficient S. cerevisiae strain, YMTAB (Section 2.2.22). Ura+ 
colonies were PCR screened with primers pYES2(FOR2) and pYX(FOR), 
using conditions: [(94°C, 1min; 50°C, 1min; 72°C, 2min) x 25; 72°C, 10min].
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Positive transformants were grown in 1 ml of SC containing 2% raffinose but 
lacking uracil for 24 hours (30°C; Section 2.2.2) Glycerol stocks were 
prepared (Section 2.2.3) and a 100pl aliquot was placed onto a SC without 
uracil/2%(w/v) raffinose agar plate (Section 2.2.2). Additionally, the pYES2 
expression vector was transformed into YMTAB for a negative expression 
control.
Table 3.7 -  Sequences of the oligonucleotides used in the construction of the scFv B7 
expression vector. Enzyme recognition sites are in bold and the sequence encoding the 
(Gly4Ser)3 linker is underlined .
Primer Name Sequence (5'-3') Description (5'-3')
VH(B2) CCCCCCTGGCCAGTGCTCAGGTGCAGC
TGCAGGAG
6 n.t. overhang; a  Msc 1 site; the last four 
n.t. of the a-agglutinin leader sequence; 18 
n.t. of homology to the 5' end of germline 
sequence, DP-67 (coding strand)
VH(F) AGAACCACCACCACCAGAACCACCACCA 
CCAGAACCACCACCACCACT CGAGACG  
GTGACCAG
45 n.t. encoding the (Gly4Ser)3 linker; 18 n.t. 
of homology to the 3' end of heavy variable 




45 n.t. encoding the (Gly4Ser)3 linker; 18 n.t. 
of homology to the 5' end of the variable 




10 n.t. overhang; a Not I site; 21 n.t. to the 
3' end of the variable kappa germline 
sequence, DPK12 (non-coding strand).
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3.4 RESULTS
3.4.1 Construction of the expression vector, pYES2-SAG1-Heavy A2
The construction of the heavy chain A2/a-agglutinin gene fusion was 
successfully achieved in two PCR steps.
In the first step, the anti-FITC Fab heavy chain A2, which consisted of 
the human variable germline sequence, DP-47 and the first human constant 
domain of the lgG1 molecule, was amplified from the E. coli expression 
vector, pUC119His6mycXba-FITC A2 (Griffiths e ta i, 1994). Additionally, the 
C-terminal anchorage domain of the a-agglutinin gene was amplified from 
plasmid pH27 (Lipke et al., 1989). The sizes of both the generated PCR 
fragments were determined by agarose gel electrophoresis (Figure 3.12) and 
were in agreement with the predicted theoretical sizes i.e. 749 b.p. for the 
heavy chain A2 and 986 b.p. for the a-agglutinin anchorage domain.
In the second PCR, these two fragments were linked together by a 
'splicing by overlap extension' reaction and the heavy chain A2/a-agglutinin 
gene fusion was created (Figure 3.12). The expression vector, pYES2 and 
the gene fusion, heavy chain A2/a-agglutinin, were digested with H/nd III and 
Xba I and ligated together. Transformation of the construct produced several 
hundred plaques and ten of these were PCR screened for the heavy/a- 
agglutinin insert.
Eight transformants were found to be positive and DNA sequencing of 
this final pYES2-SAG7-Heavy A2 vector confirmed an in-frame fusion 
between the a-agglutinin signal sequence, heavy chain A2 gene segment 
and the 3' half of the a-agglutinin gene had been created (Figure 3.7). Three 
heavy chain expression vectors were sequenced and all contained a 
nucleotide change in the first lgG1 constant domain. This nucleotide change 
converted an asparagine amino acid to a lysine residue at amino acid 
position 225 of the heavy chain A2 /a-agglutinin fusion (Figure 3.13) and was 
considered not to be an error that occurred during the polymerase chain 
reaction because it was present in all of the constructs.
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1 2 3 4 5
Figure 3.12 - A 1% agarose gel showing the various fragments used in the construction of 
the expression vectors, pYES2-SAGf-Heavy A2 and pYX-Light A2. Lane 1, 1 k.b.p. DNA 
marker; Lane 2, Fab light chain A2 (736 b.p.); Lane 3, Fab heavy chain A2 (749 b.p.); Lane 
4, a-agglutinin anchorage domain (986 b.p.); Lane 5, Heavy chain A2 -S A G 1  gene fusion 
(1716 b.p.).
2 2 5
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Figure 3.13 -  The nucleotide change (amino acid position 225) found in the lgG1 constant 
region of the heavy chain A2/a-agglutinin gene construct when compared to the published 
human lgG1 constant sequence (Kabat e t  a t., 1991). The numbering of the amino acids 
refers to the complete heavy A2/a-agglutinin fusion as indicated in Figure 3.7.
3.4.2 Construction of the light chain expression vector, pYX-Light A2
The anti-FITC Fab light chain A2 which consisted of the human variable 
germline sequence, DPL-3, and the lambda constant domain was amplified 
from vector, pUC119His6mycXba-FITC A2. A single PCR product of
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approximately 750 b.p. was obtained (Figure 3.12) and digested with 
enzymes, EcoR I and Xba I. The EcoR VXba I digested light chain was 
cloned into the yeast expression vector, pYX243-EcoR L7V/?e I due to the 
compatible cohesive ends of restriction sites, Nhe I and Xba I. 
Transformation of the construct produced several hundred plaques and ten of 
these were PCR screened for the light chain insert. Four were found to be 
positive and this result was confirmed by digestion with enzymes, Asc I and 
EcoR I. DNA sequencing of the construct revealed the a-agglutinin signal 
sequence was attached correctly to the light chain gene segment (Figure 
3.9). Two nucleotides in the light chain A2 construct differed from the 
published sequence at amino acid positions 122 (G122E) and 212 [R212K 
(Figure 3.14)]. These were presumed not to be errors that occurred during 
the amplification process due to the fact they were present in all of the 
constructs sequenced.
Figure 3.14 -  The nucleotide changes (amino acid positions 122 and 212) discovered during 
DNA sequencing of the light chain A2 gene fusion. Numbering of the amino adds refers to 
the total light A2 construct as shown in Figure 3.9.
122
V K











3.4.3 Co-transformation of pYX-light A2 and pYES2-SAG7-Heavy A2
The anti-FITC Fab expression vectors, pYX-light A2 and pYES2-SAG1 
Heavy A2, were co-transformed into the protease-deficient S. cerevisiae 
strain, YMTAB. Approximately two hundred colonies were obtained for this 
transformation and ten were PCR screened to check both plasmids were 
present.
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3.4.4 Construction of the pYES2-SAG‘/-scFv B7 expression vector
The human heavy (DP-67) and light (DPK-12) variable regions were 
amplified from vector, pUC119His6mycXba-FITC B7. The sizes of both the 
generated PCR fragments were determined by agarose gel electrophoresis 
(Figure 3.15) and were in good agreement with the predicted theoretical 
sizes i.e. 413 b.p. for the human variable heavy chain (DP-67) and 399 b.p. 
for the human variable light chain (DPK-12).
The 3' end of the variable heavy chain and the 5’ end of the variable 
light chain were complementary to each other and encoded a (Gly4Ser)3 
linker. Therefore, in a second PCR step, the heavy and light chains were 
joined together by a 'splicing by overlap extension' reaction to create the 
single-chain Fv B7 (Figure 3.15).
Figure 3.15 -  A 1.5% agarose gel showing the construction of the single chain Fv B7. Lane 
1, 100b.p. DNA marker; Lane 2, variable heavy chain (413 b.p.); Lane 3, variable light chain 
(399 b.p.); Lane 4, single chain Fv (767 b.p.).
Digestion of the pYES2-SAGf-Heavy A2 expression vector with Msc I 
and Not I removed the heavy chain gene segment. The digested scF\t-Msc 
\/Not I fragment was then inserted into this digested expression vector to 
create the pYES2-SAGf-scFv B7 construct. This was transformed into E. coli 
and twelve ampicillin-resistant colonies were PCR screened. All twelve 
colonies contained the scFv B7 insert and DNA sequencing confirmed the a- 
agglutinin leader sequence and anchorage domain flanked the anti-FITC 
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(Figure 3.16), differed from the published sequence in the variable heavy 
region (DP-67) in all five of the constructs sequenced. This change converted 
a proline to a serine amino acid (P81S) in the CDR2.
The pYES2-SAG1-scFv B7 expression vector was transformed into the 
protease-deficient S. cerevisiae strain, YMTAB. Ten colonies were screened 
from this transformation to confirm the plasmid was present.
Figure 3.16 -  The nucleotide change (amino acid position) found in the variable heavy chain 
sequence (DP-67) of the scFv B7 gene. Amino acid • numbering refers to the scFv B7/a- 
agglutinin construct as shown in Figure 3.11.
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Both the heavy and light chain surface display vectors, pYES2-SAGf-Heavy 
A2 and pYX-Light A2, respectively, were successfully constructed for the 
expression of the anti-fluorescein-5-isothiocyanate (FITC) Fab antibody 
fragment on the surface of S. cerevisiae.
The heavy chain surface display vector was constructed by separately 
amplifying the heavy chain gene segment and the 3’ half of the a-agglutinin 
gene and fusing these two fragments together using a 'splicing by overlap 
extension' reaction (Figure 3.6). An a-agglutinin signal sequence was 
attached to the 5' terminus of both the heavy (DP-47 gene segment + first 
human IgG constant heavy region) and light (DPL-3 + human lambda 
constant region) chains, to target expression to the secretory pathway 
(Figure 1.9; Section 1.6.2). The light and heavy chain constructs were cloned 
into separate expression vectors (Sections 3.4.1 and 3.4.2) containing the
S L K 
TCC CTC AAG
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same inducible promoter, GAL1. The two expression vectors used, pYX243 
and pYES2, contained different yeast auxotrophic markers, therefore were 
co-transformed in the relevant S. cerevisiae strain for expression. The S. 
cerevisiae strain used was deficient in two of the major vacuolar proteases 
(prA and prB). The proteolysis problem associated with cell breakage in 
yeast (Jones, 1991) should be overcome using this strain and theoretically 
will help in the protein analysis of cell wall extracts.
It was presumed, after induction with galactose, that the heavy and 
light chains would be simultaneously expressed through the secretory 
pathway and form functional Fab fragments in the endoplasmic reticulum. 
Hopefully, the Fab antibody fragment would then be transported through the 
rest of the secretory pathway to the cell surface where the a-agglutinin 
anchorage domain, which is attached to the C-terminus of the heavy chain, 
would become covalently associated to the p-glucan component of the cell 
wall. This attachment should lead to the surface display of the anti-FITC Fab 
fragments. Functional Fab fragments have been secreted into the yeast 
culture supernatant after simultaneously expression of the light and heavy 
chains from different expression vectors, therefore this strategy should be 
plausible (Horwitz et al.t 1988). Interestingly, the display of Fab fragments on 
the surface of phage utilizes the minor phage coat protein in a similar way 
(Section 1.4.4; Hoogenboom et al., 1991).
A Factor Xa cleavage site was placed between the heavy chain gene 
segment and the a-agglutinin anchorage domain to assist in detachment of 
the Fab molecules from the yeast cell surface. Detachment may ease the 
characterization and purification of the antibody fragments. This part of the 
strategy is intended to mimic the soluble antibody producing properties of 
plasma B-cells.
The successful construction of the anti-FITC scFv surface display 
construct, pYES2-SAGf-scFv B7, was aided by the careful design of the 
heavy chain expression vector. It was speculated that expression of the 
functional scFv antibody fragment on the surface of yeast might be more 
successful than the Fab fragment. The reasoning for this speculation was 
that the variable heavy and light chains of the scFv molecule would be
Chapter 3- Construction o f surface display vectors 99
expressed in eqimolar concentrations and would not rely on non-covalent 
association of the individually expressed light and heavy chains in the 
endoplasmic reticulum to assemble a functional antibody fragment.
The joining of the amplified variable heavy (DP-67) and light (DPK-12) 
chains using a 'splicing by overlap extension' reaction created the anti-FITC 
scFv B7 antibody fragment (Section 3.4.4). The complementary 
oligonucleotides used in this 'splicing by overlap extension' reaction encoded 
for a (Gly4 Ser) 3  linker (Huston et a/., 1988; Section 1.4.3). This linker should 
be sufficiently long and flexible enough to span the distance between the 
variable domains and allow the formation of the antigen-combining site. In 
this project, the linker fused the C-terminus of the variable heavy chain to the 
N-terminus of the variable light chain. This orientation should not affect the 
binding constant of the single chain Fv for the fluorescent antigen, FITC (Bird 
and Walker, 1991) and hopefully an affinity comparable with the anti-FITC 
Fab B7 (Ka = 6.6 x 106 M'1) should be achieved.
In the heavy chain construct, two unique restriction sites were 
designed at the 3' ends of the a-agglutinin signal sequence and heavy chain. 
These restriction sites were used to replace the heavy chain with the single 
chain Fv construct. Therefore, the created anti-FITC scFv B7 gene was 
flanked by the a-agglutinin signal sequence and 3’ half of the a-agglutinin 
gene, downstream from the inducible GAL1 promoter. The engineered 
pYES2-SAGf-scFv B7 expression vector contains the correct molecular 
information to over-express the scFv antibody fragments on the surface of S. 
cerevisiae.
DNA sequencing of all three constructs revealed the germline 
segments differed by one to two nucleotides from the published sequences 
(Kabat et al., 1991). It was presumed that these nucleotide changes were not 
errors that had occurred during the amplification process because they were 
present in all constructs sequenced. Therefore, these nucleotide changes 
must have been present in the supplied E. coli expression vectors, 
pUC119His6mycXba-FITC B7 and pUC119His6mycXba-FITC A2. The 
reasons why these changes were present could be numerous. They may 
have been introduced in previous polymerase chain reaction experiments
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(Griffiths et al., 1994). Alternatively, they may be due to polymorphisms or 
allelic variations between unrelated individuals. In the next chapter, both the 
anti-FITC Fab constructs (A2 and B7) were expressed in E. coli to check if 
they had retained their affinity for the fluorescent antigen, FITC (Section 
4.4.1).
Conclusions
The aims of this Chapter were achieved, mainly due to the careful design of 
the oligonucleotides used in the construction of the three expression vectors. 
Both the pYES2-SAGf-Heavy A2 and the pYX-Light A2 expression vectors 
were constructed for the over-expression of the anti-FITC Fab antibody 
fragment on the surface of yeast. Additionally the display vector, pYES2- 
SAGf-scFv B7, was assembled for surface expression of the anti-FITC scFv 
antibody fragment. Expression of these constructs on the surface of S. 
cerevisiae is described in Chapter 4.
101
CHAPTER 4
EXPRESSION OF ANTIBODY FRAGMENTS ON THE
SURFACE OF YEAST
4.1 INTRODUCTION
The preceding chapter described the construction of the expression vectors 
required for the display of the anti-FITC Fab A2 antibody fragment on the 
surface of S. cerevisiae. Additionally, the anti-FITC single chain Fv 
expression vector, pYES2-SAG7-scFv B7, was created. These constructs 
comprised of the appropriate antibody DNA flanked by the a-agglutinin signal 
sequence and the C-terminal half of the a-agglutinin gene, all under the 
control of the inducible GAL1 promoter (Figure 3.3). After induction with 
galactose, it is presumed the a-agglutinin leader sequence will target 
expression to the secretory pathway (Section 1.6.2) and the C-terminal a- 
agglutinin anchorage domain will covalently attach the antibody fragment to 
the glucan component of the cell wall. (Section 1.7). The 5' binding domain of 
the a-agglutinin gene is replaced by the antibody DNA, therefore once 
expressed, the antibody fragments should be exposed on the exterior 
surface of the cell wall.
This chapter investigates the individual expression of the anti-FITC 
Fab and scFv antibody fragments on the surface of S. cerevisiae. Schreuder 
and co-workers (1993) showed that non-covalently attached proteins were 
released by incubation with hot sodium dodecyl sulphate (SDS). After SDS 
treatment, proteins attached to the glucan component of the cell wall can be 
liberated by enzymatic digestion with glucanase. This approach was 
recruited in this project to determine if the antibody-agglutinin protein fusions 
were covalently attached to the cell wall’s glucan.
Expression of the antibody fragments on the surface of S. cerevisiae 
cells was investigated using antibody detection methods such as enzyme
Chapter 4 -Surface expression of antibody fragments 102
immunoassays (Wojciechowicz and Lipke, 1989) and indirect 
immunofluoresence (Schreuder et al., 1993). Antibodies cannot penetrate 
the yeast cell wall (Pringle et al., 1991), therefore these experiments should 
determine if the antibody fragments are on the exterior surface of S. 
cerevisiae and are accessible to macromolecules. Finally, the functionality of 
the antibody fragments on the surface of S. cerevisiae was examined using 
the fluorescence antigen, fluorescein-5-isothiocyanate (FITC).
Glycosylation can affect both the molecular weight and detection 
levels of the antibody-agglutinin fusions therefore the glycosylation process 
in yeast is reviewed below:
4.1.1 The glycosylation process
Proteins can be modified in various ways during their passage through the 
secretory pathway (Section 1.6.2). The addition of carbohydrates to the 
protein backbone (glycosylation) first begins in the endoplasmic reticulum 
(Romanos et al., 1992). A core oligosaccharide unit comprising of two N- 
acetyl-glucosamine, nine mannose and three glucose residues are added to 
asparagine residues (N-glycosylation) in the Asn-Xxx-Ser/Thr consensus 
sequence. The glucose residues are subsequently trimmed from the unit 
and one mannose residue is removed. This core N-glycosylation step is 
common to yeast, plants and higher eukaryotes.
Modification of the core oligosaccharide unit takes place in the Golgi 
apparatus and at this stage there is divergence between the glycosylation 
process in yeast and other eukaryotes. In S. cerevisiae, the mannose 
residues are not trimmed back as in higher eukaryotes and instead up to 75 
residues can be added to the core oligosaccharide unit. This process is 
known as hyperglycosylation and gives rise to very heterogenous proteins 
with varying degrees of oligosaccharide attachment.
Additionally, oiligosaccharides can be O-linked to serine and threonine 
residues in the endoplasmic reticulum (O-glycosylation). Extension of 0 - 
linked chains up to a final length of five mannose residues takes place in the 
Golgi. Despite extensive research, no clear rules have emerged about how
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the cells select the serine and threonine residues for O- glycosylation (Orlean 
et al. , 1991).
The C-terminal a-agglutinin anchorage domain is very rich in serine 
and threonine residues and contains seven potential N-glycosylation sites 
(Hauser and Tanner, 1989). Both N- and O-linked oligosaccharides are 
attached to the mature cell wall form of the aggiutinin molecule (Lu et al., 
1994). Hence, glycosylation of the antibody-agglutinin protein fusions will 




The protease inhibitors antipain, chymostatin, and pepstatin were purchased 
from Sigma. Additionally, lyticase, o-nitrophenyl-p-D-galactopyranoside 
(ONPG), raffinose, galactose, albumin bovine-fluorescein-5-isothiocyanate 
(FITC-BSA) and 0.2p glass beads were all obtained from Sigma (Product 
numbers -  L5763, N1127, R0514, G0750, A9771 and G1145, respectively). 
Phenylmethylsulphonyl fluoride (PMSF) and leupeptin were supplied by 
Boehringer Mannheim. Factor Xa protease was purchased from New 
England Biolabs and mounting medium was obtained from Cityfluor (Code 
No. - R1320). The concentrators, Centriprep® 10 and Microcon® 10, were 
purchased from Amicon, Beverly, USA.
4.3 METHODS
4.3.1 Expression and functional detection of anti-FITC A2 and B7 Fab 
fragments in E. coli (EMBO practical course, 1991)
Two individual TG1 E. coli colonies carrying either expression vector 
pUC119His6mycXba-FITC A2 or pUC119His6mycXba-FITC B7 were picked 
from an LB plate (supplemented with 100jag/ml ampicillin). The colonies were 
resuspended in wells (using a 96-well plate, Nuclon) containing 200jxl of XL-
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media (16g/l Bacto-tryptone, 16g/l Bacto-yeast extract, 5g/l soduim chloride), 
100 pg/ml ampicillin and 1% (w/v) glucose. These cultures were grown 
overnight (300 r.p.m.) at 37°C and .10^ 1 of each overnight culture was 
transferred to a second 96-well plate containing 200jil of XL-media, 0.1% 
(w/v) glucose and 100pg/ml ampicillin, per well. The new cultures were 
grown at 37°C until an absorbance (at 600nm) of 0.9 was reached. Twenty- 
five microlitres of XL-media supplemented with 9mM isopropyl- 
thiogalactoside (IPTG) and 100pg/ml ampicillin was added to each well and 
incubated at 30°C for an additional 24 hours. After this time, the cultures 
were centifuged at 3000 r.p.m. (1500g) for 10 minutes using a GLC4 general 
laboratory centifuge. Each of the culture supernatants (1 OOjal) was analysed 
for functional anti-FITC Fab fragments using an ELISA (Section 2.3.4). The 
supernatant from a TG1 wild type strain culture was used throughout the 
ELISA as a negative control.
A solution of albumin bovine-fluorescein-5-isothiocyanate (FITC-BSA) 
at a concentration of 1.5 x 10'6 M was used to coat the wells of the ELISA 
plate. Three different sets of antibodies were individually used to analyse the 
culture supernatant. Firstly, a primary polyclonal antibody serum specific for 
human lgG1 Fab fragments (goat anti-human IgG Fab; Table 2.1) was used 
to analyse both the Fab A2 and B7 culture supernatants. A complementary 
horseradish-peroxidase conjugated rabbit anti-goat IgG secondary antibody 
(Table 2.2) was used for detection.
The second type of antibody used was specific for human kappa light 
chains (rabbit anti-human kappa light chain; Table 2.1) and was utilised to 
detect the Fab B7 fragment that contains the human variable (DPK-12) and 
constant kappa light chain. Binding of this primary antibody was detected 
using a horseradish peroxidase conjugated goat anti-rabbit IgG secondary 
antibody (Table 2.2). The third type of antibody was specific for human 
lambda light chains (mouse anti-human lambda light; Table 2.1) and was 
recruited to detect the Fab A2 antibody fragment that comprises of a human 
lambda variable (DPL-3) and constant light chain. This primary antibody was 
detected using the secondary horseradish peroxidase conjugated goat anti­
mouse IgG antibody (Table 2.2)
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Periplasmic lysate preparation
Periplasmic lysates from E. coli cells expressing either the anti-FITC Fab A2 
or B7 antibody fragments were prepared for positive controls in Western 
blotting analysis (Section 2.3.3).
Two individual TG1 E. coli colonies, carrying either expression vector 
pUC119His6mycXba-FITC A2 or pUC119His6mycXba-FITC B7 were picked 
from a LB plate (supplemented with 100pg/ml ampicillin). These colonies 
were grown overnight at 37°C in 50ml of XL-media supplemented with 100p 
g/ml ampicillin and 0.1% (w/v) glucose. After this time, isopropyl- 
thiogalactosidase (IPTG) was added to a final concentration of 1mM and the 
cultures were incubated at 26°C for a further 3 hours. The cells were then 
collected by centrifugation (4°C) at 8000g for 10 minutes using an IRC-5B 
refrigerated superspeed centrifuge (Sorvall). The cells were resuspended in 
10ml of lysis buffer [30mM Tris-HCI, pH 8.0, 1mM EDTA, 20% (w/v) sucrose] 
and shaken for 10 minutes at room temperature. The centrifugation step was 
repeated and the cells were resuspended in 10ml of 5mM magnesium 
sulphate. This cell mixture was agitated at 4°C for 10 minutes and the 
centrifugation step was repeated. The supernatant (periplasmic lysate) was 
decanted and stored at -20°C until required.
4.3.2 Optimising galactose induction time using a p-galactosidase
assay (Adams ef a/., 1996)
The supplied control plasmid, pYX243-lacZ (R+D systems) was transformed 
into S. cerevisiae strain, YMTAB (Section 2.2.22). Leu+ colonies were PCR 
screened (Section 2.2.16) using primers pYX(FOR2) and pYX(BACK2) and 
the PCR products were analysed by agarose gel electrophoresis (Section 
2.2.8).
A single positive colony was transferred from a SC agar plate lacking 
leucine [supplemented with 2% (w/v) raffinose] into one millilitre of SC 
medium without leucine/2% (w/v) raffinose. The culture was grown for 24 
hours (250 r.p.m.) at 30°C, counted using a haemocytometer and diluted in 
the same medium to 3-5 x 106 cells/ml. Galactose was added to a final 
concentration of 2% (w/v) and the culture was incubated (250 r.p.m.) at 30°C
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Approximately 1 x 106 to 1 x 107 cells were taken from the culture directly 
after galactose induction and every 1.5-2 hours thereafter. An absorbance 
reading (at 600nm) was recorded for each culture fraction directly after 
sampling and the cells were harvested (4°C) at 2000 r.p.m. for 5 minutes. 
The cells were resuspended in 1ml of ice-cold Z buffer, pH 7.0 [58mM 
Na2HP04.7H20, 38mM NaH2P04.H20, 10mM KCI, 1mM MgS04.7H20, 0.27% 
(w/v) p-mercaptoethanol]. Three drops of chloroform and two drops of 0.1% 
(w/v) sodium dodecyl sulphate (SDS) were added and the mixture was 
vortexed vigorously for 10 seconds. The sample was then incubated at 28°C 
for 5 minutes. A 4mg/ml solution of o-nitrophenyl-p-D-galactoside (ONPG) in 
ice-cold Z buffer was prepared and 0.2ml of this ONPG solution was added 
to each sample. When a pale yellow colour developed, the reaction was 
stopped with 0.5ml of 1M sodium carbonate. The time of the reaction was 
measured from the addition of the substrate, ONPG, to termination with 
sodium carbonate. An absorbance (at 420nm) was measured for each 
sample tested and p-galactosidase activity was calculated using the 
following equation.
p-galactosidase units = Abs
Abs^ x volume x time
Abs420 = absorbance (at 420nm) of the reaction product, o-nitrophenol. 
Abs600= absorbance (at 600nm) of the culture at the time of the assay. 
Volume = amount of the culture used in the assay.
Time = time of the reaction in minutes.
4.3.3 Galactose induction of antibody fragments onto the surface of 
S. cerevisiae
All surface expression experiments in this chapter were induced with 
galactose using the following method:
A single colony containing the relevant expression vectors was grown 
for 24 hours at 30°C in 1ml of selective medium lacking the appropriate 
amino acids for maintenance of the plasmids* and supplemented with 2%
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(w/v) raffinose. The cells were counted using a haemocytometer and diluted 
to 5 x 106 cells/ml (early exponential phase) in the correct selective medium 
containing 2% (w/v) raffinose. Galactose was added to a final concentration 
of 2% (w/v) and the cultures were grown for 24 hours at 30°C. 
a = S. cerevisiae strain, YMTAB containing the anti-FITC Fab expression 
vectors, pYX-Light A2 and pYES2-SAGf-Heavy A2, was grown in SC media 
lacking uracil and leucine. The YMTAB strain carrying the anti-FITC scFv 
surface display construct, pYES2-SAGf-scFv B7, was grown in SC media 
without uracil.
4.3.4 Isolation and SDS-extraction of cell walls (Schreuder et a/., 1993)
A) Cell wall isolation
After galactose induction, the cells were collected for 2 minutes at 3000 
r.p.m. (1500g) using a Sorvall GLC-4 general laboratory centrifuge. The cells 
were washed three times in ice-cold isolation buffer (10mM Tris-HCI, pH7.8, 
1mM PMSF) and all subsequent steps were performed at 4°C. Three 
millilitres of isolation buffer and 10g of acid-washed acid beads (diameter - 
0.2pM) were added to one gram of cells (fresh weight). The mixture was 
shaken vigorously on a horizontally rotating platform (ELISA plate shaker, 
Labline instruments Inc.) at 500 r.p.m. for 30 minutes. The supernatant was 
isolated and the glass beads were washed with 1M NaCI and 1 mM PMSF, 
until the washes were clear. The supernatant and the glass bead washes 
were pooled and the cell walls were recovered by centrifugation for 5 minutes 
at 2445 r.p.m. (1000g) using a Sorvall GLC-4 general laboratory centifuge. 
The cell walls were then washed three times with 1 mM PMSF and stored at - 
20°C.
B) SDS-extraction
Non-covalently bound proteins or proteins bound through disulphide 
bridges can be released from the cell walls by boiling in sodium dodecyl 
sulphate (SDS). The isolated cell walls were weighed into a 1.5ml Eppendorf 
tube and the weight was recorded. SDS-extraction buffer [50mM Tris-HCI, pH 
7.8, 2% (w/v) SDS, 100mM EDTA, 40mM p-mercaptoethanol] was added to
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the cell walls at a ratio of 2 : 1 (SDS-extraction buffer: cell walls). The cell 
walls were boiled for 5 minutes at 100°C and the supernatant containing the 
SDS-extractable material was collected by centrifugation at 13000 r.p.m. for 
5 minutes. The supernatant (20pl) was resolved by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE; Section 2.3.1) and analysed 
by Western blotting (Section 2.3.3) using the appropriate sets of antibodies. 
Note -  This procedure was repeated until all the SDS-extractable material 
had been removed from the cell walls.
4.3.5 Identification of the individual light and heavy Fab chains in the 
SDS-extractable supernatant
After galactose induction (Section 4.3.3), cell walls were isolated (Section 
4.3.4a) from an S. cerevisiae culture theoretically expressing the anti-FITC 
Fab fragments on its surfaces. The isolated cell wall fraction was treated with 
hot SDS (Section 4.3.4b) and analysed for the individual light and heavy Fab 
chains by Western blotting (Section 2.3.3). Three sets of antibodies were 
used:
1) A polyclonal antibody serum that was specific for all human lgG1 Fab 
fragments (Goat anti-human Fab IgG; Table 2.1) followed by a 
horseradish peroxidase conjugated rabbit anti-goat IgG secondary 
antibody (Table 2.2) for detection.
2) A monoclonal primary antibody, which was specific for human lambda 
light chains (Mouse anti-human lambda light specific; Table 2.1), and a 
complementary secondary horseradish peroxidase conjugated goat anti 
mouse IgG antibody (Table 2.2) for detection.
3) A primary antibody specific for human heavy chains (rabbit anti-human 
gamma chain specific; Table 2.1) followed by the secondary peroxidase 
conjugated goat anti-rabbit IgG antibody (Table 2.2) for detection.
All western blots were run with the SDS-extracted material from a wild type 
YMTAB culture for a negative control.
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4.3.6 Detection of the individual light and heavy Fab chains on the 
surface of S. cerevisiae
The S. cerevisiae strain, YMTAB carrying the anti-FITC Fab A2 expression 
vectors, pYX-Light A2 and pYES2-SAGf-Heavy A2, was induced for 24 
hours with galactose (Section 4.3.3) The heavy and light chains were 
individually detected on the surface of yeast using two different enzyme 
immunoassays (Section 2.3.5). The Fab A2 light chain was detected on the 
surface using an antibody specific for human lambda light chains. An 
antibody specific for human heavy chains was recruited to detect for surface 
display of the Fab A2 heavy chain. The details of both sets of antibodies 
used are described in Section 4.3.5. Each enzyme immunoassay was 
performed three times on the same induced culture and the wild type strain 
(YMTAB) was used as a negative control.
4.3.7 Confirming covalent attachment of the scFv B7 to the p-glucan 
component of the cell wall
The S. cerevisiae strain, YMTAB harbouring the anti-FITC scFv B7 
expression vector, pYES2-SAGf-scFv B7 was induced with galactose for 24 
hours (Section 4.3.3). After this time, the cell walls were isolated and treated 
with SDS-extraction buffer (Section 4.3.4). The SDS-extraction procedure 
was continued until all the non-covalently bound material was released. 
Twenty microlitres of each of the SDS-extractable fractions were analysed for 
scFv B7 expression via Western blotting (Section 2.3.3) using the primary 
antibody specific for human kappa light chains (rabbit anti-human kappa light; 
Table 2.1). The secondary antibody, horseradish peroxidase conjugated goat 
anti-rabbit IgG was used for detection (Table 2.2).
After all the SDS-extractable material was removed from the cell walls, 
they were treated with lyticase (a mollusc J3-1,6-glucanase) to confirm the 
scFv B7 antibody fragment was covalently attached to the p-glucan cell wall 
component. Firstly, the SDS-treated cell walls were washed copious times 
with 1mM phenylmethylsulphonyl fluoride (PMSF) to remove the unwanted 
SDS. Forty milligrams of cell wall (wet weight) was resuspended in 40pl of 
lyticase solution (1.2M sorbitol, 1M sodium phosphate, 3000 units/ml
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lyticase). Protease inhibitors pepstatin, antipain, chymostatin and leupeptin 
were added to the mixture at a final concentration of 30pg/ml. Also, PMSF 
and EDTA were added to a final concentration of 1mM. The reaction was 
then mixed gently and incubated with rotation overnight at room temperature. 
The supernatant, which contained the glucanase extractable material, was 
collected by centrifugation at 13000 r.p.m. for 5 minutes. Twenty microlitres 
of the supernatant was resolved by SDS-PAGE (Section 2.3.1) and analysed 
by Western blotting (Section 2.3.3). The primary antibody specific for the 
human kappa light chain (Rabbit anti-human kappa light; Table 2.1) followed 
by the complementary horseradish peroxidase conjugated goat anti-rabbit 
IgG secondary antibody (Table 2.2). The SDS-treated cell walls from the wild 
type strain (YMTAB) were incubated with lyticase and analysed by Western 
blotting for a negative control.
Note -  The activity of the lyticase solution was analysed by incubating intact 
yeast cells in the solution and checking for cell lysis using phase contrast 
microscopy.
4.3.8 Verification of surface expression of the scFv B7 antibody 
fragment using an enzyme immunoassay
The S. cerevisiae strain, YMTAB carrying the anti-FITC scFv expression 
vector, pYES2-SAGf-scFv B7 was induced with galactose for 24 hours 
(Section 4.3.3). The yeast cells were analysed for surface expression of the 
scFv using an enzyme immunoassay (Section 2.3.5). The antibodies used for 
detection were the rabbit anti-human kappa chain specific primary antibody 
(Table 2.1) followed by a horseradish peroxidase conjugated goat anti-rabbit 
IgG secondary antibody (Table 2.2). The wild type strain (YMTAB) 
transformed with the expression vector, pYES2 was used throughout as a 
negative control.
4.3.9 Treatment with Factor Xa
After galactose induction, 2 x 107 cells expressing the scFv B7 antibody 
fragment of their surfaces were washed three times in PBS. The cells were 
collected by centrifugation at 13000 r.p.m. for 2 minutes and resuspended in
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50pl of Factor Xa buffer, pH 8.0 (20mM Tris-HCI, 100mM NaCI, 2mM CaCI2). 
One microgram of the Factor Xa protease and calcium chloride to a final 
concentration of 2.5mM (Wrighton et a/., 1996) were added to the cell 
suspension. Additionally, a second reaction without any Factor Xa protease 
was set up and ran concurrently as a control. All reactions were incubated 
with rotation for 24 hours at room temperature and analysed for scFv 
expression using an enzyme immunoassay (Section 2.3.5). The antibodies 
using for detection were identical to Section 4.3.8 and cycloheximide at a 
concentration of 10pg/ml was present in all solutions throughout the 
treatment and analysis of the Factor Xa experiment.
4.3.10 Indirect immunofluorescence
The YMTAB strain harbouring the anti-FITC single chain Fv expression 
vector, pYES2-SAGf-scFv B7 was induced for 24 hours with galactose 
(Section 4.3.3). The enzyme immunoassay protocol (Section 2.3.5) was then 
carried out on these cells, except instead of detecting specific binding using 
the chromogenic substrate, 3, 3’, 5, 5-tetramethylbenzidine (TMB), the cells 
were viewed under an epi-fluorescence microscope. Firstly, the cells were 
incubated with the primary antibody specific for human kappa light chains 
(rabbit anti-human kappa; Table 2.1) followed by the FITC-conjugated goat 
anti-rabbit IgG secondary antibody (Table 2.2). After treatment with the 
secondary antibody, the cell pellet was resuspended in 50 pi of mounting 
medium that contained the anti-bleaching agent, p-phenylenediamine. The 
cells were then viewed under a Leica DMRB epi-fluorescence microscope 
using the appropriate filter block (490-495nm). Photographs were taken at a 
magnification of x400 using a Leica MP548 automatic exposure meter and 
Kodak Ektachrome 400 film.
Note: A YMTAB strain carrying the control plasmid, pYES2 was prepared as 
a negative control.
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4.3.11 Functional identification of the anti-FITC antibody fragments on 
the surface of S. cerevisiae
After galactose induction (Section 4.3.3), approximately 2 x 107 cells 
expressing antibody fragments (scfv or Fab) on their cell surfaces were 
washed three times with PBS. Fifty microlitres of 0.2pM filtered FITC-BSA at 
a concentration of 1.5 x lO^M was added to the cell pellet. The pellet was 
then gently resuspended in the antigen and incubated for 1 hour at room 
temperature on a vertically rotating platform. All samples were kept in the 
dark (wrapped in aluminium foil) for this incubation time. The cells were then 
collected by centrifugation at 13000 r.p.m. for 30 seconds and the cell pellet 
was washed five times with PBS. The cells were then resuspended in a 
100pl of mounting medium containing the anti-bleaching agent p- 
phenylenediamine. The cells were then viewed under an Olympus BH2 epi- 
fluorescence microscope using the appropriate filter block (490-495nm). 
Photographs were taken using at a magnification of x400 using an automatic 
exposure meter and Kodak Ektachrome 400 film.
Note: A YMTAB strain carrying the control plasmid, pYES2 was prepared as 
a negative control.
4.4 RESULTS
4.4.1 Functional expression of anti-FITC Fab fragments A2 and B7 in 
E. coli
E. coli cells containing either vector pUC119His6mycXba-FITC A2 or 
pUC119His6mycXba-FITC B7 were shown to be expressing functional Fab 
fragments into their culture supernatant after an induction time of 24 hours 
(Table 4.1). The supernatant of a wild type E. coli culture displayed no 
fluorescein-5-isothiocyanate binding activity.
The three sets of antibodies used to detect antibody fragments on the 
surface of S. cerevisiae were analysed to confirm their specificity. As 
expected, the polyclonal antibody specific for human IgG Fab antibody 
fragments bound precisely to the anti-FITC Fab fragments, B7 and A2. The 
light chain of the anti-FITC Fab A2 antibody fragment comprised of the
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human variable (DPL-3) and constant lambda domains. Therefore, the 
monoclonal antibody raised against the human lambda light chain was shown 
to bind specifically to the anti-FITC Fab A2 antibody fragment only. 
Additionally, the polyclonal antibody specific for the human kappa light chains 
bound exclusively to the anti-FITC Fab B7 antibody fragments due to the fact 
its light chain consisted of the human variable (DPK-12) and constant kappa 
segments.
Table 4.1 - ELISA results obtained from the supernatants of IPTG-induced cultures of 
TG1 [pUC119HismycXba-FITC A2] and TG1[pUC119HismycXba-FITC B7].
Fab clone
Antibodies specific for human:
IgGi Fab fragments Lambda light chain Kappa light chain
Abs45o Abs45o Abs45o
FITC-A2 1.71,1.62 (1.67) 1.73,1.61(1.67) 0.03, 0.03 (0.03)
FITC-B7 1.72,1.45 (1.59) 0 .01,0 .00(0 .01) 1.64,1.71(1.68)
TGI cells only 0.34,0.40 (0.37) 0.09, 0.04 (0.07) 0.05, 0.04 (0.05)
The values in brackets represent the mean of the two individual determinations.
4.4.2 Optimisation of galactose induction time
A control experiment monitoring p-galactosidase activity in a culture after 
induction with galactose was performed to deduce the optimum galactose 
incubation time.
The supplied control expression vector, pYX243-LacZ, was 
transformed into the S. cerevisiae strain, YMTAB and leu+ transformants 
were PCR screened to confirm the plasmid was present. A single positive 
transformant was grown to mid-exponential phase (5 x 106 cells/ml) in 
defined medium containing the non-catabolite repressing carbon source, 
raffinose. Galactose was added to a recommended final concentration of 2% 
(Adams et al., 1996) and samples from the culture were analysed for p- 
galactosidase activity at regular intervals.
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Expression of p-galactosidase was almost immediate, due to the fact 
that the culture was grown in a non-catabolite repressing carbon source. 
Cells grown in glucose before exposure to galactose exhibit a long lag phase 
of 3-5 hours before expression is induced (Adams, 1972). Monitoring the p- 
galactosidase activity over galactose incubation time illustrated that 
expression gradually increased to a maximum approaching twenty-four 
hours. After this time, p-galactosidase activity slowly decreased and reached 
a plateau after approximately thirty-two hours.
4.4.3 Detection of the anti-FITC Fab A2 antibody fragments on the 
surface of S. cerevisiae
A) Western analysis of cell wall extracts
Cells potentially expressing the anti-FITC Fab A2 antibody fragment on their 
surfaces were broken with glass beads. Cell walls were isolated and were 
found to represent approximately 40% of the total cell weight (wet weight). 
Cells walls have been reported to account for roughly 30% of the dry weight 
of a cell (Lu et a/., 1995).
The light chain of the Fab A2 antibody fragment was located in the 
SDS-extractable material of the cell walls by Western analysis. Both the 
monoclonal antibody specific for the human lambda chain (Figure 4.1a) and 
the serum raised to human lgG1 Fab fragments (Figure 4.1b) detected the 
light chain at the expected molecular weight of approximately 28kDa.
Numerous non-specific bands were observed on the Western blot 
using the serum raised against anti-human Fab antibody. It was presumed 
that antibodies in the serum were binding to epitopes on native yeast SDS- 
extractable cell wall proteins and producing these non-specific results. Some 
of the antibodies in this serum were expected to bind to the heavy chain- 
agglutinin protein fusion of the Fab A2 molecule. The molecular weight of the 
heavy chain-agglutinin fusion was envisaged to be above 70kDa due to N- 
and O-glycosylation of the a-agglutinin anchorage domain (Section 4.1.1). A 
high molecular weight smear at approximately 200kDa was observed which 
could represent the highly heterogenous glycosylated form of the heavy 
chain-agglutinin fusion. To confirm this result, further analysis with an
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antibody specific for the human heavy chain was performed, but no 
appropriate bands at the correct molecular weight were observed.
Figure 4.1 - Western analysis of the SDS-extractable cell wall fractions obtained from cells 
expressing the anti-FITC Fab A2 antibody fragment. The applied fractions represent 
approximately 12mg of cell walls (wet weight). The periplasmic lysate from £. co// strain 
expressing the anti-FITC Fab A2 was used as a positive control.
a) Western analysis was performed using a primary monoclonal antibody specific for the 
human lambda light chain. Lane 1, first SDS fraction from wild type strain, YMTAB; Lane 2, 
first SDS fraction from isolated cell walls expressing Fab A2; Lane 3, positive control.
< -  30kDa 
< -  21.5kDa
b) The Western blot was incubated with an anti-human Fab IgG antiserum. Lane 1, positive 
control; Lane 2, first SDS fraction from isolated cell walls expressing Fab A2; Lane 3, first 
SDS fraction from the wild type strain control (YMTAB); Lane 4, second SDS fraction from 
isolated cell walls expressing Fab A2; Lane 5, second SDS fraction from the wild type strain 
control (YMTAB).
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B) Individual identification of the Fab light and heavy chains on the surface 
of S. cerevisiae
Enzyme immunoassays were performed on 2 x 107 galactose-induced cells 
to determine if the individual light and heavy chains of the anti-FITC Fab 
antibody fragment were present on the surface of S. cerevisiae (Table 4.2). 
An average absorbance of 0.27 and 0.15 above background were observed 
for the separate light and heavy Fab chains, respectively. These results 
confirm that both the heavy and light chains were on the surface of S. 
cerevisiae, but the expression levels compared to the anti-FITC scFv B7 
(Table 4.3) were considerably lower.
Table 4.2 - Enzyme immunoassay results verifying the expression of the individual light and 
heavy Fab chains on the surface of S. cerevisiae.
Strain
Antibodies specific for human: 
Lambda light chains Heavy chains
A b S 4 5 0 A b S 4 5 0
YMTAB[pYX-Light A2 + 
pYES2-SAG f-Heavy A2]
0.37, 0.35, 0.38 (0.37) 0.43, 0.45, 0.47 (0.45)
YMTAB 0.12, 0.12, 0.06(0.10) 0.31,0.29, 0.29(0.30)
The values in brackets represent the mean of the three independent determinations.
C) Functional detection of anti-FITC Fab fragments using fluorescence 
microscopy
Yeast cells expressing the Fab light and heavy chains were incubated with 
the fluorescent antigen, fluorescein-5-isothiocyanate. After extensive 
washing, the cells were viewed using epi-fluorescence microscopy. 
Theoretically, cells expressing the functional anti-FITC Fab fragment on their 
cell surfaces should bind the fluorescent antigen. Unfortunately, the degree 
of fluorescent labelling observed on the surface of the cells expressing the 
Fab light and heavy chains was very similar to the wild-type control. This 
result indicated that the individually expressed light and heavy chains were
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unable to form functional anti-FITC Fab fragments on the surface of S.
cerevisiae.
4.4.4 Identification of the anti-FITC single chain Fv B7 on the surface of 
S. cerevisiae
A) Covalent attachment to the cell wall
Cells potentially expressing the scFv-agglutinin protein fusion on their cell 
surfaces were disrupted with glass beads and separated into intracellular and 
cell wall fractions. The cell walls were treated with hot SDS and the SDS- 
extractable material was analysed by Western blotting (Figure 4.2). A specific 
band at approximately 30kDa was detected in the first five SDS extracts. It 
was presumed that this band represented the scFv B7 part of the protein 
fusion and the a-agglutinin anchorage domain had been removed by 
proteolysis. Additionally, a high molecular weight smear (70kDa to >200kDa) 
was observed to be more reactive in the samples expressing the scFv- 
agglutinin fusion compared to the wild type control. It was postulated that this 
smear could represent a highly heterogenous glycosylated form of the scFv- 
agglutinin protein fusion.
Figure 4.2 - Western analysis of the SDS-extractable cell wall fractions obtained from cells 
expressing the anti-FITC scFv B7 antibody fragment. The blot was incubated with an anti­
human kappa chain antiserum. The applied fractions represent approximately 20mg of cell 
walls (wet weight). Lane 1, second SDS fraction from the wild type strain, YMTAB; Lane 2, 
second SDS fraction from isolated cell walls expressing scFv B7; Lane 3, first SDS fraction 
from the wild type strain, YMTAB; Lane 4, first SDS fraction from the isolated cell walls 
expressing the scFv B7; Lane 5, Molecular weight protein markers (Broad range).




< -  47.5kDa
< -  32.5kDa 
+ -  25kDa
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The SDS-extracted cell walls were treated with glucanase to 
investigate whether or not the scFv-agglutinin fusion was covalently attached 
to the cell wall's p-glucan. After numerous unsuccessful attempts, a large 
diffuse smear was observed between approximately 28 to 83kDa (Figure 
4.3). In this smear, there were prominent bands at approximately 30 and 40 
kDa, which could represent the individual scFv and a-agglutinin components 
of the protein fusion, respectively. As mentioned above, these fragments 
could have been generated by proteolysis, which may have occurred in the 
long enzymatic incubation step. The expected high molecular weight band 
(>200kDa) for the glycosylated form of the scFv-agglutinin fusion was not 
observed. Hyperglycosylation and/or proteolysis may have affected the 
detection of the entire scFv-agglutinin protein fusion either by the loss of 
available epitopes or by extensive protein degradation, respectively.
Figure 4.3 - Western analysis of the glucanase-extractable material from SDS-treated cell 
walls expressing the anti-FITC scFv B7. The blot was incubated with a primary antibody 
specific for human kappa chains and each lane represents approximately 30mg of SDS- 
treated cell walls. Lane 1, glucanase-extracted material from the wild type SDS-treated cell 
walls (YMTAB); Lane 2, glucanase-extracted material from SDS-treated cell walls expressing 
the scFv B7; Lane 3, Molecular weight protein markers (Broad range).
< - 175kDa
■<- 83kDa 
< -  62kDa 
«- 47.5kDa
32.5kDa 
+ -  25kDa
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B) Detection of scFv B7 in the culture supernatant
Culture supernatants were obtained from cells expressing the anti-FITC scFv 
and a wild type strain harbouring the control vector, pYES2. Both 
supernatants were concentrated five-hundred fold using ultrafiltration and 
analysed by Western blotting (Figure 4.4). A band of approximately 30kDa 
was observed in the concentrated culture supernatant of 1 x 109 cells 
expressing the scFv antibody fragment. This band was presumed to 
represent the scFv part of the scFv-aggiutinin protein fusion as it was absent 
in the wild type control. It was speculated that protein degradation of the 
antibody-agglutinin fusion after cell death might account for the scFv antibody 
fragment in the culture supernatant.
Figure 4.4 - Western analysis of the concentrated culture supernatants. Each lane 
represents the culture supernatant from approximately 1 x 109 cells and the blot was 
incubated with a primary antibody specific for human kappa light chains. The periplasmic 
lysate from E. c o l i cells expressing the anti-FITC Fab B7 was used as a positive control. 
Lane 1, Molecular weight protein marker (Broad range); Lane 2, concentrated supernatant 
from cells expressing the scFv B7; Lane 3, concentrated supernatant from cells harbouring 
the control vector, pYES2; Lane 4, positive control.
1 2 3 4
32.5kDa ->  
25kDa ->
C) Identification of the scFv B7 antibody fragment on the surface of S. 
cerevisiae
An enzyme immunoassay using a primary antibody specific for human kappa 
light chains was performed on galactose-induced intact cells harbouring the 
anti-FITC scFv expression vector, pYES2-SAG7-scFv B7 (Table 4.3). A 
mean absorbance (at 450nm) of 0.94 for the three samples expressing the
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scFv compared to 0.09 for the three control samples was obtained. This 
result confirms that scFv B7 antibody fragments are on the surface of S. 
cerevisiae and are accessible to macromolecules.
Table 4.3 - Enzyme immunoassay results verifying the expression of the anti-FITC scFv B7 
on the surface of S. cerevisiae. The primary antibody specific for human kappa light chains 
was used for detection.
Strain AbS45o
YMTAB[pYES2-SA G 7-scFv B7] 0.95, 0.92,0.94 (0.94)
YMTAB 0.09, 0.08, 0.10 (0.09)
Values in brackets represent the mean of the three individual determinations.
D) Treatment with the Factor Xa protease
Galactose-induced cells carrying the anti-FITC single chain Fv surface 
expression vector, pYES2-SAGf-scFv B7, were incubated with the Factor Xa 
protease for 24 hours. Cells without any Factor Xa were also incubated for 24 
hours. After this time, both sets of cells were analysed for surface expression 
of the scFv B7-agglutinin fusion using an enzyme immunoassay (Table 4.4).
Cycloheximide was used throughout the experiment to stop protein 
production; therefore the results of the enzyme immunoassay ought to 
represent the scFv-agglutinin protein fusions which have become accessible 
directly after galactose induction. It was presumed if the Factor Xa protease 
was cutting at its particular recognition site (lle-Glu-Gly-Arg), present in- 
between the scFv and a-agglutinin anchorage domains in the fusion protein, 
a decrease in the level of scFv expression would be noted. The absorbance 
readings for the protease-treated and untreated samples were very similar 
(Table 4.4). Therefore, these preliminary results indicate that the Factor Xa 
protease was unable to cut at the cleavage site and the scFv antibody 
fragment was not released from the cell wall. Since earlier experiments 
(Section 4.4.4c) indicated that at least some of the scFv antibody fragment 
was present on the yeast cell surface, it was speculated that the cleavage
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site may have been hidden in the outer fibrillar layer of the cell wall and 
therefore may not have been accessible to the Xa protease.
Table 4.4 - Enzyme immunoassay results investigating the Factor Xa treatment of cells 
expressing the scFv-agglutinin protein fusion (two experiments).
Strain Factor Xa Abs450




The immunofluorescent labelling of cells expressing the scFv-agglutinin 
protein fusion was achieved using a serum specific for human kappa light 
chains followed by a complementary FITC-labelled conjugated secondary 
antibody (Figure 4.5a). All galactose-induced cells harbouring the anti-FITC 
scFv expression vector were fluorescently labelled but a large variation in 
fluorescent intensities from cell to cell was observed. The differences in 
fluorescent intensities were presumed to be due to variation in expression 
levels caused by the changes in copy number of the surface display vector 
between cells. Even the very small buds of the cells were labelled which 
suggests the scFv-agglutinin fusions were continuously incorporated into the 
yeast cell wall throughout the cell cycle.
No fluorescent labelling was observed on the surface of cells 
harbouring the control vector, pYES2 (Figure 4.5b). Therefore, it can be 
assumed the detection antibodies did not react with any native epitopes on 
the surface of S. cerevisiae. These indirect immunofluorescence results 
support the enzyme immunoassay results (Section 4.4.4c) and imply the 
scFv B7 antibody fragments are present in the outer fibrillar layer of the cell 
wall.
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Figure 4.5 - Indirect immunofluorescence results using a primary antibody specific for the 
human kappa chain followed by an FITC-conjugated goat anti-rabbit IgG serum. Nomarsky 
image (top) and matching fluorescent photograph (bottom). Magnification: x 400.
a) Galactose-induced cells harbouring the scFv B7 expression vector, pYES2-S7\Gf-scFv 
B7.
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Figure 4.5 cont:
b) Galactose-induced cells carrying the control expression plasmid, pYES2.
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F) Functional identification of the scFv B7 using the antigen FITC-BSA 
Fluorescence microscopy was used to illustrate that functional anti-FITC 
single chain Fv antibody fragments were on the exterior surface of S. 
cerevisiae. All cells expressing the scFv B7, which had been incubated with 
the fluorescein-5-isothiocyanate antigen, were fluorescently labelled (Figure 
4.6a). As expected, the level of fluorescence varied greatly from cell to cell 
due to the differences in expression levels. The wild type cells harbouring the 
control plasmid, pYES2, were barely detectable when observed by 
fluorescence microscopy (Figure 4.6b).
These results indicate the single chain Fv's antigen-binding site is 
functional and accessible to large macromolecules on the surface of S. 
cerevisiae.
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Figure 4.6 - Fluorescence microscopy (bottom) and phase contrast images (top) of yeast 
cells displaying the anti-FITC scFv B7. Cells were incubated with the fluorescein-5- 
isothiocyanate antigen. Magnification: x 400.
a) Galactose-induced cells harbouring the scFv B7 expression vector, pYES2-S A G 1 -scFv 
B7.
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Figure 4.6 cont:
b) Galactose-induced cells carrying the control expression plasmid, pYES2.
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4.5 DISCUSSION
The anti-FITC Fab A2 and B7 antibody fragments (Griffiths etal., 1994) were 
shown to be functionally expressed in the bacterial supernatant (Table 4.1). 
These ELISA results and the analysis of the DNA sequences (Section 3.4) 
determined that the E. coli expression vectors, pUC119HismycXba-FITC A2 
and pUC119HismycXba-FITC B7, were correctly supplied.
The optimum galactose induction time for maximum expression using 
the S. cerevisiae strain, YMTAB was unknown. Therefore, a control 
expression vector containing the p-galactosidase reporter gene was 
transformed into YMTAB and its activity was monitored over time after 
galactose induction. An optimum galactose incubation time of approximately 
24 hours was established and all further expression experiments were 
carried out over a 24-hour time period for consistency.
4.5.1 Detection of antibody fragments on the surface of S. cerevisiae
Antibodies cannot penetrate the yeast cell wall (Pringle et a i, 1991), 
therefore the enzyme immunoassay results obtained for both the light and 
heavy Fab chains (Section 4.4.3b) and the single chain Fv (Section 4.4.4c) 
proved that these antibody fragments were on the surface of S. cerevisiae. In 
the case of the single chain Fv, additional results acquired from the direct 
(Section 4.4.4f) and indirect immunofluorescence (Section 4.4.4e) 
experiments reinforced this conclusion.
Cells expressing the anti-FITC scFv B7 were shown to be specifically 
binding the antigen, fluorescein-5-isothiocyanate, on their cell surfaces 
(Section 4.4.4f). Hence, it can be assumed that the single chain Fv's antigen- 
combining site was functional on the yeast's surface. It was unknown how 
many scFv molecules on the cell surface were forming functional antigen- 
combining sites. An additional quantitative double labelling experiment using 
a second fluorophore, which is excited at a different wavelength to 
fluorescein-5-isothiocyanate and can recognise an unmutated part of the 
scFv antibody fragment, could have been used to compare the level of 
surface expression to functionality. Furthermore, examination of the single or
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doubly labelled yeast cells by laser-scanning confocal microscopy would 
have given additional information about the surface distribution of the 
functional antibody fragments.
The indirect and direct immunofluoresence results obtained for cells 
expressing the single chain Fv antibody fragment determined that the level of 
surface expression varied widely from cell to cell (Sections 4.4.4e and 
4.4.4f). It was presumed that the differences in the level of expression was 
due to the variance in the copy number of the expression vector and this 
problem could be overcome by integrating the antibody DNA into the a- 
agglutinin locus (Schreuder etal, 1996). Homogenous surface expression is 
essential for the development of an antibody selection procedure. It was 
intended that a successful selection process that can discriminate between 
cells that are expressing high and low affinity antibodies on their surfaces 
would be developed in the next part of the project (Part II).
Unfortunately, anti-FITC Fab antibody fragments were not functionally 
identified on the surface of S. cerevisiae (Section 4.4.3c). The reasons for 
this unsuccessful outcome could be numerous. The experimental strategy of 
this part of the project relies on disulphide bond formation between the Fab 
heavy and light chains in the endoplasmic reticulum for a functional anti-FITC 
Fab antibody fragment to be created. The light chain expression construct, 
pYX-Light A2, contains an a-agglutinin signal sequence that targets 
expression to the secretory pathway and the attachment of the light chain to 
the cell wall is reliant on the heavy chain. The heavy chain surface display 
construct, pYES2-SAGf-Heavy A2, includes the molecular information 
encoded by the a-agglutinin gene, therefore should covalently attach the 
formed Fab antibody fragment to the glucan of the cell wall. If the Fab 
molecule does not form, the light chain should be secreted into the culture 
supernatant (Wojciechowicz et ai., 1993). Enzyme immunoassay results 
(Section 4.4.3b) indicated that the Fab light chain was present at a low level 
on the yeast's cell surface. Therefore, it was presumed that the light and 
heavy chains were imprecisely associating and the antigen-combining sites 
were forming incorrectly. Another factor affecting the detection of anti-FITC 
Fab fragments on the cell surface could be the permeability of the cell wall
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(Klis, 1994). The scFv (~32 kDa) is half the molecular weight of the Fab (~ 
57kDa) antibody fragment, therefore the Fab molecule may have had more 
difficulties passing through the cell wall owing to its size. Further analysis of 
the direct immunofluorescence results with imaging enhancing equipment 
may have detected a low level of functional anti-FITC Fab fragments.
4.5.2 Covalent attachment of antibody fragments to the cell wall
An important objective of this chapter was to determine if the antibody 
fragments were covalently attached to the cell wall's p-glucan. The native ex- 
agglutinin is exclusively extractable with glucanase but fusion proteins 
created with the C-terminal half of the a-agglutinin gene have been shown to 
be partly extractable with hot SDS [non-covalently bound (Schreuder et al.t 
1993)]. Schreuder and colleagues (1993) expressed an a-galactosidase/a- 
agglutinin anchorage domain fusion protein on the surface of S. cerevisiae. In 
these experiments, 31% of the fusion protein was released with hot SDS and 
69% by treatment with glucanase. It was reasoned that the higher level of 
expression of the fusion protein compared to the native a-agglutinin was the 
cause of this difference. The SDS-extraction experiments carried out in this 
Chapter (Section 4.4.3a and 4.4.4a) indicated that a large fraction of the 
antibody-agglutinin fusion was present in the non-covalently attached 
fractions, although no quantitative experiments were carried out. The total 
removal of the non-covalently associated proteins from isolated cell walls 
expressing the scFv B7 fragment required five concurrent SDS treatments. 
Previously, it has been reported that two hot SDS treatments are sufficient to 
remove all the non-covalently bound protein (Schreuder et a/., 1993). It was 
anticipated that a small amount of the antibody-agglutinin construct would be 
identified in the SDS fractions due to biosynthetic intermediates that are not 
associated with the glucan such as the GPI anchored plasma membrane and 
the soluble periplasmic forms (Lu et al., 1995). But the reasons why 
additional SDS treatments were required are unknown.
To demonstrate the scFv-agglutinin protein fusion was covalently 
attached to the p-glucan, the SDS-treated cell walls were incubated with an 
impure p-1-6-glucanase, lyticase (Section 4.4.4a). However, the results of
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these experiments were not totally conclusive. After treatment with 
glucanase, the expected high molecular weight band (>200kDa) representing 
the highly heterogenous glycosylated form of the scFv-agglutinin was not 
observed. Nevertheless after several attempts, a lower molecular weight 
smear of 28-83kDa was identified. Within this smear, two prominent bands of 
approximately 30 and 40kDa were detected, which theoretically could 
represent the scFv and a-agglutinin components of the protein fusion. This 
suggests proteolysis may be affecting these results, although an S. 
cerevisiae strain deficient in two main vacuolar proteases and numerous 
protease inhibitors were used.
Hyperglycosylation of the fusion proteins may have resulted in the loss 
of available epitopes, which could have affected detection sensitivity 
(Romanos et al., 1992). N-linked carbohydrates can be easily removed from 
a protein using the enzyme, endoglycosidase H (endo H). This enzyme 
cleaves the N-chains after the first N-acetyl glucosamine residue and 
removal of the N-chains can be monitored by an increase in electrophoretic 
mobility due to loss of molecular mass (de Nobel, 1996). Treatment of the 
glucanase-extractable material with Endo H may have increased the 
sensitivity of the immunoblotting experiments. Additionally using tunicamycin, 
a drug that inhibits the addition of the N-chains to a protein or a mmn9 yeast 
mutant that produces glycoproteins with truncated N-chains, would have had 
the same effect. Due to the difficulties experienced with the glucanase 
treatment of cell walls expressing the scFv B7 antibody fragment, the 
detection of the Fab heavy chain in the glucanase-extractable material was 
never attempted.
4.5.3 Conclusions
The aim of this chapter, to express a functional antibody fragment on the 
surface of S. cerevisiae, was achieved. Functional anti-FITC scFv antibody 
fragments were detected on the surface of the yeast cells by fluorescence 
microscopy. Unfortunately, the fluorescence-activated cell sorting (FACS) 
antibody selection system that was devised to separate yeast cells displaying 
high affinity antibodies from a mixed population of yeast cells was not
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established. This was due to the fact that another research group 
demonstrated the capabilities of a FACS-based antibody selection system 
first (Boder and Wittrup, 1997). Hence, Part II of this project attempted to 
develop a novel strategy for the selection of high affinity antibodies on the 
surface of S. cerevisiae using the mating characteristic of agglutinin mutants.
PART II
IMITATING THE GERMINAL CENTRE REACTION BY
MATING YEAST
Strategy
During the germinal centre reaction (Section 1.3.3), B-lymphocytes with 
mutated antigen receptors (centrocytes) are selected on the basis of their 
capacity to bind antigen which is held in a limited amount on follicular 
dendritic cells. Binding to follicular dendritic cells is an unconditional 
prerequisite for centrocyte survival and cells which do not bind die rapidly by 
apoptosis (reviewed in Maclennan, 1994; Kelsoe, 1996; Camacho et al, 
1998). This is the presumed basis of affinity maturation during immune 
responses and is the selection process this project is aiming to mimic (Figure 
1.11).
S. cerevisiae a- and a-haploid cells express complementary cell 
surface receptors known as a- and a-agglutinins that mediate cell to cell 
adhesion during mating (Section 1.6.2). Agglutinins are critical for mating 
under conditions that do not promote stable cell to cell contact (liquid media) 
but are not essential under conditions that promote such contact [solid media 
(Lipke et al., 1989; Roy et al., 1991)]. This characteristic of agglutination is 
paramount in this proposed strategy, which is as follows?
Firstly, the centrocytes of the germinal centre reaction will be 
represented by a-cells with a single chain Fv antibody fragment replacing the 
N-terminal binding domain of the a-agglutinin gene (SAG1) to produce an in­
frame fusion with the C-terminal a-agglutinin anchorage domain. Thus in the 
presence of a-factor, it is intended that the engineered a-cells will express 
the antibody fragment on their cell surfaces.
The follicular dendritic cells will be imitated by a-cells using the a- 
agglutinin molecule. An antigen gene is intended to be fused to the 3' 
terminus of the DNA segment encoding the a-agglutinin binding domain 
(AGA2) to provide the antigen cell surface display system.
In liquid mating conditions, diploid formation using the engineered 
agglutinin mutants is dependent on the antigen-antibody interaction. The 
mating efficiency of these mutants can be easily assessed by using haploid 
cells that complement each other's nutritional requirements. Therefore, 
diploid formation can be assayed by plating mated cells onto the appropriate 
selective media. Cells unable to form a stable cell to cell contact (antiger)- 
antibody interaction) will not form diploids and therefore die because their 
nutritional requirements are not met. Consequently, a-cells which have 
antibodies with a moderate to high affinity for the chosen antigen on their cell 
surfaces are selected.
If this selection procedure was shown to be successful, antibody 
affinities could then be improved in a step-wise manner. The antibody DNA 
in the genome of a-cells could be mutated by various mutagenic techniques 
(i.e. error-prone PCR or a yeast/bacterial mutator strain) and advantageous 
mutations could then be chosen using the diploid selection procedure. An 
effective diploid selection process will be a very fast and efficient way of 
screening a mutant antibody surface display library. By growing the selected 
diploid cells under nutritional starvation, meiosis will occur and haploid a- 
cells displaying the beneficially mutated antibody could be isolated. If a yeast 
mutator strain is used, an 'in-cell' mutational system could be developed 
which would overcome the necessary DNA manipulations required after 
antigen-selection when using methods such as error-prone PCR. Therefore, 
single yeast cells, analogous to the B-cells in the germinal centre reaction, 
could undertake rounds of mutation and selection.
The attempted realisation of this strategy forms the subject of the next 
two chapters; Chapter 5 deals with the construction of the agglutinin mutants 
and Chapter 6 details the attempted mating of these mutants to imitate the 
germinal centre reaction.
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Outline of the strategy proposed to imitate the germinal centre reaction:
STEP 1 - Integration of the antibody and antigen DNA into the appropriate 
agglutinin loci.
i) Integrate the antibody fragment into the a-cell genome to create an in- 
frame fusion with the 3' half of the a-agglutinin gene (SAG1). Select an a- 
strain that has a mutation in gene Y and therefore can not synthesise the 
amino acid, Y.
ii) Integrate the DNA encoding the antigen gene into the a-cell genome to 
generate an in-frame fusion to the 3' terminus of the a-agglutinin binding 
domain gene (AGA2). Choose an a-strain which has a mutation in gene X  
and therefore can not make the amino acid, X.
a-cell a-cell
AGA2 AntigenAntibody SAG 1
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STEP 2 - Mating of the engineered yeast strains
Mate the engineered yeast strains under conditions that do not promote 
stable cell to cell contact (liquid media). If the antibody on the surface of the 
engineered a-cell has a moderate affinity for the antigen displayed on the 
surface of the a-cell they ought to interact to form a diploid.
a-cell a-cell
Antibody SAG 1 Antigen
= antibody/a-agglutinin fusion = antigen/a-agglutinin fusion
STEP 3 - Analysis of diploid formation
Select for diploids by growing mated cultures on the appropriate selective 
plates (without amino acids X and Y). Non-mated cells (haploids) die 
because their nutritional requirements are not fulfilled.
STEP 4 - Mutation of antibody DNA
Allow the selected diploid cells to undergo meiosis and isolate the haploid a- 
cells. Mutate the antibody DNA in the genome of the a-cells and mate with 
engineered a-cells for a further round of antigen selection.
CHAPTER 5
CONSTRUCTION OF AGGLUTININ MUTANTS
5.1 INTRODUCTION
The previous chapter showed that a single chain Fv antibody fragment can 
be functionally expressed on the surface of Saccharomyces cerevisiae 
using the molecular information of the signal sequence and C-terminal half 
of the a-agglutinin gene. Immunofluorescence experiments indicated that 
all cells were expressing the scFv/a-agglutinin protein fusion but the 
expression level varied widely from cell to cell. Variation of the expression 
levels was presumed to be dependent on the copy number of the genes 
present in each cell (Schreuder et al., 1996). Selection of high affinity 
antibodies from cells with considerably different expression levels would be 
difficult, because undesirable cells with moderate affinity antibodies but 
higher expression levels maybe selected. Consequently, an alternative 
strategy has been designed which overcomes the unstable inheritance of 
the yeast episomal plasmid by integrating the antibody gene into the 
genome of S. cerevisiae.
Theoretical arguments suggest that the larger and more diverse an 
antibody library, the higher the probability of finding a high affinity antibody 
(Perelson and Oster, 1979). In anticipation that a mutant antibody library 
will eventually be created, the Cre-/ox recombination system was chosen to 
integrate the chosen DNA fragments into the appropriate sites in the 
genome. This approach should overcome the low transformation efficiency 
achievable by standard integration techniques such as the one-step gene 
replacement method [1-100 transformants per |ig of DNA (Wach, 1996)]. 
Hypothetically, a Cre recombinase integrated library should only be 
restricted in size by the transformation efficiency of the exchange vector. 
Transformation efficiencies in the order of 106 transformants per jig of 
plasmid DNA per 108 cells are attainable (Schiestl et al., 1993). Moderate
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affinity (juM) antibodies, similar to antibodies from a primary immune 
response, could possibly be isolated directly if a library of 107 colonies was 
generated (Hoogenboom, 1997). The affinity of the antibody of interest could 
then be improved in a stepwise fashion by rounds of random mutation and 
antigen-selection, analogous to the germinal centre reaction (Section 1.3.3).
The background information concerning the Cre-/ox recombination 
system and the chosen antibody-antigen interaction is reviewed below:
5.1.1 Cre-lox site-specific recombination system
In 1981, N. Sternberg and D. Hamilton discovered the Cre-/ox site-specific 
recombination system in bacteriophage P1. It consists of a site, loxP, where 
recombination takes place and a protein, Cre, which carries out the 
recombination reaction. In the bacteriophage P1 life cycle, the Cr e-lox 
system performs at least two functions: it cyclises the viral DNA after its 
infection into bacteria and it breaks down any DNA dimers that form 
following replication (Austin et al., 1981). Consequently, the phage genome 
is maintained as a monomeric, unit-copy plasmid.
The Cre recombinase gene was localised using a series of deletion 
mutants known to contain the gene. Each of the mutants were screened for 
Cre activity and as a result a 1.1 kilobase DNA sequence was located which 
encoded a 343 amino acid (38kDa) protein (Sternberg e ta l, 1986). Cre is a 
member of the integrase family of site-specific recombinases and consists of 
two distinct domains that are separated by a short linker. Both the N- and C- 
terminal domains bind DNA, but only the C-terminal domain mediates actual 
strand-exchange between loxP sites via a catalytic tyrosine residue 
(Tyr324). The strand-exchange mechanism occurs in a step-wise fashion 
through a four-way Holliday junction intermediate, with four recombinases 
and two loxP sites (Guo et al., 1997).
The loxP site (34 b.p.) consists of two inverted 13 b.p. repeats 
separated by an asymmetric 8 b. p. spacer region (Figure 5.1). Cleavage 
and strand exchange of the recombining loxP sites occurs within this spacer 
region (Hoess and Abremski, 1985). This spacer region dictates whether
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excision (loxP sites in the same orientation) or inversion (loxP sites in 
inverted orientation) of the intervening DNA sequence occurs after 
recombination. Intermolecular recombination can also be carried out by Cre, 
but is less efficient than intramolecular recombination (Abremski et al., 
1983).
Hoess and collegues (1986) constructed various mutant loxP sites 
containing single base substitution in the spacer region and discovered that 
homology was required between recombining loxP sites (Table 5.1). By 
changing the base at position 7 in the loxP spacer region, a new loxP 511 
site was created (Figure 5.1).
Figure 5.1 The DNA sequences of the loxP 511 and loxP recognition sites. The single base 
substitution at position 7 in the loxP511 site is indicated in bold.
REPEAT SPACER REPEAT
1 2 3 4 5  6 7  8
loxP site ATAACTTCGTATA ATGTATGC TATACGAAGTTAT
loxP 511 site A
Table 5.1 The recombination results of the loxP and mutant loxP 511 sites (Hoess et al., 
1986).
loxP sites in vivoa in vitro0
loxP x loxP 100 61
loxP511 xIoxP 0 1
loxP 511 x loxP 511 100 68
a The percentage of colonies that have become sensitive to kanamycin as a result of the 
excision of the kanamycin resistance gene via Cre-mediated recombination between loxP 
sites.
b Percentage of plasmid DNA in which recombination between loxP sites has resulted in the 
formation of two new products.
Due to the simplicity of the Cre-lox system i.e. the Cre protein requires 
no cofactors and the loxP site is sufficiently large that it is unlikely to occur
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naturally in genomes, this system is being increasingly used to manipulate 
prokaryotic and eukaryotic genomes. Analysis of the eukaryotic yeast, S. 
cerevisiae, indicated there was no authentic loxP sites present in its genome 
(Sauer, 1992). Applications of the Cre-lox system so far include: the 
engineering of synthetic antibody libraries in phage (Waterhouse et al., 
1993; Tsurushita et al., 1996), the removal of selectable markers to generate 
gene knockouts in yeast and mice (Sauer, 1987; Sauer, 1993), site-directed 
chromosome translocations in plants and mice (Qin et al., 1994; van 
Deursen eta /., 1995) and recombination-activated gene expression (RAGE) 
in mice (Lakso etai., 1992).
Cre recombinase in yeast
Sauer (1987) reported Cre recombinase could act upon a yeast 
chromosome and therefore showed Cre was functional in an eukaryotic 
nucleus. In these experiments, the Cre recombinase gene was placed under 
the control of the yeast GAL1 inducible promoter and expression was 
regulated by the carbon source. A selectable marker (LEU2) flanked by two 
loxP sites was placed on two different chromosomes in different orientations. 
The ability of the cells to become leu' was shown to be due to LEU2 excision 
via functional Cre recombinase. No nuclear localisation sequence was used, 
therefore the ability of Cre to enter the eukaryotic nucleus is believed to be a 
consequence of its size. The nuclear pore has a functional radius of 45-55 A 
and hence, in principle, the passage of the spherical proteins as large as 50- 
60 kDa is possible (Barnes and Rine, 1985). Successful multiple gene 
disruptions using a loxP-kanMX-loxP reusable disruption cassette and Cre 
recombinase have also been reported (Giildener eta!., 1996).
Additionally, a yeast multipurpose transposon-based system containing 
a loxP and a loxR site flanking the coding regions of either p-galactosidase 
or green fluorescent protein has been developed (Ross-Macdonald et al., 
1997). The loxR site was identified in a study investigating recombination 
between the loxP site on the bacteriophage P1 plasmid and the loxB site on 
the bacterial chromosome (Sternberg e ta l, 1981). Recombination between
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the loxP and loxB sites results in the integration of the P1 plasmid DNA into 
the bacterial chromosome and the generation of two new hybrid sites, loxR 
and loxL. Analysing the recombination frequency between the loxR and loxP 
in bacteriophage X showed that they can recombine at an efficiency 20- to 
100-fold lower than two homologous loxP sites. The loxP and loxR sites 
were chosen for the yeast transposon system because they only contain 16 
identical base pairs and therefore should overcome any problems with 
spontaneous excision of the transposon. This multipurpose transposon 
system allows the rapid generation and analysis of yeast disruption mutants. 
After phenotype analysis, the inserted transposon can be reduced by Cre- 
mediated site-specific recombination to a smaller element that leaves an 
epitope tag which can be utilized for immunodetection purposes.
5.1.2 The scFv D1.3-HEWL antibody-antigen interaction
The antigen-antibody interaction chosen for this strategy is that between the 
single chain antibody fragment D1.3 (scFv D1.3) and hen egg white 
lysozyme (HEWL). The affinity constant for the scFv D1.3-HEWL interaction 
[Ka = 3 x 108 M'1 (Hawkins et al., 1993)] is similar to the a-/a-agglutinin 
interaction [Ka = 1 x 109 M*1(Lipke et al., 1987)] and therefore should mimic 
the agglutinin function.
Single-chain FvD1.3
The monoclonal anti-HEWL D1.3 antibody was derived by immunizing 
Balb/c mice with lysozyme three times over a period of 36 days and was 
obtained as part of a project attempting to define antigen-antibody 
interactions at the molecular level (Harper et al, 1987). Its affinity (Ka = 2.7 x 
108 M"1) is characteristic of a good antibody-antigen interaction from a 
secondary immune response (Foote and Winter, 1992). The D1.3 antibody 
contains five non-silent mutations (VH - S er^A sn; VH - Glu86-> His; VL - 
A sn ^ T yr; VL - Ala51-> Thr; VL - Lys52 -> Thr; Figure 5.2a) and is believed 
to originate from the germline sequences PJ14 (VH) and K2 [VK (Hawkins et 
al., 1993; England et al., 1999)]. The somatic mutations are mainly situated
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in the complementarity determining regions and increase the affinity of the 
antibody by 60-fold. Most of the affinity improvement is due to a single 
residue change (VL - Asn50 -> Tyr) which is found at the D1.3-lysozyme 
interface (England etal., 1999).
The scFv of antibody D1.3 was constructed by joining the VH and VL 
domains together using a flexible linker, (Gly4Ser)3 and was the first scFv 
antibody fragment to be functionally expressed on the surface of phage 
(McCafferty et al., 1990). Its affinity constant of 3 x 108 M'1 (Hawkins et al., 
1993) is similar to the affinity of the parent antibody [Ka = 2.7 x 108 M'1 
(Foote and Winter, 1992)] which indicates the scFv D1.3 antibody fragment 
binds tightly to the antigen, lysozyme.
The antibody fragments of D1.3 have been used in numerous studies 
including being ‘humanised’ for therapy (Verhoeyen et al., 1988; Foote and 
Winter, 1992) and random mutated for a phage display affinity maturation 
strategy (Hawkins etal., 1993). Consequently, scFv D1.3 is one of the most 
well characterised antibody fragments available.
Hen egg white lysozyme
Lysozymes are bacteriolytic enzymes that occur widely in cells and 
secretions of vertebrates. Hen egg white lysozyme is a small, well- 
characterised enzyme consisting of a single polypeptide chain of 129 amino 
acids (14.6 kDa). It destroys bacterial cell walls by hydrolysing the p(1 —>4) 
glycosidic linkages in the alternating N-acetyl-mu ramie acid/N- 
acetylglucosamine polysaccharide component of the cell wall 
peptidoglycans. Hen egg white lysozyme was the first enzyme to have its 
three-dimensional structure determined (Blake et al., 1965) and is therefore 
very well understood structurally.
The HEWL DNA sequence was obtained from a cDNA isolate (Jung et 
al., 1980) and is encoded by four exons, each of which carries a main 
structural element. Exon 2 and 3 determine the active site, exon 1 encodes 
for the translational signal sequence and exon 4 increases the stability of the 
molecule.
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There have been numerous reports of different lysozymes, including 
HEWL, being expressed in Saccharomyces cerevisiae under the control of 
different yeast promoters and leader sequences (Oberto and Davison, 
1985; Jigami et a/., 1986; Castandn et al., 1988). All cases claim that the 
lysozyme is correctly processed, biologically active and has no deleterious 
effects on the yeast cells. Human lysozyme has also been expressed in E. 
coli cells, but inactive enzyme with incorrect disulphide bonds was found in 
inclusion bodies (Muraki et al., 1985). Hen egg white lysozyme has been 
studied extensively in order to understand the role of glycosylation (Kato et 
al., 1994a; Ueda et al., 1996) and protein stability (Kato et al., 1994b) and 
hence is one of the most well-defined antigens in the literature.
D1.3-HEWL complex
The structural features of the D1.3 antibody (Figure 5.2b) were established 
initially with the X-ray crystal structure of the Fab fragment complexed with 
the HEWL at 2.8A resolution (Amit et al., 1986) and at 2.5A resolution 
(Fischmann et al., 1991). Further structural features have also been 
obtained from high resolution crystal structures of the free D1.3 Fv 
fragment (Bhat et al., 1990) and the Fv-HEWL complex (Bhat et al., 1994).
The antibody-antigen interface is tightly packed, with 16 lysozyme 
and 17 antibody residues making close contact. The interacting surfaces 
are complementary, with protruding side chains of one lying in the 
depressions of the other. Many water molecules are observed at the 
antibody-antigen interface and are believed to play an important role in the 
stabilization of the complex (Bhat et al., 1994). The lysozyme antigenic 
determinants recognised by D1.3 consist of two stretches of polypeptide 
chain: residues 18 to 27 and 116 to 129. All complementarity-determining 
regions (CDRs) of the D1.3 antibody interact with the lysozyme, especially 
the variable heavy CDR3. In fact, the VH domain has been expressed 
individually in E. coli and was found to bind to the lysozyme at an affinity 
only 10-fold weaker (Ward et al., 1989). The D1.3-HEWL complex is one of 
the most well understood antibody-antigen interactions in the literature and 
therefore D1.3 antibody fragments are ideal candidates for further 
mutagenic studies.
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Figure 5.2 The D1.3-HEWL complex.
a) The structural location of the five non-silent mutations of antibody D1.3. The a-carbon 
traces of the variable fragments of Ab D1.3 (VH, solid lines; VL, dashed lines) and of 





b) Space-filling representation of the Fab D1.3-HEWL complex. The antibody heavy chain 
is shown in blue, the light chain in yellow, lysozyme in green and Gin121 in red. 
Reproduced from Amit e t  a l., 1986.
5.1.3 Experimental design for the construction of the agglutinin 
fusion mutants
Figures 5.3 and 5.4 illustrate the construction of the scFv D1.3/a-agglutinin 
and the HEWL/a-agglutinin gene fusions, respectively. The first stage in 
the construction of the HEWL and scFv D1.3 agglutinin mutants was to 
integrate a selectable marker, flanked either side by a loxP or loxP 511
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site, into the agglutinin loci of the respective genomes. Special 
consideration in the auxotrophic mutations of the haploid yeast strains to 
be manipulated was taken. The mutations were complementary to the 
selectable markers of the vectors used in these experiments and also 
compatible with the diploid selection strategy (Chapter 6).
Classically, null mutants of a particular locus are produced by using a 
one-step gene transplacement method (Rothstein, 1983). This involves 
placing small DNA fragments of the gene of interest either side of the 
selectable marker. After transformation into yeast, homologous 
recombination between the flanking regions results in a deletion of the 
gene and the simultaneous integration of the marker gene. Yeast contains 
very efficient mechanisms for homologous recombination and it is often 
possible to reduce the flanking DNA to 35-45 b.p. This sometimes leads to 
problems with mis-integration due to occurrence of sequence 
polymorphisms in strains with different genetic backgrounds.
In these experiments, the agglutinin disruption cassettes with several 
hundred base pairs of flanking DNA were constructed to overcome the mis- 
integration problem and also increase the transformation efficiency (Wach, 
1996). Long-flanking homology PCR (LFH-PCR) disruption cassettes were 
made by linking two PCR-amplified fragments (~1000 b.p. each) produced 
from genomic DNA of the target locus to the marker gene via a 'splicing by 
overlap extension' reaction (Horton et al., 1989). Oligonucleotides used to 
amplify these PCR-amplified fragments were also designed to incorporate 
the loxP and loxP 511 recognition sites. Hence after transformation, the 
loxP/loxP 511 sites were either side of the selectable marker at the 
relevant agglutinin locus.
The selectable marker chosen for this project was the heterologous 
dominant resistance marker, kanMX4, which encodes for an 
aminoglycoside phosphotransferase that permits selection of transformants 
resistant to the drug geneticin (G418). Wach et al. (1994) constructed this 
module which contains the kanr opening reading frame of the E. coli 
transposon Tn903 fused to the transcriptional and translational control 
sequences of the TEF gene of the filamentous fungus Ashbya gossypi 
(Figure 5.6a). This module can be transformed into any strain and
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therefore solves the problem of gene conversion associated with the use of 
yeast marker genes (Guldener etal., 1996).
The second stage in the creation of the agglutinin mutants was the 
construction of plasmids with the scFv D1.3 or HEWL open-reading frames 
flanked by the loxP and loxP 511 sites. The loxP/loxP 511 sites on these 
vectors were equivalent in orientation to the loxP/loxP 511 sites either side 
of the kanMX4 selectable marker in the genome. Special consideration in 
the design of the oligonucleotides used at this stage was also taken to 
conserve the open-reading frames of the agglutinin-fusions, especially 
avoiding any undesirable start or stop codons.
After co-transformation of one of the above vectors and the Cre 
recombinase expression vector, site-specific recombination between the 
loxP sites may be induced with galactose. Due to the fact that identity is 
required between loxP sites for recombination to take place (Table 5.1), 
exchange should only occur between the kanMX4 cassette on the genome 
and the antibody (or antigen) DNA on the vector. After Cre recombinase 
expression, in-frame gene fusions with the relevant agglutinins should be 
created.
This Chapter describes the construction of both the agglutinin gene 
fusions. Also, the creation of the HEWL/oc-agglutinin and scFv D1.3/a- 
agglutinin expression vectors is detailed.
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Figure 5.3 - Schematic representation of the construction of the scFv D1,3-a-agglutinin gene 
fusion.
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Figure 5.4 A flow diagram summarising the production of the a-agglutinin-HEWL gene 
fusion.
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5.2 MATERIALS
5.2.1 Saccharomyces cerevisiae strains
The two S. cerevisiae strains, FY22 and FY10 were isogenic derivatives of 
strain S288C. These strains were chosen because they were galactose 
inducible and contained the appropriate auxotrophic mutations for plasmid 
maintenance and for the proposed diploid antigen-selection strategy 
(Chapter 6). A diploid strain, FY1679 from the Fred Winston’s collection was 
used as the source of DNA for the European Union yeast genome 
sequencing programme.
Table 5.2 Saccharomyces cerevisiae strains used.
Strain Genotype Source Reference
FY10 MATa ura3-52 ieu2A1 F. Winston, Harvard 
Medical School
Winston eta!., 1995
FY22 MATa ura3-52 his3A200 n  h m n
5.2.2 Escherichia coli strains and plasmids
The plasmids used in this chapter were either supplied as an E. coli slant 
culture (Table 5.3a) or in an aqueous DNA solution (Table 5.3b).
Table 5.3a Plasmids supplied in E. coli strains.
Plasmid Strain Genotype Source Reference
pBS39 DH1 supEAA hsdR 17 recA1 
endAI gyrA96 thi-1 relA1
ATCC Sauer, 1987
pUC8-HEWL XL1-Blue supEAA /)sdR17 recA1 
endA^ gyrA9Q thi-1 re/A1 
lac FfproAB* lacf 
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When the plasmids were supplied in an aqueous DNA solution, the 
solution was transformed into TOPI OF' E  coli cells (Section 2.2.15) and 
plasmid DNA was prepared (Section 2.2.17).
Table 5.3b Plasmids supplied in aqueous DNA solutions.
Plasmid Source Reference
pFA6a-kanM4X A. E. Wheals, University of Bath. Wach etal., 1994
pUC119His6mycXba- 
scFv D1.3
R. E. Hawkins, University of 
Bristol.
Hawkins etal., 1993
pTG5756 Transgene, France. Langle-Rouault etal., 1995
pRS313 S. Oliver, UMIST. Sikorski and Hieter, 1989
pYX243 R+D Systems.
For long term storage, glycerol stocks (Section 2.2.3) were made for all 
plasmids.
5.2.3 Plasmid descriptions
A) The pUC8-HEWL vector
The plasmid, pUC8-HEWL is an E  coli cloning vector and confers ampillicin 
resistance. It encodes the cDNA of HEWL which contains three silent 
polymorphisms: a GCT codon at Ala3 i; an AAC codon at Asnio6i a GGC 
codon at Glyn7  (D. J. Jeenes, personal communication) when compared to 
the published sequence (Jung etal., 1980).
B) The pUC119His6mycXba-scFv D1.3 vector
The pUC119His6mycXba-scFv D1.3 vector contains the anti-HEWL Vh and 
VL antibody domains joined together by a fifteen residue peptide linker, 
(Gly4Ser)3 . It is a high copy number E. coli cloning vector containing a c-myc 
and His6 tag which can be used for detection and purification, respectively. It 
confers ampicillin resistance and the vector promoter is from the lacZ gene,
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therefore protein expression can be induced by isopropyl-p-D- 
thiogalactoside (IPTG).
C) The Cre recombinase expression vector, pBS39 (Sauer, 1987).
The pBS39 vector (Figure 5.5) comprises of the Cre recombinase gene from 
bacteriophage P1, downstream from an inducible GAL1 promoter. It contains 
a centromere (CEN4) and an autonomously replicating sequence (ARS1) to 
permit autonomous replication in S. cerevisiae. The ampillicin and URA3 










Figure 5.5 A plasmid map of the Cre recombinase expression vector, pBS39.
D) The pFA6a-kanMX4 vector
The pFA6a-kanMX4 plasmid comprises of an ampicillin resistance selectable 
marker, an origin of replication for propagation in E. coli and a kanMX4 
marker cassette. The kanMX4 cassette (Figure 5.6a) was cloned into the 
Pme I enzyme recognition site at the centre of the pFA6a multiple cloning 
site [MCS (Figure 5.6b)]. The flanking MCS sequences were essential in the 
design of the primers for the PCR-generated disruption cassettes due to the 
fact they contained the two 25 nucleotide stretches of homology essential for 
the 'splice by overlap extension' assembly reactions (Figures 5.8 and 5.13).
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Two Not I enzyme recognition sites were present at the ends of the MCS for 
ease of excision of the kanlAXA cassette from the pFA6a plasmid.
Figure 5.6a A map of the k a n M X 4  cassette. P tef and Ttef indicate the promoter and 
terminator of the A  g o s s y p i i TEF gene, respectively, and k a n r denotes the open reading 
frame of the E. c o li transposon, T n 9 0 3 .
Pme I Karl Pme I
b- The sequence of pFA6a multiple cloning site (MCS). Important restriction enzyme sites 
are in bold and the primer recognition sites for the LFH-PCR assemblies are underlined.
N o t I < -  5’ k a n M X 4  primer site
5’ GCGGCCGCCAGCT GAAGCTT CGT ACGCTGCAGGT CG ACGGAT CCCCGGGT 
3’ CGCCGGCGGTCGACTTCGAAGCATGCGACGTCCAGCTGCCTAGGGGCCCA
P m e  I 3' k a n M X 4  primer site -»
5’ T AATT AAGGCGCGCC AGAT CT GTTTAAACG AGCT CGAATT CAT CG AT GAT AT 
3’ ATTAATT CCGCGCCGT CT AG AC AAATTTGCT CG AGCTTAAGTAGCTACTATA
N o t  I
5’ CAGATCCACTAGTGGCCTATGCGGCCGC 
3’ GTCTAGGTGATCACCGGATACGCCGGCG
E ) The centromeric yeast shuttle vectors, pRS313 and pRS315 
The yeast shuttle vectors, pRS313 and pRS315 contain either a HIS3 or 
LEU2 selectable marker, respectively. They both have similar general 
structures (Figure 5.7a) and possess all the attributes of pBLUESCRIPT 
(Stratagene) including an extensive multiple cloning site (Figure 5.7b). 
Consequently, due to the fact they contain a bacterial origin of replication, all 
the standard DNA manipulations can be performed in E. coli. The Not I and 
Apa I enzyme recognition sites were found at either end of the multiple 
cloning site.
F) The pYX243 vector
The pYX243 plasmid is described in Section 3.2.3b (Figure 3.5).
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b - Multiple cloning site for the pRS3XX vector series. All the vectors in the series have the 
same multiple cloning site, but not all the restriction sites are unique for each vector. The 
restriction sites N o t  I and A p a  I are shown in bold.
S a c  II N o t  I
S a c  I B s fX  I E a g  I X b a  I S p e  I B a m H  I S m a  I P s t  I
TGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAG
BspD I K p n  I
EcoRI EcoRV H in d  III C/a I S a l I X h o  I A p a  I A c c 6 5 1
G AATT CG ATAT CAAGCTTAT CGAT ACCGT CGACCT CG AGGGGGGGCCCGGTACC
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5.3 METHODS - CONSTRUCTION OF THE scFv D1.3-S/VG* 
FUSION IN a-CELLS
5.3.1 Generation of the loxP-kanMX4-loxP 511 SAG1 gene disruption 
cassette.
A) Primer design
The sequences of the four primers used to generate the SAG1 disruption 
cassette (Table 5.4) were derived from the promoter and C-terminal regions 
of the a-agglutinin gene (SAG1 locus). The DNA sequences were obtained 
from the Saccharomyces cerevisiae genome database [SGD (http://genome- 
www.Stanford.eduA/L-yeast.html.)] and the accession number for the SAG1 
open reading frame is YJR004C.
The fundamental design parameters for primers were as described in 
section 2.2.4. The sagPlx and sagClx primers were designed to have their 
5’ ends homologous to 25 nucleotides of the pFA6a-MCS, each side of the 
kanMX4 cassette (Section 5.2.3d). Therefore, in the second PCR step, the 
disruption cassette can be assembled using a 'splicing by overlap extension' 
reaction (Figure 5.8). Both these primers also incorporated a loxP (or loxP 
511) site and contained 20 nucleotides of homology to the relevant regions 
of the SAG1 locus. The design of primer sagClx required extra 
consideration because the loxP 511 site is very adenine/thymine rich. To 
avoid any stop codons between the scFv D1.3 and C-terminal a-agglutinin 
gene fusion, two extra nucleotides (cytosine/adenine) were added after the 
loxP 511 site, to maintain the open reading frame (Figure 5.9). The loxP and 
loxP 511 sites were also 'inverted' due to the fact that only one reading 
frame was available which did not contain any stop codons.
B) PCR amplification of the promoter and C-terminal a-agglutinin regions 
Two separate Expand™ PCRs (Section 2.2.7c) were performed to amplify 
the promoter and C-terminal regions of the a-agglutinin gene from yeast 
genomic DNA. The genomic DNA was prepared from the S. cerevisiae a- 
strain, FY10 following the procedure outlined in Section 2.2.21.
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The primer combination sagP1x/alp1(p) was used to amplify the 
promoter region of the a-agglutinin gene. The reaction was performed for 25 
cycles using the following parameters: [94°C, 2min; (94°C, 15s; 55°C, 30s; 
72°C, 55s) x 10; (94°C, 15s; 55°C, 30s; 72°C, 55s + 20s/cycle) x 15; 72°C, 
5min].
The C-terminal region of a-agglutinin was amplified using the primer 
combination sagClx/a(F) and the PCR conditions for this reaction were the 
same as above, except the annealing temperature was 52°C.
Both PCR products were purified (Section 2.2.9b) and quantified by 
agarose gel electrophoresis (Section 2.2.8).
Figure 5.8 Schematic representation of the two-step PCR synthesis of the lo x P -k a n M X 4 -  
lo x P  5 1 1  S A G 1  disruption cassette. L represents the a-agglutinin leader sequence and the 
different shaded boxes illustrate the promoter, N-terminal and C-terminal parts of the a- 














lo x  P511
I C-terminal
a(F)
I’Splicing by overlap extension' reaction
lo x  P lo x  P511
IPromoter ■  kanMX4 ■  C-terminal
Figure 5.9 S c h e m a t i c  r e p r e s e n t a t i o n  o f  t h e  s c F v  D 1 . 3 / a - a g g l u t i n i n  g e n e  f u s i o n  i n c l u d i n g  s e q u e n c e  d e t a i l s  o f  t h e  
r e g i o n s  e n c o d i n g  t h e  N -  a n d  C - t e r m i n a l  e n d s .  R e s t r i c t i o n  s i t e s  a r e  r e p r e s e n t e d  i n  b o l d  a n d  t h e  e x t r a  n u c l e o t i d e s  
a r e  u n d e r l i n e d .
Hind I I I Sph I
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Table 5.4 Sequences of the oligonucleotides used in the generation of the loxP-kanMX4- 
loxP 511 SAG1 disruption cassette. The loxP and loxP 511 sites are underlined.
Primer Name Sequence (5'-3') Description (5'-3')
alp1(p) TGATGATTTGAACGATCTCC Binds 950-930 b.p. upstream from 




TATGCTATACGAAGTTA11 I T 
GAAAACTGGCGAATTGT
25 n.t. of homology to the 5' end of 
pFA6a-MCS; 34 n.t loxP site; 20 
n.t. of homology to the promoter 
region directly before the SAG1 





25 n.t. of homology to the 3' end of 
pFA6a-MCS; 34 n.t. loxP 511 site; 
two extra n.t.; 20 n.t of homology to 
the Watson strand of the N/C 
junction of a-agglutinin (975-955 
b.p. upstream from the SAG1 stop 
codon).
a(F) AACT GTACAGTACCCGTT Binds 18 n.t. directly after the SAG1 
stop codon (Crick strand).
C) Digestion of pFA6a-kanMX4 vector with Not I
The vector, pFA6a-kanMX4 (~1pg) was digested with 10units of Not I 
overnight at 37°C (Section 2.2.12). The 1.5 k.b.p. kanMX4 cassette was 
separated from the pFA6a plasmid by low melting point agarose gel 
electrophoresis (Section 2,2.8) and purified (Section 2.2.9b).
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D) PCR mediated generation of the SAG1 disruption cassette 
Approximately equal amounts (~50ng) of the Not I digested kanMX4 
cassette, the promoter and C-terminal a-agglutinin fragments were added 
together in an Expand™ PCR (Section 2.2.7c) with the primer pair 
alp1(p)/a(F). The reaction conditions were: [94°C, 2min; (94°C, 15s; 60°C, 
2min; 68°C, 2min) x 10; (94°C, 15s; 60°C, 2min; 68°C, 2min + 20sec/cycle) x 
15; 72°C, 5min]. The assembled product (3.6 k.b.p.) was separated from the 
other non-specific bands by low melting point agarose gel electrophoresis 
(Section 2.2.8) and recovered using p-agarase (Section 2.2.9a).
5.3.2 Integration of the loxP-kanMX4-loxP 511 SAG1 disruption 
cassette into FY10
A ) Transformation ofSAGI gene disruption cassette into FY10 
The assembled kanMX4 SAG1 disruption cassette (~250ng) was 
transformed into the S. cerevisiae a-strain (FY10) using a lithium 
acetate/polyethylene glycol transformation protocol (Section 2.2.24).
B ) Verification of G418r transformants by PCR
Yeast genomic DNA was made (Section 2.2.21) for three geneticin resistant 
transformants. Two sets of primers were used to check both novel joints that 
were formed upon integration (Table 5.5; Figure 5.10) via Taq PCRs 
(Section 2.2.7b).
Genomic integration of the disruption cassette at the promoter end of the 
SAG1 locus was verified using the FL2B/Apl(seq) primers. The cycling 
parameters were: [(94°C, 1min; 50°C, 1min; 72°C, 1.30min) x 30; 72°C, 
10min].
The C-terminal integration event was examined using the primer 
combination FL1F/YJR003C and the conditions were the same as above 
except that the elongation time was one minute. All PCR products were 
analysed by agarose gel electrophoresis (Section 2.2.8).
N.B. A wild type genomic DNA PCR control was run in conjunction.
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C ) Analysis of the integration sites by DNA sequencing 
The primer pair APL(seq)/YJR003C was used to amplify a 4.1 k.b.p. PCR 
product containing both integration sites from the yeast genomic DNA of one 
positive transformant. An Expand™ PCR (Section 2.2.7c) was performed 
and the conditions were: [94°C, 2min; (94°C, 15s; 50°C, 30s; 68°C, 2.30min) 
x 10; (94°C, 15s; 50°C, 30s; 68°C, 2.30min + 20s/cvcle) x 15; 72°C, 5min]. 
The total PCR (5 0 jliI) was resolved on a low melting point agarose gel 
(Section 2.2.8) and purified using p-agarase (Section 2.2.9a).
Five separate DNA sequencing reactions (Section 2.2.18) were carried 
out to check the various parts of the integrated construct. The primers 
Apl(seq) and YJR003C were used to analyse the promoter and C-terminal 
integration sites, respectively. The loxP and loxP 511 sites were analysed 
with primers FL2B and FLIF. The middle section of the C-terminal a- 
agglutinin was examined with primer AggSeq2 (Figure 5.10). This a-strain 
containing the correct integrated loxP-kanMX4-loxP 511 disruption cassette 
was named CAY1 (Table 5.11).
Figure 5.10 Diagrammatic representation of the primer sites used for the verification and 
sequencing of the integration events at the SAG1 locus. Symbols ’ X • represent the novel 
joints formed by homologous recombination and ’ symbolises the oligonucleotides. 
Figure is not to scale.
FL1F AggSeq2
APL(seq) lo x P  lo x P 5 1 1
Promoter | k a n M X 4 |  C-terminal X
FL2B YJR003C
Chapter 5 - Construction o f agglutinin mutants 159
Table 5.5 Sequences of the oligonucleotides used in the verification and sequencing of the 
SAG1 integration events.
Primer Name Sequence (5'-3') Description (5'-3')
AggSeq2 CCATCTGAAGAGCCCACTTT 434-454 b.p. upstream from the 
SAG1 stop codon (Watson 
strand).
APL(seq) TCGCCATAGTTTCCTAGAAC 1195-1215 b.p. from SAG1 start 
codon (Watson strand).
FL2B GGCGACAGT CACAT CAT GCC 163-183 b.p. downstream of 5' 
end of kanMX4 (non-coding 
strand).
FL1F CCT CG AC AT CAT CTG CCC 162-180 b.p. upstream of 3' end of 
kanMX4 (coding strand).
YJR003C ATTATTGAATGGCGGTTAGC 337-357 b.p. downstream from the 
SAG1 stop codon (Crick strand).
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5.3.3 Construction of pYX243-/ox D1.3 vector
Figure 5.11 A flow diagram summarising the construction of the vector, pYX243-/ox D1.3.
pYX(FOR)




AMP L E U 2
i Inverse PCR
H in d  III X h o  I
-  MCS
AMP L E U 2
i I) Freeze-dry ligation of the lo x P  5 1 1  cassette.II) Ligation of lo x P  5 1 1  cassette into pYX243-/oxP- H in d  IIIIX h o  I vector.
H in d  III S p h  I X h o  I
p YX243-loxP/loxP511
AMP L E U 2
H in d  III
Ligation of scFv D1.3-H/nd III/S p h  I into pYX243- 
lo x P / lo x P  5 1 1 -H in d  III/ S p h  I
S p h
pYX243-/ox D1.3
AMP L E U 2
scFv D1.3 lo x P  5 1 1
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A) Construction of pYX243-loxP using inverse PCR
An 8 k.b.p. inverse DNA fragment was generated using pYX243 (~75ng) as 
a DNA template and the primer pair pYX(FOR)/243LXB in an Expand™ 
PCR (Section 2.2.7c; Figure 5.11).The inverse PCR method requires the use 
of primers complementary to opposite strands of DNA and orientated so that 
primer extension proceeds 5' to 3' from each primer towards the other primer 
(Triglia et ai, 1988). The primer pYX(FOR) was designed to bind to the 
coding strand at the 3' end of the GAL1 promoter and 243LXB was designed 
to bind to the non-coding strand at the 5' end of the GAL1 promoter. The 
primer 243LXB also incorporated a loxP site and a Hind III restriction site. 
This vector created by inverse PCR did not have a GAL1 promoter and was 
named pYX243-/oxP. The basic design parameters for primers were 
followed (Section 2.2.4) and table 5.6 describes the oligonucleotides in more 
detail.
The cycling parameters for the PCR were: [94°C, 2min; (94°C, 15s; 50° 
C, 30s; 68°C, 6min) x 10; (94°C, 15s; 50°C, 30s; 68°C, 6min + 20s/cycle) x 
15; 72°C, 6min]. Two identical PCR products (100^1) were analysed on a low 
melting point agarose gel (Section 2.2.8), purified (Section 2.2.9b) and the 
aliquots were pooled together for subsequent manipulations.
The vector, pYX243-loxP was digested with Hind III (10units) and Xho I 
(20units) overnight at 37°C (Section 2.2.12). This digested fragment was 
resolved on a low melting point agarose gel (Section 2.2.8) and purified 
(Section 2.2.9b).
B) Freeze-dry ligation of loxP 511 cassette into pYX243-loxP
A double stranded oligonucleotide loxP 511 building block cassette (56 b.p.) 
was constructed by annealing oligonucleotides, loxP511A(NEW) and 
loxP511B(NEW) [Table 5.6]. The primers were designed to contain a loxP 
511 site, a nine nucleotide spacer region, a Sph I site and one extra 
nucleotide to maintain the open reading frame of the scFv D1.3-a-agglutinin 
fusion. They also both contained partial Xho I and Hind III recognition sites 
at appropriate ends for cloning into pYX243-loxP.
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Each primer (200 pmoles) was phosphorylated at the 5' terminus with T4 
polynucleotide kinase at 37°C for 60 minutes. The reaction mixture 
contained 10units of T4 polynucleotide kinase and 5^ 1 of 10 x polynucleotide 
kinase buffer [700mM Tris-HCI (pH7.6), 100mM MgCh, 50mM DTT] in a total 
volume of 50 nl. After the incubation period, the T4 polynucleotide kinase 
was heat inactivated at 65°C for 20 minutes. Annealing was performed in a 
0.5ml Eppendorf by mixing an equimolar amount of each oligonucleotide 
(0.1 pmoles) and 2.5|il of T4 DNA ligase buffer (Section 2.2.13), in a final 
volume of 25jj.I. The lid of the 0.5ml Eppendorf was pierced with a needle 
and then the Eppendorf was dipped in liquid nitrogen for 60 seconds. The 
Eppendorf was then quickly transferred to a 500ml round bottom flask (pre­
chilled at -20°C) and lyophilised using a Lyoprep-300 freeze-drier 
(International Equipment Company, Dunstable, UK) at less than 0.05mbar 
for 2 hours. The lyophilised pellet was resuspended in 25 i^l of water (4°C) 
and used as an insert in a standard ligation reaction (Section 2.2.13) with 
digested vector, pYX243-/oxP-H/nd IIIIXho I. Ligations with molar ratios 
(insert:vector) of 50:1,10:1 and 1:1 were carried out and transformed directly 
into E  coli cells (Section 2.2.15).
C) Verification ofloxP 511 site in vector pYX243-loxP/loxP 511
Eight putative positive transformants were PCR screened (Section 2.2.16) 
with the primer pair lnvpYX(FOR)/lnvpYX(BACK) (Table 5.6). The PCR 
products were alcohol precipitated (Section 2.2.10) and the DNA pellets 
were resuspended in 10jil of water. Each precipitated PCR product was 
digested with Sph I (5units) overnight at 37°C (Section 2.2.12), in a total 
reaction volume of 15pil. The entire reactions were analysed by agarose gel 
electrophoresis (Section 2.2.8) and glycerol stocks (Section 2.2.3) were 
made of transformants that contained the vector with the Sph I recognition 
site. This constructed vector was then referred to as pYX243-/oxP/7oxP 511.
D) PCR amplification of scFv D1.3
The scFv D1.3 open reading frame was amplified by an Expand™ PCR 
(Section 2.2.7c) using the vector pUC119His6mycXba-scFv D1.3 as a DNA
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template and the primer pair DF/DB(Sphl) (Table 5.6). The primer DF was 
designed to anneal to the first 19 b.p. of the 5' end of scFv D1.3 and also 
encoded the a-agglutinin leader sequence. The oligonucleotide DB(Sphl) 
annealed to the last 18 b.p. of scFv D1.3 (before the stop codon) and 
incorporated an extra two cytosine nucleotides to maintain the open reading 
frame of the scFv D1.3/a-agglutinin gene fusion. To facilitate cloning, either 
a Hind III site (DF) or Sph I site [DB(Sphl)] were introduced to the 5' ends of 
the oligonucleotides. The PCR conditions for this amplification were: [94°C, 
2min; (94°C, 15s; 60°C, 30s; 72°C, 50s) x 10; (94°C, 15s; 60°C, 30s; 72°C, 
50s + 20s/cycle) x 15; 72°C, 5min]. The amplified DNA fragment (804 b.p.) 
was purified (Section 2.2.9b) and quantified using agarose gel 
electrophoresis (Section 2.2.8).
E) Construction of plasmid pYX244-lox D1.3
The vector, pYX243-/oxP/7oxP 511 and the amplified scFv D1.3 fragment 
were digested with Hind III (10units) and Sph I (5units) overnight at 37°C 
(Section 2.2.12). Both were purified using the appropriate DNA extraction 
kits (Section 2.2.9b) and quantified by agarose gel electrophoresis (Section
2.2.8). ScFv D1.3-Hind UUSph I was ligated with pYX243-/oxP/7oxP 511-Hind 
III/Sph I (Section 2.2.13) and transformed into E. coli cells (Section 2.2.15). 
The ampicillin-resistant colonies were PCR screened (Section 2.2.16) using 
primers lnvpYX(FOR)/lnvpYX(BACK). The PCR products were analysed by 
agarose gel electrophoresis (Section 2.2.8) and transformants with insert 
were grown overnight in 3ml of LB (Section 2.2.1). Glycerol stocks were 
prepared (Section 2.2.3) and the remaining cultures were used for plasmid 
DNA preparations (Section 2.2.17). DNA sequencing (Section 2.2.18) was 
performed using primers InvpYX(BACK) and InvpYX(FOR).
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Table 5.6 Sequences of oligonucleotides used in the construction of vector pYX243-/ox 
D1.3. The loxP and toxP 511 sites are underlined and the restriction endonuclease 
recognition sites are in bold.
Primer Name Sequence (5'-3') Description (5'-3')
243LXB GCGAGAAGCTTATAACTTCGTA 
TAATGTATGCTATACGAAGTTAT 
AAT GACAGCT C AGTTACA
5 n.t. overhang, a Hind III site, 34n.t. loxP site, 
18n.t. of homology to non-coding strand of 
pYX243 (7934-7942).
pYX(FOR) TACTTTAACGTCAAGGAG 18 n.t. of homology to the coding strand of 
pYX243 (8592-8610).
loxp511A(NEW) AGCTTGCAGGTCAGGCATGCAA  
TAACTTCGT AT AGTAT ACATT AT 
ACGAAGTTATC
5 n.t. partial Hind III site; 9  n.t. spacer region; a 
Sph 1 site; 1 extra n .t; 34  n.t. loxP 511; 1 n.t. 
partial Xho I.
loxp511B(NEW) TCGAG ATAACTT CGTATAATGTA 
TACTATACGAAGTTATTGCATGC  
CTGACCTGCA
5 n.t. partial Xho  I site, 34 n.t. loxP 511 site, 1 
extra n.t.; a Sph 1 site; 9 n.t. spacer region.l n .t 
partial Hind III site.
InvpYX(FOR) ATTAGCTCTACCACAGTG 18 n.t. of homology to the coding strand of 
pYX243 (7924-7942).
InvpYX(BACK) CCAGT CACGACGTT GTAA 18 n.t. of homology to the non-coding strand of 
pYX243 (245-263).
DF GCGAGAAGCTTATGTTCACTTT  
T  CTCAAAATTATTCT GTGGCTTT  
TTT CCTT GGCATTGGCTAGCGC  
TCAGGT GCAGCT GCAGGAGT
5 n.t. overhang; a Hind III site; 56 n.t. a - 
agglutinin leader sequence and 19 n.t. of 
homology to the &  end of scFv D1.3 (coding 
strand).
DB(Sph1) CTGAGATACTGCATGCCCCCGT 
TT GAT CT CGAGCTT
10 n.t. overhang; a Sph I site; 2 cytosine n.t.; 18 
n.t. of homology to the 31 end of scFv D1.3 
(non-coding strand).
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5.3.4 Verification of the Cre recombinase expression vector, pBS39
The Cre expression vector, pBS39 (~1pg) was digested with Xho I (20units) 
overnight at 37°C (Section 2.2.12) and analysed by agarose gel 
electrophoresis (Section 2.2.8). DNA sequencing was performed (Section 
2.2.18) using primers Cre(Back) [Table 5.7] and pYX(FOR) [Table 5.6].
5.3.5 Transformation of the SAG1 disrupted a-strain with pBS39 and 
pYX243-/ox D1.3
The vectors, pYX243-/ox D1.3 (~2pg) and pBS39 (~2pg) were co­
transformed (Section 2.2.23) into the a-strain containing the loxP-kanMX4- 
loxP 511 cassette integrated into its SAG1 locus (CAY1; Table 5.11). Leu+ 
Ura+ transformants were PCR screened (Section 2.2.16) for the presence of 
both plasmids in separate PCRs. The pBS39 plasmid was detected using 
primers Cre(back)/pYX(FOR) and the pYX243-/ox D1.3 plasmid was 
identified using primers lnvpYX(FOR)/lnvpYX(BACK). Each PCR was 
analysed by agarose gel electrophoresis (Section 2.2.8) and positive 
transformants were grown in 1ml of SC lacking uracil and leucine 
(supplemented with 2% raffinose) for 24 hours, at 30°C. Glycerol stocks 
were prepared (Section 2.2.3) and a 100jal aliquot of one culture was plated 
onto an SC agar plate containing 2% raffinose but lacking uracil and leucine. 
This was used as a stock plate.
Note: 2pg of pBS39 only, was also transformed into the SAG1 disrupted a- 
strain (CAY1; Section 2.2.23) and SC without uracil/2% raffinose media was 
used throughout.
5.3.6 Solid plate galactose induction of Cre recombinase (Sauer et 
at., 1987)
A single colony of the SAG1 disrupted a-strain (CAY1; Table 5.11) 
containing plasmids pBS39 and pYX243-/ox D1.3 was streaked onto a 
minimal media plate [0.67% (w/v) Bacto-yeast base without amino acids, 2% 
(w/v) Bacto-agar] supplemented with either 2% (w/v) glucose (SD) or 2% 
(w/v) galactose (SG). These plates were incubated at 30°C for 4 days. Three 
individual galactose grown colonies and one glucose grown colony were
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picked and dispersed into 10ml of YPD. These cultures were incubated at 
30°C, overnight. After this time, 200jil of each culture were transferred to 
fresh YPD (10ml) and incubated again overnight. This process was repeated 
for 3 days to remove both of the plasmids. The cultures were then counted 
using a haemocytometer, appropriately diluted in water and plated onto YPD 
agar plates. These plates were incubated for 16-24 hours at 30°C and the 
resulting colonies were replica-plated to YPD plates supplemented with 
200mg/l genetidn (G418). These were then grown at 30°C for 16-24 hours 
and the geneticin-sensitive colonies were re-streaked onto YPD/G418 plates 
to determine 100% sensitivity. The colonies were also replica-plated onto the 
appropriate selective media to determine plasmid loss.
5.3.7 Liquid galactose induction of Cre recombinase
Three separate colonies of the SAG1 disrupted a-strain (CAY1; Table 5.11) 
containing plasmids pBS39 and pYX243-/ox D1.3 were grown in SC media 
without uracil and leucine [supplemented with 2% (w/v) raffinose] overnight 
at 30°C. The cells were then counted using a haemocytometer and diluted to 
5 x 106 cells/ml in the same media. Galactose [20% (w/v)] or glucose [20% 
(w/v)] were added to a final concentration of 2% (w/v) and incubated at 30°C 
for either 5 or 24 hours. After this time, 200^1 of the induced culture was 
transferred to 10ml of YPD and grown overnight at 30°C. This process was 
repeated for 3 days to remove the plasmids. The cells were then counted, 
diluted appropriately with water and spread onto YPD plates. These plates 
were incubated for 24-36 hours at 30°C and the resulting colonies were 
replica-plated onto YPD plates supplemented with 200mg/l geneticin (G418). 
These were then grown at 30°C for 16-24 hours and the geneticin-sensitive 
colonies were re-streaked onto YPD/G418 plates to determine 100% 
sensitivity. The colonies were also replica-plated onto the appropriate 
selective media to determine plasmid loss.
5.3.8 Verification of scFv D1.3 integration into the SAG1 locus
Colonies that could not grow on geneticin (G418) were selected from the 
original YPD plate and transferred to 10 ml of YPD. These cultures were
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grown overnight (30°C) and total yeast genomic DNA was prepared for each 
(Section 2.2.21). Individual genomic DNA samples were screened using 
three primer pairs in separate standard Taq PCRs (Section 2.2.7b). Primers 
Apl(seq)/DB(Sph1) analysed the 5' end, d13scb/YJR003C checked the 3' 
end and Apl(seq)/YJR003C amplified the total SAG1 locus (Figure 5.12).The 
PCR conditions for the total amplification of the SAG1 locus were: [(94°C, 
1min; 50°C, 1min; 72°C, 3min30s) x 30; 72°C, 10min] and the PCR 
parameters for the amplification of the 5' and 3' ends were the same, except 
the elongation time was 2 minutes.
Figure 5.12 illustrates the primer sites used for the analysis and sequencing of scFv D1.3 in 
the S A G 1  locus. S y m b o l r e p r e s e n t s  the oligonucleotides (not to scale).
APL(seq) alpha(p) d13scb
Promoter scFv D1.3 I C-terminal
lo x P  lo x P  5 1 1
YJR003C
DB(Sphl) AggSeql
The PCR products were analysed by agarose gel electrophoresis 
(Section 2.2.8) and one positive integrant was chosen for DNA sequencing. 
An Expand™ PCR (Section 2.2.7c) was used to amplify the total scFv D1.3- 
SAG1 gene fusion with primers APL(seq)/YJR003C. The PCR conditions 
were: [94°C, 2min; (94°C, 15s; 50°C, 30s; 68°C, 3min) x 10; (94°C, 15s; 
50°C, 30s; 68°C, 3min + 20s/cycle) x 15; 72°C, 5min] and the 3.4 k.b.p. DNA 
fragment obtained was purified using p-agarase (Section 2.2.9a). The scFv 
D1.3, loxP and loxP 511 sites were sequenced using primers AggSeql and 
alpha(p) [Table 5.7]. The a-strain containing the correctly integrated scFv 
D1.3 at the SAG1 locus was named CAY2 (Table 5.11).
Chapter 5 - Construction of agglutinin mutants 168
Table 5.7 Sequences of the oligonucleotides used in the screening of pBS39 and for the 
sequencing of integrated scFv D1.3 at the SAG1 locus.
Primer Name Sequence (5'-3’) Description (5-31)
d13scb CCAAGCT CG AGAT CAAAC 
GG
Binds to the coding strand at the 3' end 
of scFv D1.3, before the Sph I site.
Cre(Back) TTGAAGGCTCTCAAGGG
C
Binds 4 b.p. after the Sal I site on pBS39 
(non-coding strand).
Agg Seq 1 GCCTGTTTCTACTGTGGA
AAT
Binds to the Crick strand of SAG1, 859- 




Binds to the Watson strand of SAG1, 
462-482 b.p. upstream from start.
5.3.9 Construction of plasmid pRS315-lox D1.3
A) Removal of Kluyveromyces lactis URA3 marker from TG5756 to 
generate pRS315-Apa I/Not I
A restriction digestion (Section 2.2.12) with enzymes Apa I and Not I was 
performed sequentially on plasmid TG5756 because the reaction 
requirements were incompatible. The vector, TG5756 (~1.5pg) was first 
digested with 10units of Apa I overnight at 25°C. The linearised plasmid was 
purified (Section 2.2.9b) and then incubated with Not I (1 Ounits) overnight at 
37°C. An 6 k.b.p DNA fragment was resolved by low melting point agarose 
gel electrophoresis (Section 2.2.8) and recovered using the DNA Clean Up 
System (Section 2.2.9b).
Chapter 5 - Construction of agglutinin mutants 169
B) PCR amplification of loxP-scFv D1.3-loxP 511
Primers pRS315(Apal)/pRS315(Notl) were designed to anneal to the 
pYX243-/ox D1.3 vector either side of the loxP/loxP 511 sites (Table 5.8). To 
facilitate cloning, an Apa I or a Not I recognition site were incorporated into 
the 5’ ends of the oligonucleotides. An Expand™ PCR (Section 2.2.7c) was 
used to amplify the 907 b.p. fragment containing the loxP/loxP 511 sites and 
the scFv D1.3 gene. The following PCR conditions were used: [94°C, 2min; 
(94°C, 15s; 55°C, 30s; 72°C, 1min) x 10; (94°C, 15s; 55°C, 30s; 72°C, 1min 
+ 20s/cycle) x 15; 72°C, 5min]. The PCR product was purified (Section 
2.2.9b) and then digested sequentially with Not I and Apa I (Section 5.3.9a). 
The double digested product was then quantified using agarose gel 
electrophoresis (Section 2.2.8).
C) Cloning of loxP-scFv D1.3-loxP 511 into pRS315
The scFv D1.3-Apa VNot I insert was ligated into plasmid pRS315-Apa VNot 
I (Section 2.2.13). The ligation reaction was transformed into E. coli (Section
2.2.15) and ampicillin-resistant colonies were PCR screened (Section
2.2.16) to check for the scFv D1.3 insert using primers T7/M13 (Table 5.8). 
The PCR products were analysed by agarose gel electrophoresis (Section
2.2.8) and positive transformants were grown overnight in 3ml of LB (Section 
2.2.1). Glycerol stocks (Section 2.2.3) and plasmid DNA (Section 2.2.17) 
were prepared. The construct of one transformant was checked for 
mutations using primers T7 and M13 by DNA sequencing (Section 2.2.18).
5.3.10 Transformation of the SAG1 disrupted a-strain with pBS39 and 
pRS315-/ox D1.3
The vectors, pRS315-/ox D1.3 (~2^g) and pBS39 (~2pig) were co­
transformed (Section 2.2.23) into a-strain containing the loxP-kanMX4-loxP 
511 cassette integrated into its SAG1 locus (CAY1; Table 5.11). Ura+ Leu+ 
transformants were PCR screened (Section 2.2.16) for both plasmids using 
the primer pairs T7/M13 and pYX(FOR)/Cre(Back) for detection of pRS315- 
lox D1.3 and pBS39, respectively. Each PCR was analysed by agarose gel 
electrophoresis (Section 2.2.8) and positive transformants were grown in 1 ml
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of SC lacking uracil and leucine [supplemented with 2% (w/v) raffinose] for 
24 hours (30°C). Glycerol stocks were made (Section 2.2.3) and a 100pl 
aliquot of one culture was plated onto an SC without uracil and leucine 
containing 2% (w/v) raffinose] agar plate. This was used as a stock plate.
Table 5.8 Sequences of the oligonucleotides used in the construction and sequencing of 
plasmid pRS315-/ox scFv D1.3. Enzyme recognition sites are in bold.
Primer name Sequence (5'-3') Description (5'-3')
pRS315(Apal) CAGATGGGCCCTGTAACT 
GAGCT GT CATT
5 n.t. overhang: an Apa I site; 18 n.t. of 
homology to the coding strand of 




10 n.t. overhang : a Not I site; 18 n.t. of 
homology to the non-coding strand of 
pYX243-/ox D1.3 (primer annealed to 8 
n.t. of the loxP 511 site and 10 n.t. to 
the following vector sequence).
17 GTAATACGACTCACTATAG
GGC
Binds 13 b.p. downstream from the 




Binds 67 b.p. upstream from the Not I 
site on pRS315 (coding strand).
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5.4 METHODS - CONSTRUCTION OF THE AGA2-HEWL 
FUSION IN a-CELLS
The methods described in this section are similar to the construction of the 
scFv D1.3-SAG7 gene fusion in a-cells.
5.4.1 Generation of the loxP 511-kanMX4-loxP AGA2 gene disruption 
cassette.
A) Primer design
The sequences of the four primers used to generate the AGA2 disruption 
cassette were derived from the open-reading frame of the a-agglutinin gene 
(AGA2 locus) and the surrounding loci. The DNA sequences were obtained 
from the Saccharomyces cerevisiae genome database (SGD) and the 
accession number for the AGA2 open reading frame was YGL032C.
Figure 5.13 outlines the scheme for the production of the loxP 511- 
kanMX4-loxP AGA2 disruption cassette. A description of each primer can be 
found in table 5.9 and the basic design parameters for primers were as 
described in Section 2.2.4. The AGA2FUSP(BACK) and HOP2P(FOR) were 
designed to have their 5' ends homologous to 25 nucleotides of the pFA6a- 
MCS, each side of the kanMX4 cassette (Section 5.3.2d). These two primers 
also incorporated the loxP and loxP 511 sites. The primer, 
AGA2FUSP(BACK) was designed to remove the stop codon at the 3' end of 
the AGA2 ORF and the loxP 511 sequence was kept in a frame which did 
not encode any stop codons (Figure 5.14). The primer, HOP2(BACK) was 
designed to anneal directly after the HOP2 gene to avoid disrupting its 
function.
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Figure 5.13 Schematic representation of the two-step PCR synthesis of the lo x P  5 1 1 -  
k a n M X 4 - lo x P  A G A 2  disruption cassette. RPL30A is a ribsomal protein present 219 b.p. 
upstream from the A G A 2  locus. H O P 2  is a meiosis-specific gene important in the process of 
pairing homologous chromosomes and is 634b.p. downstream from the A G A 2  locus. (Figure 
is not to scale).
AGA2FUS(FOR) HOP2P(FOR)









'Splicing by overlap 
extension' reaction
H O P 2
HOP2(BACK
AGA2 kanMX4 HOP2. .
lo x P  5 11  Io x P
Figure 5.14 Schematic representation of the a-agglutinin/HEWL gene fusion including details of the 5' and 3' 
recombination sites. Restriction sites are represented in bold and the extra nucleotides are underlined. The stop 
codons are shown using the letter 0.
Sph I  Hind I I I
START
AG A2 lo x P  511 HEWL 11
111
STOP STOP
5 '  DNA r e c o m b i n a t i o n  s i t e
l o x P  511
82 90 100
I I I
N T Q Y V F I  T S Y N V Y Y T K L L H A K V F G R C  
AACACAC AGT AT GT T TT T ATAAC T T C GT AT AAT GT AT AC TAT AC GAAGT T ATXGCATGCAAAAGT CT T T GGAC GAT GT
S p h  I  . .
AGA2 HEWL
3 '  DNA r e c o m b i n a t i o n  s i t e
230 l o x P
I i------------------------------------------ 1R G C R L 0  0
AGAGGCTGCCGGCTGTGATAAAAGCTTATAACTTCGTATAATGTATGCTATACGAAGTTATTGAGCCTTCCCCCCCAAGTT
H ind  I I I
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Table 5.9 Sequences of the oligonucleotides used in the generation of the toxP 511- 
kanMX4-loxP AGA2 disruption cassette. The loxP and loxP 511 sites are underlined.
Primer name Sequence (5’-3’) Description (5'-3*)
AGA2FUS(FOR) TCGAACTTATTAT GTACAAT Binds 604-624 b.p. upstream 






25 n.t. of homology to the 5’ end 
of pFA6a-MCS; a 34 n.t. loxP 
511 site; 20 n.t. of homology to 
the AGA2 gene directly 






25 n.t. of homology to the 3' end 
of pFA6a-MCS; a 34 n.t. loxP 
site; 20 n.t. of homology to the 
AGA2 locus directly from the 
stop codon (Watson strand).
HOP2(BACK) ATTAACTTGTAGT CGGAT CG Binds 1323-1343 b.p. 
downstream from the AGA2 stop 
codon (Crick strand).
B) PCR amplification of the AGA2 and HOP2 gene fragments 
Two separate Expand™ PCRs (Section 2.2.7c) were performed to 
generate the AGA2 and HOP2 regions of the AGA2 disruption cassette 
from FY22 genomic DNA (Section 2.2.21).
The primer combination AGA2FUS(FOR)/(iteA2FUSP(BACK) was 
used to amplify the AGA2 DNA fragment (884 b.p.) and the reaction
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conditions were: [94°C, 2min; (94°C, 15s; 50°C, 30s; 72°C, 1min) x 10; 
(94°C, 15s; 50°C, 30s; 72°C, 1min + 20s/cycle) x 15; 72°C, 5min].
The HOP2 DNA fragment (1343 b.p.) was amplified using the primer 
pair HOP2P(FOR)/HOP2(BACK) and the cycling parameters were the 
same as above, except the annealing temperature was 45°C.
Both PCR products were purified (Section 2.2.9b) and quantified by 
agarose gel electrophoresis (Section 2.2.8).
C) PCR-mediated generation of the loxP 511-kanMX4-loxP AGA2 
disruption cassette
Approximately equal amounts (~50ng) of the Not I digested kanMX4 
cassette, the AGA2 and HOP2 PCR fragments were added together in a 
standard Expand™ PCR (Section 2.2.7c) with the primer pair 
AGA2FUS(FOR)/HOP2(BACK). The reaction conditions were: [94°C, 2min; 
(94°C, 15s; 50°C, 2min; 68°C, 2min30s) x 10; (94°C, 15s; 50°C, 2min; 
68°C, 2min30s+ 20s/cycle) x 15; 72°C, 5min].
The assembled product (3.8 k.b.p.) was separated from the other non­
specific bands by low melting point electrophoresis (Section 2.2.8) and 
purified using p-agarase (Section 2.2.9a).
5.4.2 Integration of the loxP 511-kanMX4-loxP AGA2 disruption 
cassette into the FY22 genome
A) Transformation of the AGA2 gene disruption cassette into FY22 
Approximately 250ng of the assembled kanMX4 AGA2 disruption cassette 
was transformed into the S. cerevisiae a-strain (FY22) using a lithium 
acetate/polyethylene glycol transformation protocol (Section 2.2.24).
B) Verification of G41& transformants by PCR
Genomic DNA was prepared (Section 2.2.21) for two geneticin resistant 
transformants. Two sets of primers (Tables 5.5 and 5.10) were used to 
check the two novel joints formed upon homologous recombination by 
standard Tag PCRs (Section 2.2.7b).
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Integration of the disruption cassette at the 5' end of the AGA2 locus was 
verified using primers RPL30A(seq)/FL2B (Tables 5.10 and 5.5). The 3‘ 
HOP2 integration event was verified using primers FLIF/HOP2(seq) [Tables
5.5 and 5.10]. Figure 5.15 illustrates the regions of the AGA2 locus that were 
amplified by the designed primers. The reaction conditions were the same 
for both PCRs. [(94°C, 1min; 50°C, 1min; 72°C, 1min) x 25; 65°C, 5min] and 
the PCR products were analysed by agarose gel electrophoresis (Section
2 .2 .8).
Figure 5.15 Diagrammatic representation of the primer sites used for the verification and 
sequencing of the integration events at the A G A 2  locus. Symbols 'X ' represents the novel 
joints formed by homologous recombination and 1 -► ’ symbolises the oligonucleotides 
(Figure is not to scale).
RPL30A(seq) FL1F
A G A 2 I
lo x P  511




H O P 2  .
HOP(seq)
C) Analysis of the AGA2 integration sites by DNA sequencing 
The primer pair RPL30A(seq)/HOP(seq) [Table 5.10] was used to amplify an 
4.0 k.b.p. PCR product containing both the integration sites from the 
genomic DNA of one of the positive transformants. An Expand ™ PCR was 
followed (Section 2.2.7c) using the reaction conditions: [94°C, 2min; (94°C, 
15s; 50°C, 30s; 68°C, 3min) x 10; (94°C, 15s; 50°C, 30s; 68°C, 3min+ 
20s/cycle) x 15; 72°C, 5min], The total PCR (50pl) was loaded onto a low 
melting point agarose gel (Section 2.2.8) and recovered using p-agarase 
(Section 2.2.9a). Two separate DNA sequencing reactions (Section 2.2.18) 
were carried out with the primers FL1F and FL2B to check the loxP/loxP 511 
sites of the integrated construct. The constructed a-strain containing the 
correctly integrated loxP 511-kanMX4-loxP disruption cassette at its AGA2 
locus was named CAY3 (Table 5.11).
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5.4.3 Construction of the pRS313-lox HEWL plasmid
A) Cloning of HEWL into pYX243-loxP/loxP 511
The HEWL gene was amplified using pl)C8-HEWL as a DNA template and 
the primer pair, LysF(Sphl)/LysB(Hindlll), in an Expand™ PCR (Section 
2.2.7c). The primer, LysF(Sphl) was designed to anneal to the first 18 b.p. of 
the 5' end of HEWL and incorporated an extra adenine nucleotide to keep 
the 3' terminal AGA2 gene fusion with HEWL in the correct ORF. The 
oligonulceotide, LysB(Hindlll) annealed to the last 15 b.p. of the 3' end of 
HEWL and also encoded two extra stop codons (Figure 5.14). To facilitate 
cloning, either a Sph I [LysF(Sphl)] or a Hind III [Lys(Hindlll)] site was 
introduced to the 5’ ends of the oligonucleotides (Table 5.10). The reaction 
conditions were: [94°C, 2min; (94°C, 15s; 50°C, 30s; 72°C, 1min) x 7; (94°C, 
15s; 50°C, 30s; 72°C, 1 min+20s/cycle) x 8; 72°C, 5min]. The PCR (472 
b.p.) was analysed by agarose gel electrophoresis (Section 2.2.8) and 
purified (Section 2.2.9b).
The vector, pYX243-/oxP/7oxP 511 and the amplified HEWL fragment 
were digested with Hind III (10units) and Sph I (5units) overnight at 37°C 
(Section 2.2.8). Buffers were removed using the appropriate DNA extraction 
kits (Section 2.2.9b) and the digested fragments were quantified by agarose 
gel electrophoresis (Section 2.2.8). These were then ligated together 
(Section 2.2.13) and directly transformed into E. coli cells (Section 2.2.15). 
Ampicillin-resistant colonies were PCR screened (Section 2.2.16) using 
primers lnvpYX(BACK)/lnvpYX(FOR) and positive transformants were grown 
overnight in 3ml of LB (Section 2.2.1). Glycerol stocks (Section 2.2.3) and 
‘minipreps’ (Section 2.2.17) were prepared from the overnight cultures. DNA 
sequencing was performed (Section 2.2.18) on one positive transformant 
using primers InvpYX(FOR) and InvpYX(BACK).
B ) Sub-cloning ofloxP 511-HEWL-loxP into vector, pRS313 
The loxP 511-HEWL-loxP DNA fragment was amplified from construct 
pYX243-/ox HEWL using the primer pair pRS315(Apal)/pRS315(Notl) [Table
5.8]. An Expand™ PCR (Section 2.2.7c) was performed using the following 
conditions: [94°C, 2min; (94°C, 15s; 55°C, 30s; 72°C, 1min) x 7; (94°C, 15s;
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55 °C, 30s; 72°C, 1 min+20s/cycle) x 8; 72°C, 5min]. The PCR product was 
examined by agarose gel electrophoresis (Section 2.2.8) and the PCR 
buffers were removed (Section 2.2.9b).
The vector, pRS313 and the amplified loxP 511-HE\NL-loxP fragment 
were digested sequentially with Apa VNot I (Section 5.3.9a) and ligated 
together (Section 2.2.13). After transformation (Section 2.2.15), the 
ampicillin-resistant transformants were PCR screened using primers T7 and 
M13 (Section 2.2.16). Glycerol stocks (Section 2.2.3) and ‘minipreps’ 
(Section 2.2.17) were prepared from positive colonies which had been grown 
overnight in 3ml of LB (Section 2.2.1). Primers 17 and M13 were used to 
sequence one positive transformant (Section 2.2.18).
Table 5.10 Sequences of the oligonucleotides used in the verification of the AGA2 
integration events and the PCR amplification of HEWL. Enzyme recognition sites are in 
bold.
Primer Name Sequences (5'-3') Description (5'-3')
RPL30A(seq) GGCTAAGT CT GCT GGTACT 
C
Binds 701-721 b.p. upstream from the 
AGA2 start codon (Watson strand).
HOP2(seq) AATAACTTGTAGT CGGAT C 
G
Binds 1426-1446 b.p. downstream from 
the AGA2 stop codon (Crick strand).
LysF(Sphl) CTGAGATACTGCATGCAAA 
AGT CTTTGG ACGAT GT
10 n.t. overhang; a Sph I site; one 
adenine n.t.; 18 n.t. of homology to the 
5* end of HEWL (coding strand).
LysB(Hindlll) GCGAGAAGCTTI IATCACA 
GCCGGCAGCCTCT
5 n.t. overhang; a Hind III site; two stop 
codons; 15 n.t. of homology to the 3' 
end of HEWL (non-coding strand).
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5.4.4 Transformation of FY22 with pBS39 and pRS313-/ox HEWL
The vectors, pRS313-/ox HEWL (~2 pg) and pBS39 (~2 pg) were co­
transformed into the a-strain containing the loxP 511-kanMX4-loxP cassette 
integrated into its AGA2 genome (CAY3; Section 2.2.23). His+ Leu+ 
transformants were PCR screened (Section 2.2.16) for the presence of both 
plasmids in separate PCRs. The plasmid pBS39 was detected using primers 
Cre(back)/pYX(FOR) and the pRS313-/ox HEWL vector was identified using 
the primer combination T7/M13. Positive transformants were grown in 1ml of 
SC lacking uracil and histidine [supplemented with 2% (w/v) raffinose] for 24 
hours (30°C). Glycerol stocks were prepared (Section 2.2.3) and a 100pl 
aliquot of one culture was plated onto an SC without uracil and histidine 
(containing 2% (w/v) raffinose) agar plate. This was used as a stock plate. 
Note: pBS39 (~2pg) only was also transformed into the FY22 AGA2 
disrupted strain (Section 2.2.23) and SC without uracil/2% raffinose media 
was used throughout.
5.4.5 Cre-mediated integration of HEWL into the AGA2 locus
The AGA2 disrupted a-strain (CAY3; Table 5.11) containing both the pBS39 
and pRS315-/ox HEWL plasmids was treated with galactose using two 
different protocols: the liquid galactose method (Section 5.3.7) and the solid 
galactose method (Section 5.3.6). These protocols were followed exactly 
except the selective media used throughout was SC without histidine and 
uracil.
Colonies that could not grow on geneticin (G418) were selected from the 
original YPD plate and transferred to 10ml of YPD. These cultures were 
grown overnight at 30°C and genomic DNA was prepared for each (Section 
2.2.21). Individual genomic DNA samples were screened using three primer 
sets in separate Taq PCRs (Section 2.2.7b). The primer set 
Rpl30A(seq)/LysB(Hindlll) analysed the 5' end, HOP2(seq)/LysF(Sphl) 
checked the 3' end and RPL30A(seq)/HOP2(seq) amplified the total AGA2 
locus (Table 5.10; Figure 5.16). The PCR conditions for the amplification of 
the 5' and 3' ends were: [94°C, 1min; 50°C, 1min; 72°C, 2min) x 30; 72°C 
10min] and the parameters for the amplification of the total AGA2 locus were
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exactly the same except the elongation time was four minutes. Agarose gel 
electrophoresis (Section 2.2.8) was used to analyse the PCR products and 
one positive transformant was chosen for DNA sequencing. A 2.8 k.b.p. 
Expand™ amplified (Section 2.2.7c) PCR product was generated using the 
AGA2FUS(FOR)/HOP2(BACK) [Table 5.9] and the PCR conditions were: 
[94°C, 2min; (94°C, 15s; 52°C, 30s; 72°C, 2min) x 10; (94°C, 15s; 52°C, 
30s; 72°C, 2min+20s/cycle) x 15; 72°C, 5min], This fragment was purified 
using p-agarase (Section 2.2.9a) and the HEWL, loxP and loxP 511 sites 
were sequenced with primers LysB(Hindlll) and LysF(Sphl). The a-strain 
contained the correctly integrated HEWL at its AGA2 locus was named 
CAY4 (Table 5.11).
Figure 5.16 illustrates the primer sites used for the analysis and sequencing of HEWL at the 
3' end of the A G A 2  locus.
RPL30A(seq) LysF(Sphl)
■ ................
AGA2 1 HEWL ; - H O P 2  ■■ m
LysB(Hindlll) HOP(seq)
Table 5.11 Strains constructed in this chapter.
Strain Name Genotype
CAY1 M A T a  u ra  3 -5 2  le u 2 A l  s a g 1 -A 9 7 6 ::k a n M X 4
CAY2 M A T a  u ra  3 -5 2  le u 2 A 1  s a g 1 -A 9 7 6 :.s c F v  D1.3
CAY3 M A T a  u ra 3 -5 2  h is 3 A 2 0 0  a g a 2 v .k a n M X 4
CAY4 M A T a  u ra 3 -5 2  h is 3 A 2 0 0  a g a 2 \.HEWL
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5.5 METHODS - CONSTRUCTION OF scFv D1.3 AND HEWL 
OVEREXPRESSION VECTORS
5.5.1 Construction of pYES2-SAGf-scFv D1.3 overexpression vector
The open reading frame of scFv D1.3 was amplified using 
pUC119His6mycXba-scFvD1.3 as a DNA template and the primer 
combination DF (Table 5.6) and DB(Notl) [Table 5.12]. An Expand™ PCR 
(Section 2.2.7c) was performed using the following cycling parameters: [94° 
C, 2min; (94°C, 15s; 50°C, 30s; 72°C, 50s) x 7; (94°C, 15s; 50°C, 30s; 72°C, 
50s + 20s/cycle) x 8; 72°C, 5min]. The PCR buffers were removed (Section 
2.2.9b) and the PCR product was examined by agarose gel electrophoresis 
(Section 2.2.8).
The vector constructed in Chapter 3, pYES2-SAG7-scFv B7 (Section
3.3.4) and the amplified scFv D1.3 were digested with Hind III (1 Ounits) and 
Not I (1 Ounits) overnight at 37°C (Section 2.2.12). The Not \/Hind Ill-digested 
pYES2-SAG7-scFv B7 vector was resolved on a low melting point agarose 
gel (Section 2.2.8) and the 6.7 k.b.p. fragment was purified (Section 2.2.9b). 
The restriction digestion buffers were also removed from the digested scFv 
D1.3 fragment (Section 2.2.9b). Both Not \/Hind Ill-digested products were 
quantified by agarose gel electrophoresis (Section 2.2.8) and ligated 
together (Section 2.2.13). After transformation (Section 2.2.15), ampicillin- 
resistant colonies were PCR screened (Section 2.2.7) using primers 
pYES2(FOR)/pYES2(BACK). Positive transformants were grown in 3ml of 
LB overnight (Section 2.2.1) and ‘minipreps’ were prepared (Section 2.2.17). 
A diagnostic restriction digest (Section 2.2.12) with Hind III (1 Ounits) and 
Xho I (20units) was performed on one plasmid DNA preparation to check the 
scFv D1.3 insert was present.
5.5.2 Transformation of the SAG1 disrupted a-strain with pYES2-SAG1- 
scFv D1.3
The expression vector, pYES2-SAG7-scFv D1.3 (2 pg) was transformed into 
the a-strain containing the loxP-kanMX4-loxP 511 cassette in its SAG1 locus
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(CAY1; Section 2.2.23). Ura+ colonies were PCR screened using 
pYES(FOR)/pYES2(BACK) and positive transformants were grown in 1ml of 
SC lacking uracil [containing 2% (w/v) raffinose] for 24 hours (30°C). 
Glyercol stocks were made and a 100pl aliquot was plated onto a SC 
without uracil/ 2% (w/v) raffinose agar plate.
Table 5.12 - Sequences of the oligonucleotides used in the amplification of HEWL and scFv 
D1.3 in the construction of the overexpression vectors. Enzyme recognition sites are in bold.




10 n.t. overhang; a Not I site; 18 n.t. of 




6 n.t. overhang; a Msc I site; 5 n.t. 
encoding the end of the a-agglutinin 
leader sequence; 18 n.t. of homology to 
the 5' end of HEWL (coding strand).
LyspYES2(B) CTGAGATACTGCGGCCG
CCAGCCGGCAGCCTCT
10 n.t. overhang; a Not I site; 15 n.t. of 
homology to the 3' end of HEWL (non­
coding strand).
5.5.3 Construction of pYES2-SAG7-HEWL overexpression vector
The HEWL open reading frame was amplified using pl)C8-HEWL as a DNA 
template and the primers, lyspYES2(F)/lyspYES2(B) Uable 5.12]. An 
Expand™ PCR (Section 2.2.7c) was performed and the cycling parameters 
were: [94°C, 2min; (94°C, 15s; 50°C, 30s; 72°C, 45s) x 7; (94°C, 15s; 50°C, 
30s; 72°C, 45 s + 20s/cycle) x 8; 72°C, 5min]. The amplified HEWL fragment 
and pYES2-SAG7-scFv B7 were digested with Msc I (3units) and Not I 
(1 Ounits) overnight at 37°C (Section 2.2.12). The Msc \/Not l-digested vector 
was resolved on a low melting point agarose gel (Section 2.2.8) and
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recovered using a DNA extraction kit (Section 2.2.9b). The Msc \/Not I- 
digested HEWL was also purified (Section 2.2.9b) and both fragments were 
ligated together (Section 2.2.13). The ligation mixture was transformed into 
E. coli cells (Section 2.2.15) and the resulting colonies were PCR screened 
(Section 2.2.16) using pYES(FOR)/pYES2(BACK). Positive transformants 
were grown in 3ml of LB (Section 2.2.1) overnight and glycerol stocks were 
prepared (Section 2.2.3). Plasmid DNA was prepared from one overnight 
culture and transformed directly into S. cerevisiae.
5.5.4 Transformation of the AGA2 disrupted strain with pYES2-SAG1- 
HEWL
The expression vector, pYES2-SAG7-HEWL (~2pg) was transformed into 
the a-strain containing the loxP 511-kanMX4-loxP cassette in its AGA2 locus 
(CAY3; Section 2.2.23). Ura+ colonies were PCR screened using 
pYES(FOR)/pYES2(BACK) and positive transformants were grown in 1ml of 
SC lacking uracil [containing 2% (w/v) raffinose] for 24 hours (30°C). 
Glyercol stocks were made and a 100pl aliquot was plated onto a SC 
without uracil/ 2% (w/v) raffinose agar plate.
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5.6 RESULTS - CONSTRUCTION OF THE scFv D1.3- 
SAG1 GENE FUSION
5.6.1 Construction of the loxP-kanMX4-loxP 511 SAG1 disruption 
cassette
The construction of the kanMX4 marker flanked by two regions of 
homology to the SAG1 locus was constructed using a 'splicing by overlap 
extension' reaction (Figure 5.8).
In the first step, two DNA fragments encoding the promoter and the 3' 
anchorage domain of the SAG1 locus were individually amplified from 
yeast genomic DNA. The sizes of both the generated PCR fragments were 
determined by agarose gel electrophoresis (Figure 5.17) and were in good 
agreement with the predicted theoretical sizes i.e. 1008 b.p. for the 
promoter region of SAG1 locus and 1057 b.p. for the 3' half of the a- 
agglutinin gene. These DNA fragments were also designed to encode loxP 
and toxP 511 sites which flanked either side of the kanMX4 cassette.
Figure 5.17 A 1.0% agarose gel showing the various fragments used in the construction 
of lo x P -k a n M X 4 - lo x P  5 1 1  S A G 1  disruption cassette (Figure 5.8). Lanes 1 and 6, 1 k.b.p. 
DNA marker; Lane 2, S A G 1  promoter (1008 b.p.); Lane 3, C-terminal S A G 1  anchorage 
domain (1057 b.p.); Lane 4, N o t  l-digested k a n M X 4  cassette (1.5 k.b.p.); Lane 5, lo x P -  
k a n M X 4 - lo x P  5 1 1  S A G 1  disruption cassette (3.6 k.b.p.).
1 2 3 4 5 6
< -  3.0 k.b.p. 
<*-1.6 k.b.p.
<*-1.0 k.b.p.
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In the second PCR, these two DNA fragments were linked to the Not I 
digested-/ca/?MX4 cassette by a ‘splicing by overlap extension’ reaction 
(Horton et a/., 1989). This was possible due to the presence of the 25 
nucleotides of homology each of the DNA fragments contained to the 
kanMX4 cassette. A SAG1 disruption cassette of 3.6 kilobases was 
obtained (Figure 5.17) which was in agreement with the expected size.
5.6.2 Integration of SAG1 disruption cassette into the a-strain, FY10
The loxP-kanMX4-loxP 511 SAG1 disruption cassette was successfully 
integrated into a-strain, FY10, at the 'N-terminal/C-terminal' junction of the 
SAG1 locus, using a lithium acetate/polyethylene glycol transformation 
procedure (Section 2.2.24). A transformation efficiency of 63 geneticin- 
resistant (G418r) transformants per pg of DNA was achieved.
PCR analysis of three G418r colonies showed that two of these had the 
kanMX4 disruption cassette correctly integrated into the SAG1 locus 
(Figure 5.18). As expected, the wild-type genomic DNA control did not 
produce any amplified products (data not shown).
Figure 5.18 A 1.5% agarose gel confirming the integration of the lo x P -k a n M X 4 - lo x P  
51 1  cassette into the N-terminal/C-terminal junction of the S A G 1  locus (Figure 5.10) for 
two G418r transformants. Lanes 1 and 2, Analysis at the 5' (promoter) end of the S A G 1  
locus (1.4 k.b.p.); Lane 3, No DNA control; Lanes 4 and 5, PCRs confirming the 
integration at the 3' (C-terminal) end of the S A G 1  locus (1.5 k.b.p.); Lane 6, No DNA 
control, Lane 7, 1 k.b.p. DNA marker.
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One of these transformants was examined by DNA sequencing and 
both the novel joints created by the homologous recombination event were 
correctly formed. Sequencing analysis also showed the loxP and loxP 511 
sites flanked either side of the kanamycin cassette and contained no DNA 
polymerase errors. The 3’ half of the a-agglutinin gene was compared to 
the published sequence (Hauser and Tanner, 1989; SGD) and was found 
to be mutation-free. Additionally, the two extra nucleotides after the loxP 
511 site were present, therefore maintaining the desired reading frame for 
the scFv D1.3-loxP 51 f/a-agglutinin gene fusion (Figure 5.9).
5.6.3 Construction of the pYX243-/ox D1.3 vector
The GAL1 promoter was removed from the pYX243 vector using an 
inverse PCR (Triglia et al., 1988). An 8 kilobase PCR product was 
obtained, which also incorporated a loxP site and a Hind III recognition site 
(Figure 5.19). This linear fragment was digested with Hind \UIXho I and a 
56 b.p. loxP 511 oligonucleotide cassette with Hind III/Xho I cohesive ends 
was inserted by ligation. The most efficient transformation was achieved 
using a molar ratio of 50:1 (insert:vector). Eight ampicillin-resistant colonies 
were PCR screened from the 50:1 transformation plate and a PCR product 
of approximately 370 b.p. in size was achieved for each. These PCR 
products were ethanol precipitated and digested with Sph I. The two 
expected DNA fragments of 146 b.p. and 223 b.p. were observed for five 
transformants, confirming that the two loxP 511 oligonucleotides had 
annealed correctly and the Sph I recognition site had been created (data 
not shown).
The scFv D1.3 open reading frame (ORF) was amplified using primers 
DF and DB(Sphl), and pUC119His6mycXba-scFvD1.3 as a DNA template. 
An 804 b.p. single PCR product was obtained, which was comparable with 
the expected size (Figure 5.19).
The scFv D1.3 fragment and the vector, pYX243-/oxP/7oxP 511 were 
digested with Hind III/Sph I and then ligated together. Transformation of the 
construct produced several hundred plaques of which sixteen were PCR 
screened for the scFv D1.3 insert. Fourteen transformants were found to
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be positive and DNA sequencing of this final pYX243-/ox D1.3 construct 
exposed a problem with mutations in the scFv D1.3 gene. Of the three 
constructs sequenced only one vector was found to be mutation-free and 
the other two plasmids contained deleterious point mutations at various 
positions (Table 5.13). There was also an encoded amino acid in the 
amplified scFv D1.3 antibody fragment which was different (Lys100 -> Glu) 
from the published sequence (Kabat et a/., 1991). This difference was 
present in all the constructs sequenced and therefore was highly unlikely to 
be a polymerase error introduced during the amplification process. In fact, 
the supplied E. coli expression vector, pUC119His6mycXba-scFv D1.3 was 
analysed by DNA sequencing and was found to contain the Lys100 -> Glu 
mutation. Sequencing of the final pYX243-/ox D1.3 construct also 
determined the a-agglutinin signal sequence and the loxP and loxP 511 
sites were mutation-free. Additionally, the stop codon had been removed 
from the end of scFv D1.3 gene as intended. The extra adenine nucleotide 
after the Sph I recognition sequence was in place to maintain the in-frame 
fusion to the 3' half of the a-agglutinin gene (Figure 5.9).
Figure 5.19 A 0.8% agarose gel showing the results of the PCR amplification of the 
scFv D1.3 antibody fragment and vector, pYX243-/oxP. Lane 1, scFv D1.3 (804 b.p.); 
Lane 2,1 k.b.p. marker; Lane 3, pYX243-/oxP (8 k.b.p.).
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Table 6.13 Mutations found in the scFv D1.3 open reading frame. The numbering of the 
amino acid residues refers to the assembled scFv D1.3/a-agglutinin gene fusion (Figure 
5.9).







2 Light FR3 G ln ^  His
5.6.4 Verification of the Cre expression vector, pBS39
The Cre expression vector, pBS39 was digested with Xho I and gave the 
two diagnostic DNA fragments of 5.5 k.b.p. and 4.1 k.b.p. when analysed 
by agarose gel electrophoresis (data not shown).
The Cre recombinase gene sequence was also analysed and found to 
be mutation-free when compared to the published sequence (Sternberg et 
a/., 1986).
5.6.5 Cre-mediated integration of scFv D1.3 into the SAG1 locus 
using a 2\i plasmid
Plasmids pBS39 and pYX243-/ox D1.3 were co-transformed into the a- 
strain containing the loxP-kanMX4-loxP 511 cassette in its SAG1 locus 
(CAY1; Table 5.11). Approximately 300 Ura+ Leu+ transformants were 
obtained and three colonies were PCR screened to confirm both the 
plasmids were present.
The expression plasmid pBS39 containing the Cre recombinase gene 
under the control of the GAL1 promoter was induced using the liquid 
galactose induction protocol. Cells were grown to mid-log phase in 
synthetic complete (SC) media containing raffinose as the carbon source, 
and then induced for 24 hours with galactose. After this time, Cre 
recombinase expression was stopped by transferring the cells to non- 
selective media containing glucose (YPD). Theoretically, the pYX243- 
loxP/loxP 511 plasmid should now have the kanMX4 cassette (Figure 5.3; 
Stage 4). This vector contains elements that allow autonomous replication
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in yeast, therefore could make the recombinants geneticin-resistant 
(G418r). Consequently, to detect colonies with a geneticin-sensitive 
(G418s) phenotype, this plasmid was removed by 3-4 days growth in non- 
selective medium.
Removal of the kanMX4 cassette from the SAG1 locus was detected 
by transferring the cells which had been grown in non-selective media for 
3-4 days onto YPD plates and replica plating these colonies onto 
YPD/G418 plates.
The percentage of recombination between the loxP and loxP 511 sites 
was determined from the ratio of the number of colonies which grew on the 
YPD/G418 plates to the number of colonies on the YPD plates (Table
5.14).
Approximately 17% of galactose-induced cells containing plasmids 
pBS39 and pYX243-/ox D1.3 had lost the kanMX4 cassette. This loss 
appeared to be specific to Cre recombinase expression because in glucose 
media, where little Cre recombinase activity was expected, the kanMX4 
cassette was not removed. From this limited set of data, the expression 
level of Cre recombinase seemed to fluctuate in different induction 
experiments. This data also indicates that undesirable recombination was 
occurring between loxP and loxP 511 sites. Hypothetically, the disrupted 
SAG1 a-strain (CAY1) containing only pBS39 should not generate G418s 
colonies when grown in media containing galactose as a carbon source.
Fourteen G418s Leu' colonies were randomly picked for further PCR 
analysis from the double plasmid (pBS39 and pYX243-/ox D1.3) galactose 
induction experiments. Expected DNA fragments of 2.0 k.b.p. for the 5' 
promoter end and 1.4 k.b.p. for the 3' end of the SAG1 locus were obtained 
(Figure 5.20) for six of these colonies. This indicated the scFv D1.3 gene 
had been correctly integrated into the SAG1 locus using Cre recombinase. 
One of these positive colonies was analysed by DNA sequencing and this 
showed that the scFv D1.3 gene was correctly placed between the 
promoter and 3' half of the a-agglutinin gene in the yeast genome (Figure
5.9). The DNA encoding the a-agglutinin leader sequence, scFv D1.3
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antibody fragment and the C-terminal half of the a-agglutinin was mutation- 
free.
Table 5.14 Table showing the percentage of observed* recombination (% Rec.) between 












pBS39/pYX243-/ox D1.3 Galactose Liquid/
24hrs
44/463 10
m IV m 75/330 23
pBS39 only Galactose Liquid/ 
24 hrs
31/400 8
pBS39/pYX243-/ox D1.3 Glucose Liquid/ 
24 hrs
0/300 0
a - The recorded percentage recombination does not include any double recombination 
events i.e. the kanMX4 cassette can be replaced by the scFv D1.3 at the SAG1 locus and 
a further recombination event can occur where the genomic scFv D1.3 is substituted for 
the kanMX4 cassette from the exchange vector. Any double (or quadruple etc.) 
recombination events that occur in these experiments are undetectable, 
b - All plasmids were transformed into strain CAY1 (MATa ura3-52 leu2A1 sagl- 
A976::kanMX4).
PCR amplification of the entire SAG1 locus of the remaining eight 
G418s Leu' colonies indicated that they had lost the kanMX4 cassette 
without acquiring the scFv D1.3 gene since PCR products of 2.5 k.b.p. 
instead of the expected size of 3.3 k.b.p were observed. These results 
indicate that the loxP and loxP 511 sites were undesirably recombining and
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the kanMX4 cassette could be lost from the SAG1 locus without exchange 
for the scFv D1.3 gene.
Two colonies were also PCR screened from the galactose induction 
experiment containing the Cre recombinase expression vector (pBS39) 
only. These colonies were also shown to have lost the kanMX4 cassette. 
Analysis of the DNA sequence of one of these colonies exposed a single 
loxP 511 site flanked by the promoter and the 3' half of the a-agglutinin 
gene. This resuit confirmed the speculation that undesirable recombination 
was occurring between the ioxP and loxP 511 sites.
1 2 3 4 5 6 7 8
<*-2.0 k.b.p. 
<*-1.0 k.b.p.
Figure 5.20 A 0.8% agarose gel verifying the Cre-mediated integration of scFv D1.3 
gene into the S A G 1  locus of strain CAY1. The PCR analysis was performed on two 
individual colonies at the 5' and 3' ends of the S A G 1  locus (Figure 5.12). Lanes 1 and 8,1  
k.b.p. DNA marker; Lanes 2 and 3, 5' (promoter) end of the S A G 1  locus (2. k.b.p); Lane 4, 
No DNA control; Lanes 5 and 6, 3' (C-terminal) end of the S A G 1  locus (1.4 k.b.p.); Lane 7, 
No DNA control.
Due to the loxP and IoxP 511 sites recombining at the SAG1 locus (or 
on the exchange vector), a centromeric vector was constructed. It was 
reasoned that the conversion between the A and B isomeric forms of the 
native 2p plasmid (Figure 5.21) and the exchange vector, pYX243-/ox 
D1.3, maybe producing intermediates which were affecting the fidelity of 
the Cre-lox system. Yeast shuttle vectors containing inverted repeats have
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been shown to exist as a variety of recombinants with the native 2\x 
plasmid (Gerbaud et a/., 1979).
Figure 5.21 The A and B forms of the 2p plasmid. The inverted repeats are shown as 
triangles.
The native 2jx plasmid (6.3 k.b.p.) is present in most S. c e re v is ia e  strains at about 50 
copies per haploid genome (Broach, 1982). It can interconvert between two distinct states 
by an autocatalysed, intramolecular recombination. Recombination occurs between the 
two inverted repeats (599 b.p.) and is catalysed by the protein encoded by the 2\x circle 
FLP gene. Additionally, the 2p circle contains an origin of replication (ORI) for autonomous 
replication and genes, R E P 1  and R E P 2 , which are essential for stable propagation and 
high copy number.
FO RM  A
FO RM  B
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5.6.6 Construction of the pRS315-/ox D1.3 vector
The Kluyvermyces lactis URA3 gene was removed from plasmid TG5756 
(Langle-Rouault et a/., 1995) by performing a Not IlApa I digest. This 
generated the digested centromeric vector, pRS315-A/of I lApa I.
The IoxP-scFv D1.3-/oxP 511 DNA fragment was amplified using 
primers, pRS315(Apal) and pRS315(Notl), and the construct pYX243-/ox 
D1.3 as a DNA template. A single PCR product of approximately 900 b.p. 
was obtained. This PCR product was digested with Not I lApa I and cloned 
into pRS315-A/ofl/Apa I. Transformation of the construct produced several 
hundred plaques of which ten were PCR screened for the scFv D1.3 gene. 
Nine were found to be positive and DNA sequencing analysis of one of 
these transformants revealed a deleterious point mutation [Ser222 -> Pro 
(numbering corresponds to scFv D1.3-SAG7 gene fusion; Figure 5.9)] in 
the open reading frame of the scFv D1.3 gene. The IoxP and IoxP 511 
sites were mutation-free, therefore the plasmid was used. This centromeric 
vector was only required for a parallel study in the percentage of 
recombination between loxP/loxP 511 sites compared to the 2p plasmid, 
therefore the mutation was unimportant.
5.6.7 Cre-mediated integration of scFvD1.3 into the SAG1 locus 
using the centromeric plasmid
Plasmids pBS39 and pRS315-/ox D1.3 were co-transformed into the a- 
strain containing the loxP-kanMX4-loxP 511 cassette in its SAG1 locus 
(CAY1; Table 5.11). Approximately 200 Ura+ Leu+ transformants were 
obtained and six colonies were PCR screened to confirm both plasmids 
were present.
The Cre recombinase expression vector was induced using two 
different protocols: the solid and liquid galactose induction methods. The 
liquid galactose induction method (Section 5.3.7) was analogous to the 
protocol used for the 2\x plasmid (Section 5.6.5).
Cre recombinase expression was also induced on minimal media 
supplemented with either galactose or glucose (Solid galactose induction 
method; Section 5.3.6). These plates were incubated for 4 days and then
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individual colonies were picked from each plate and resuspended in non- 
selective glucose media (YPD) to suppress Cre recombinase expression. 
These cultures were grown for 3-4 days in non-selective media to remove 
the pRS315-/ox-/ca/?MX4 plasmid (Figure 5.4; discussed in Section 5.6.5).
Removal of the kanMX4 cassette from the SAG1 locus was detected 
by transferring cells which had grown in non-selective media for 3-4 days 
onto YPD plates and replica-plating these colonies onto YPD/G418 plates.
The solid galactose induction experiments with plasmids, pBS39 and 
pRS315-/ox D1.3 resulted in approximately 27% of the colonies becoming 
geneticin-sensitive (Table 5.15). PCR analysis of twelve G418s Leu' 
colonies randomly picked from these plates indicated that none of the 
colonies contained the scFv D1.3 gene in their SAG1 loci. Further 
examination showed that all twelve colonies had removed the kanMX4 
cassette from the SAG1 locus without acquiring the scFv D1.3 gene. The 
glucose control plate did not generate any G418s colonies. Therefore, the 
loss of the kanMX4 cassette appears to be related to Cre recombinase 
expression.
The liquid galactose induction experiments with plasmids pBS39 and 
pRS315-/ox D1.3 showed that the number of G418s colonies increased 
with incubation time (Table 5.15). Ten G418* Leu' colonies from each time 
point were further analysed by the PCR and only one colony from the 5- 
hour time point had incorporated the scFv D1.3 gene into its SAG1 locus. 
At the 24-hour time point, three colonies had correctly integrated the scFv 
D1.3 gene. Consequently, from this limited set of data, it can be deduced 
that induction time appears to have no effect on the fidelity of the Cre-lox 
system. Further experiments are required to confirm this conclusion.
The results obtained using the centromeric vector supports the data 
acquired from the 2|i plasmid (Section 5.6.5), namely that the IoxP and 
IoxP 511 sites appear to be illegitimately recombining at the SAG1 locus.
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Table 5.15 Table showing the percentage of observed* recombination (% rec.) 











pBS39/pRS315-/ox D1.3 Galactose Solid/ 
4 days
60/203 30
II Galactose Solid/ 
4 days
63/313 20
II Galactose Solid/ 
4 days
62/210 30
H Glucose Solid/ 
4 days
0/250 0
pBS39/pRS315-/ox D1.3 Galactose Liquid/ 
5 hours
81/790 10
II Galactose Liquid/ 
24 hours
170/555 31
a - The recorded percentage recombination does not include any double recombination 
events i.e. the k a n M X 4  cassette can be replaced by the scFv D1.3 at the S A G 1  locus and 
a further recombination event can occur where the genomic scFv D1.3 is substituted for 
the k a n M X 4  cassette from the exchange vector. Any double (or quadruple etc.) 
recombination events that occur in these experiments are undetectable, 
b - All plasmids were transformed into strain CAY1 (M A T a  u ra 3 -5 2  le u 2 A 1  s a g 1 -A  
9 7 6 ::k a n M X 4 ).
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5.7 RESULTS - CONSTRUCTION OF THE AGA2-HEWL 
GENE FUSION
5.7.1 Construction of IoxP 511-kanMX4-loxP AGA2 disruption 
cassette
The kanMX4 cassette flanked by two regions of homology to the 3' end of 
the AGA2 locus was constructed by a 'splicing by overlap extension' 
reaction.
Firstly, two DNA fragments encoding the AGA2 or HOP2 ORFs and 
surrounding sequences were individually amplified from yeast genomic 
DNA. The sizes of the amplified DNA fragments (Figure 5.22) were in good 
agreement with the expected sizes i.e. 885 b.p. for the AGA2 DNA 
fragment and 1343 b.p. for the HOP2 DNA fragment.




Figure 5.22 A 0.8% agarose gel showing the various fragments used in the construction 
of the Io x P  5 1 1 - k a n M X 4 - lo x P  A G A 2  disruption cassette (Figure 5.13). Lanes 1 and 6, 1 
k.b.p. marker; Lane 2, Amplified A G A 2  fragment (885 b.p.); Lane 3, H O P 2  fragment (1343 
b.p.); Lane 4, N o t  l-digested k a n M X 4  cassette (1.5 k.b.p.); Lane 5, Assembled Io x P  5 1 1 -  
k a n M X 4 - lo x P  A G A 2  disruption cassette (3.7 k.b.p.).
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In the second PCR, these two fragments were annealed to the Not I- 
digested kanMX4 cassette by a ‘splicing by overlap extension' reaction and 
a IoxP 511-kanMX4-loxP 511 AGA2 disruption cassette of 3.7 kilobase 
pairs was obtained (Figure 5.22).
5.7.2 Integration of the AGA2 disruption cassette into the a-strain, 
FY22
The IoxP 511-kanMX4-loxP AGA2 disruption cassette was successfully 
transformed into the a-strain (FY22). A transformation efficiency of 96 
geneticin-resistant (G418r) transformants per pg of DNA was achieved 
using a lithium acetate/polyethylene glycol transformation procedure 
(Section 2.2.24).
PCR analysis of two of the G418r colonies showed that both contained 
the kanMX4 disruption cassette integrated into the AGA2 locus (Figure
5.23).
Figure 5.23 A 0.8% agarose gel confirming the integration of the Io x P  5 1 1 -k a n M X 4 -  
lo x P  at the 3' terminus of the A G A 2  ORF. The PCR analysis was performed on two 
individual G418r colonies at the 5' and 3' integration sites (Figure 5.15). Lanes 1 and 6, 1 
k.b.p. marker; Lanes 2 and 3, 5' integration site of the A G A 2  locus (1178 b.p.); Lane 4, No 
DNA control; Lanes 7 and 8, 3' integration site of the A G A 2  locus (1644 b.p.); Lane 9, No 
DNA control.
1 2 3 4 6 7 8 9
<-1 .6  k.b.p. 
<-1 .0  k.b.p.
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Analysis of the DNA sequence of one of the transformants showed the 
IoxP 511 and IoxP sites flanked the kanMX4 cassette and the total 
disruption cassette was correctly integrated at the 3’ terminus of the AGA2 
locus. The stop codon had been deliberately removed from the 3’ end of 
the AGA2 ORF in the amplification process, therefore maintaining the 
correct reading frame for the AGA2-loxP 51 f-HEWL gene fusion (Figure
5.14). Both the loxP/loxP 511 sites and the AGA2 coding sequence were 
mutation-free.
5.7.3 Construction of the pRS313-/ox HEWL vector
The hen egg white lysozyme (HEWL) open reading frame was amplified 
using the primer pair, lysF(Sphl) and lysB(Hindlll), and the vector, pUC8- 
HEWL as a DNA template. A single PCR fragment of approximately 400 
b.p. in size was produced (Figure 5.24) and digested with Sph I and Hind 
III, along with the pYX243-/oxP/7oxP 511 vector. After ligation, 
transformation of the construct produced several hundred plaques, of 
which seven were screened for the HEWL insert. Five transformants were 
found to be positive and one of these was analysed by DNA sequencing. 
The lysozyme and loxP/loxP 511 sites were found to be mutation-free and 
the designed extra stop codon at the 3' end of the lysozyme gene was 
present. The extra adenine nucleotide at the 5' end of the lysozyme gene 
was also in place to maintain the correct frame for the AGA2/HEWL gene 
fusion (Figure 5.14). This plasmid was only used for the construction of the 
pRS313-/ox HEWL vector.
The lysozyme flanked by the two loxP/loxP 511 sites was amplified 
from the previous construct using the primer combination pRS315(Apal) 
and pRS315(Notl). A single 503 b.p. PCR product was obtained and 
digested with the enzymes Apa I and Not I, along with the centromeric 
vector, pRS313. These digested fragments were ligated together and 
seven of the resulting ampicillin-resistant colonies were screened for insert. 
Six transformants were positive and DNA sequencing confirmed the 
loxP/loxP 511 sites flanked the lysozyme gene. No DNA polymerase errors 
were discovered in the desired construct.
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Figure 5.24 A 1.5% agarose gel showing the PCR amplification of hen egg white 
lysozyme. Lane 1, HEWL product (421 b.p.); Lane 2,1 k.b.p. DNA Marker.
5.7.4 Cre-mediated integration of HEWL into the AGA2 locus
The vectors pRS313-/ox HEWL and pBS39 were co-transformed into the a- 
strain containing the IoxP 511-kanMX4-loxP cassette at the 3' terminus of 
its AGA2 locus (CAY3; Table 5.11). Approximately two hundred Ura+ His+ 
transformants were obtained and all colonies screened contained both 
plasmids.
The Cre recombinase expression vector, pBS39, was induced using 
both the liquid and solid galactose induction protocols (Sections 5.3.6 and 
5.3.7). The removal of the kanMX4 cassette from the AGA2 locus was 
detected as previously described in Section 5.6.5 and Table 5.16 
summarises the recombination results obtained.
When disrupted a-cells (CAY3) containing plasmids pBS39 and 
pRS313-/ox HEWL were induced on solid media, approximately 49% of the 
colonies became sensitive to geneticin. Analysis of twelve G418s His* 
colonies by the PCR showed that all transformants screened had lost the 
kanMX4 cassette without acquiring the lysozyme gene.
Liquid induction data also demonstrated undesirable recombination 
between the IoxP and IoxP 511 sites at the AGA2 locus. The number of 
colonies that were G418s increased over the course of the induction
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experiment and was specific to galactose induction. The number of G418s 
colonies obtained by the solid galactose induction method was three-fold 
higher than the number of G418s colonies achieved for the liquid galactose 
induction experiment. This result can also be assumed to be a product of a 
longer galactose induction time. Twenty-two G418s His' colonies from the 
24-hour time point and twelve G418s his' colonies from the 5-hour time 
point were further analysed by the PCR. Again, most of the colonies had 
lost the kanMX4 cassette between the recombination sites at the AGA2 
locus without gaining the HEWL gene. Only two colonies from the 24h-time 
point had the lysozyme gene correctly integrated into the AGA2 locus 
(Figure 5.25).
DNA sequencing of one of these colonies proved that the lysozyme 
gene was correctly exchanged for the kanMX4 cassette at the 3' terminus 
of the AGA2 locus, inbetween the IoxP 511 and IoxP sites. The IoxP 511 
recombination site formed a peptide linker between the coding region of 
AGA2 and HEWL. The desired 3' AGA2 gene fusion with lysozyme was in 
the correct reading frame and mutation-free (Figure 5.14).
1 2 3 4 5 6 7 8
Figure 5.25 A 0.8% agarose gel verifying the Cre-mediated integration of HEWL gene 
into the 3' end of the A G A 2  locus of strain, CAY3. PCR analysis was performed on two 
individual G418s colonies to verify exchange had taken place at the 5' and 3' A G A 2  
recombination sites (Figure 5.16). Lanes 1 and 8, 1 k.b.p. DNA Marker; Lanes 2 and 3, 3' 
recombination end of the A G A 2  locus (2.0 k.b.p.); Lane 4, No DNA control, Lanes 5 and 6, 
5’ recombination end of the A G A 2  locus (1.5 k.b.p.); Lane 7, No DNA control.
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Table 5.16 Table showing the percentage of observed recombination11 (% rec.) between 













4 days 64/125 51
II II ii 136/293 46
II II H 268/529 51
II Glucose
Solid/ 
4 days 0/250 0
pBS39/pRS313- lo x  HEWL Galactose
Liquid/ 
5 hrs 67/650 10
pBS39/pRS313- lo x  HEWL Galactose
Liquid/ 
24 hrs 46/324 14
II ii II 57/374 15
II ii H 104/518 20
pBS39/pRS313-/ox HEWL Glucose
Liquid/ 
24 hrs 0/300 0
pBS39 only Galactose
Liquid/ 
24 hrs 51/423 12
II Glucose
Liquid/ 
24 hrs 0/300 0
a - The recorded percentage recombination does not include any double recombination 
events i.e. the k a n M X 4  cassette can be replaced by the HEWL gene at the A G A 2  locus 
and a further recombination event can occur where the genomic HEWL is substituted for 
the k a n M X 4  cassette from the exchange vector. Any double (or quadruple etc.) 
recombination events that occur in these experiments are undetectable, 
b - All plasmids were transformed into S . c e re v is ia e  strain, CAY3 (M A T a  u ra 3 -5 2  h is 3 A 2 0 0  
a g a 2 ::k a n M X 4 ) .
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5.8 RESULTS - CONSTRUCTION OF scFv D1.3 AND
HEWL OVEREXPRESSION VECTORS
5.8.1 Construction of pYES2-SAGf-scFv D1.3 expression vector 
and transformation into the SAG1 disrupted a-strain
The scFv D1.3 antibody fragment was amplified from vector 
pUC119His6mycXba-scFv D1.3 using the primers DF and DB(Notl). A 
PCR product of approximately 800 b.p. in size was obtained and digested 
with Hind \\\/Not I, along with the plasmid pYES2-SAGf-scFV B7 (Section
3.4.4). After ligation, screening of seven ampicillin-resistant colonies 
revealed each one contained the scFv D1.3 insert. A diagnostic restriction 
digest with Hind III and Xho I produced the expected DNA fragment of 
approximately 750 b.p. in size. This confirmed the pYES2-SAGf-scFv D1.3 
overexpression vector was constructed.
The expression vector, pYES2-SAGf-scFv D1.3 was transformed into 
the SAG1 disrupted a-strain, CAY1. Numerous Ura+ transformants were 
obtained and several colonies contained the vector when screened.
5.8.2 Construction of pYES2-SAG?-HEWL expression vector and 
transformation into the AGA2 disrupted a-strain.
The hen egg white lysozyme gene was amplified from vector pUC8-HEWL 
with the primers, lyspYES2(F) and lyspYES2(B). A PCR product of 
approximately 400 b.p. in size was achieved and digested with Msc \INot I. 
The vector pYES2-SAGf-scFv B7 (Section 3.4.4) was also digested with 
Msc \INot I and these two fragments were ligated together. After 
transformation, several hundred ampicillin-resistant colonies were obtained 
and all colonies screened were positive for the lysozyme insert. The 
pYES2-SAGf-HEWL overexpression vector was successfully transformed 
into the AGA2 disrupted a-strain, CAY3.
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5.9 DISCUSSION
5.9.1 Integration of the agglutinin disruption cassettes
The PCR-generated disruption cassettes were a fast and effective way of 
producing mutants at the appropriate agglutinin loci. The efficiency of 
integration of the disruption cassettes was approximately 60-100 
transformants per pg of DNA (Sections 5.6.2 and 5.7.2) which is 
comparable to published results (Wach, 1996). Analysis by PCR screening 
and DNA sequencing confirmed the dominant resistance selectable 
marker, kanMX4, flanked by the loxP/loxP 511 sites, was at the correct 
location in both the agglutinin loci. Extra nucleotides were also present at 
the required positions in the integrated constructs to maintain the reading 
frames of the agglutinin gene fusions (Figures 5.9 and 5.14).
5.9.2 Construction of the exchange vectors
The construction of the exchange vectors containing either the HEWL or 
scFv D1.3 genes flanked by the loxP/loxP 511 sites was also successful. 
Careful design of oligonucleotides containing restriction endonuclease 
recognition sites that were compatible with the chosen vector’s unique 
recognition sites facilitated the cloning of the antigen and antibody DNA.
The sequencing of scFv D1.3 gene exposed a mutational problem 
although eventually a construct that was mutation-free was identified 
(Section 5.6.3). The constructs containing deleterious point mutations 
could have been used in a pilot experiment to demonstrate the 
effectiveness of the yeast 'germinal centre' strategy (Part II). A mixed 
population of a-cells displaying the native or either of the two mutated scFv 
D1.3 antibody fragments could have been created. Hopefully, after mating 
of this mixed a-cell population with the engineered a-cells displaying 
lysozyme, results would have indicated that the yeast a-cells expressing 
the native scFv D1.3 antibody fragments were able to mate with greater 
efficiency than a-cells displaying the mutated antibody fragments. Hence, 
this pilot experiment would have illustrated the ability of the yeast 'germinal
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centre' reaction to distinguish between antibody fragments with different 
affinity constants for the chosen antigen.
Sequence analysis of the scFv D1.3 antibody fragment also 
discovered an amino acid residue (Lys100 -» Glu) which differed from the 
published sequence in all the pYX243-/ox D1.3 constructs. Based on 
computer graphic models of the lysozyme-scFv D1.3 complex, this residue 
was considered to be unimportant in the antibody-antigen interaction due 
to the fact it was remote from the antibody recognition site (personal 
communication, Dr. S. Searle). Functional expression of the scFv D1.3 
antibody fragment in E. coli suggests this assumption is correct (Section 
6.4.1).
5.9.3 Cre-mediated integration
Cre-mediated integration of the antigen and antibody DNA into the relevant 
agglutinin loci was achieved, although problems with the Cre-/ox 
recombination system were encountered. All results indicated that the IoxP 
and IoxP 511 sites were illegitimately recombining at the agglutinin loci and 
the kanMX4 cassettes were lost without the incorporation of the scFv 
D1.3/HEWL DNA. It is also possible that the IoxP and IoxP 511 sites were 
additionally recombining on the vectors and removing the HEWL/scFv D1.3 
genes before exchange could ever take place. Preliminary results 
investigating the ability of the exchange vector to remove the HEWL/scFV 
D1.3 DNA indicates that this event can take place (personal 
communication, Bryn Davies, this laboratory). Using a centromeric vector 
instead of a 2p plasmid did not overcome the undesirable IoxP x IoxP 511 
recombination problems. Hence, it can be assumed that any intermediates, 
which could occur between the native 2\x plasmid and the exchange vector 
(Section 5.6.5; Figure 5.21), were not affecting the fidelity of the Cre-/ox 
system.
Recombination appeared to be a consequence of Cre recombinase 
expression due to the fact that manipulated strains did not generate any 
geneticin-sensitive colonies in experiments where Cre recombinase 
expression was inhibited by growth on medium containing glucose. The
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percentage recombination between loxP (or loxP 511) sites increased with 
induction time, presumably because of the increase in the expression level 
of Cre recombinase. The maximum percentage recombination (~50%) was 
observed in experiments using solid media after a four-day induction period 
(Section 5.7.4). All the colonies analysed from these experiments had 
removed the kanMX4 cassette without acquiring the desired DNA. It was 
therefore speculated that a longer induction time could be affecting the 
fidelity of the Cre recombinase system. Further examination of induction 
times using the liquid media method contradicted this view.
The maximum level of recombination achieved using the liquid media 
method was approximately 30%, although this level fluctuated greatly from 
experiment to experiment (Section 5.6.7). It was presumed that this 
fluctuation was due to the variation in the copy number of the Cre 
recombinase expression vector. The limited set of data available from the 
liquid media experiments demonstrated that the induction time had no 
affect on the fidelity of the Cre-lox system. Colonies analysed at the five- 
hour time point had not exchanged the kanMX4 cassette more efficiently 
than colonies at the twenty-four hour time point.
The levels of recombination in all these experiments were much lower 
than published results where selectable markers were flanked by two 
homologous loxP sites (Sauer, 1987; Guldener et al., 1996). The result of 
these studies reported approximately 90% of the relevant selectable 
marker gene had been removed from cells after an induction time of one 
hour. This may be an indication that the non-homologous loxP and loxP511 
are not recombining at the same efficiency in the genome as two 
homologous loxP sites.
Interestingly, recombination between non-homologous loxP and loxR 
sites in the yeast genome also results in a 90% loss of the selectable 
marker (Section 5.1.1; Ross-Macdonald et al., 1997). Studies in 
bacteriophage X indicate that loxR and loxP sites recombine at a rate 20- 
to 100-fold lower than two homologous loxP sites (Sternberg et ai, 1981). 
The fact that the non-homologous loxP and loxR sites recombine at the 
same efficiency as two homologous loxP sites in the yeast genome may
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indicate that some degree of selectivity of the Cre recombinase enzyme is 
lost in a eukaryotic nucleus. This data appears to support the decrease in 
Cre recombinase fidelity observed in this project.
Intermolecular recombination of loxP sites has been reported to be 
less effective than intramolecular recombination (Abremski et al., 1983). 
Hence, if the loxP and loxP 511 sites are recombining undesirably, the 
recombination results obtained in this Chapter are not surprising i.e. 
intramolecular recombination is favoured, therefore the majority of colonies 
have lost the kanMX4 cassette.
Cre-mediated integration of HEWL gene into the AGA2 locus appears 
to be less effective than integrating scFv D1.3 DNA into the SAG1 locus. 
There could be many reasons to explain this observation. For instance, the 
smaller size of the lysozyme gene could facilitate more intramolecular 
recombination because the loxP/loxP 511 sites are physically closer, or 
possibly Cre recombinase activity is favoured at one of the chromosomal 
locations.
The factors affecting the fidelity of the Cre-/ox recombination system 
could be numerous and were not investigated further in this project. The 
initial study, which determined that homology was required between loxP 
sites for efficient recombination, was performed in E. coli at 37°C (Hoess et 
al., 1986). Consequently, the fact that these experiments were carried out 
in S. cerevisiae (an eukaryotic nucleus) at 30°C (not 37°C) maybe 
important.
5.9.4 Conclusions
Overall, the aims of this Chapter were achieved, but unexpected problems 
with the novel yeast Cre-lox recombination system were encountered. The 
maximum integration efficiency obtained using the Cr e-lox system was 
appropriately 104 transformants per pg of plasmid DNA. The theoretical 
size of an antibody library using the Cre-lox system was predicted to be 106 
transformants per pg of plasmid DNA (Section 5.1; Schiestl et al., 1993). 
Although this was not achieved, the efficiency obtained in this Chapter is 
still two magnitudes higher than attainable by standard yeast integration
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methods (1-100 transformants per pg of DNA; Wach, 1996). Further 
improvements to the Cre-/ox system may generate the potential to create a 
small antibody library (~106 transformants) where moderate affinity 
antibodies (pM) could be isolated directly.
Both the antibody and antigen surface display systems, required for 
the yeast 'germinal centre' strategy, were produced using the Cre-/ox 
system. The antibody DNA (scFv D1.3) successfully replaced the 5' a- 
agglutinin binding domain and an in-frame gene fusion with the 3' a- 
agglutinin anchorage domain was created (the antibody display system). 
The antigen display model was also constructed by fusing the HEWL DNA 
to the 3' terminus of the a-agglutinin binding domain gene. Both these 
engineered strains were Individually analysed for the appropriate protein 
expression in the following Chapter and the artificial yeast 'germinal centre' 
reaction was also attempted.
Additionally, vectors were constructed for overexpression of scFv 
D1.3 and HEWL on the surfaces of a- and a-cells, respectively. Yeast 
strains transformed with these vectors were used as positive controls in the 
expression studies carried out in Chapter 6.
CHAPTER 6
ATTEMPTED MATING OF AGGLUTININ MUTANTS
6.1 INTRODUCTION
The overall aim of this part of the project is to produce an antigen-selection 
process which can distinguish between yeast cells displaying antibodies 
with different affinities for a chosen antigen on their cell surfaces (Part II). 
Antibody improvement in the human body occurs in the germinal centre via 
stepwise rounds of mutation and antigen-selection (Section 1.3.3). Our 
proposed strategy intends to mimic the germinal centre reaction as closely 
as possible by mating engineered a- and a-cells displaying antibody 
fragments or antigen on their cell surfaces, respectively (Figure 1.11).
The preceding chapter described the construction of both the sagl- 
A976::scFv D1.3 and aga2::HEWL genomic fusions in the a- and a-strains, 
respectively. This chapter details the individual expression of Aga2p- 
lysozyme and Sag1p-scFvD1.3 protein fusions on the surface of these 
engineered cells in both the presence and absence of pheromone. 
Exposure of cells to pheromone secreted by the opposite mating type (a-/a- 
factor) results in an increase in the number of agglutinin molecules on the 
cell surface [(2-5 x 104 agglutinin molecules per cell) Terrance and Lipke, 
1987; Watzele et al., 1988; Wojciechowicz and Lipke, 1989]. Additionally, 
the functionality of the scFv D1.3 and lysozyme on the surface of these 
engineered cells was examined using either biotinylated lysozyme or 
Micrococcus lysodeikitus cells, respectively.
Imitation of the germinal centre reaction was attempted by mating 
these a- and a-engineered cells (strains; CAY4 and CAY2) under conditions 
that did not promote stable cell-to-cell contact (liquid media; Lipke et al., 
1989) and then selecting for diploids. Theoretically, a-cells expressing the 
scFv D1.3 on their surface should form a stable cell-to-cell contact with a-
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cells expressing hen egg white lysozyme. This antibody-antigen interaction 
should promote the formation of cell aggregates (agglutination) and 
eventually diploid production. The affinity constant for the scFv 
D1.3/lysozyme interaction [Ka =3 x 108 M'1 (Hawkins et a/., 1993)] is similar 
to the a-/a-agglutinin interaction [Ka = 1 x 109 M*1 (Lipke et a/., 1987)] 
therefore should mimic the agglutinin's function. The mutants, CAY1 (sag1- 
A976\\kanMX4) and CAY3 (aga2::kanMX4) were also mated under the same 
conditions to ensure that the agglutinins had been properly disrupted.
Overexpression of vectors, pYES2-SAGf-HEWL and pYES2-SAG1- 




Hen egg white lysozyme, a-factor and Micrococcus lysodeikitus cells were 
purchased from Sigma (Product Numbers - L2879, T6901 and M3770, 
respectively). An Immunoprobe™ biotinylation kit, dialysis tubing (Product 
No - D0405), phosphocellulose (Product No - C2383) and FAST™ p- 
nitrophenyl phosphate (pNPP) substrate tablet set were also obtained from 
Sigma. Streptavidin-alkaline phosphatase (Product No - RPN1234) was 
purchased from Amersham International and the 0.22pM GS filter papers 
were obtained from Millipore.
6.2.2 Strains
Saccharomyces cerevisiae strain D665-1A (MATa) was obtained from the 
Yeast Genetics Course (1996), Cold Spring Harbor Laboratory, New York.
Note: The parental strains used in this germinal centre strategy (FY10 and 
FY22) originated from strain S288C (Winston et al., 1995) of which X2180- 
1A and X2180-1B are derivatives (Mortimer and Johnston, 1986). Strains 
X2180-1A and X2180-1B have been used in many principal agglutination
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studies, hence their agglutinin expression levels and characteristics have 
been extremely well studied (Terrance et al., 1987; Lipke et a/., 1987; 
Hauser and Tanner, 1989; Lipke et al., 1989).
6.3 METHODS
6.3.1 Estimation of protein concentration
Protein concentrations were estimated by absorbance measurements at 
280nm. The molar extinction coefficient used for hen egg white lysozyme 
was 37932 M'1cm'1 (Sophianopoulos et al., 1962).
6.3.2 Functional detection of scFvD1.3 in E. coli (EMBO practical 
course, Pomezia, 1991)
Two individual TOP10P E. co// colonies carrying the vector
pUC119His6mycXba-scFv D1.3, were picked from an LB plate 
(supplemented with 100pg/ml ampicillin) and resuspended in 3ml of XL 
medium (16g/l Bacto-tryptone, 16g/l Bacto-yeast extract, 5g/l sodium 
chloride) containing 1% (w/v) glucose and 100jig/ml ampicillin. These 
cultures were grown overnight at 37°C and 100pl of each overnight culture 
was transferred to 2ml of XL medium supplemented with 0.1% (w/v) glucose 
and 100pg/ml ampicillin. The new cultures were grown at 37°C until an 
absorbance (at 600nm) of 0.9 was reached. Isopropyl-p-D-thiogalactoside 
(IPTG) was added to a final concentration of 1mM and the cultures were 
shaken (250 r.p.m.) at 30°C for a further 24 hours. After this time, the 
cultures were centrifuged at 4000 r.p.m. for 10 minutes and the supernatant 
from each sample was analysed for functional scFv D1.3 using an ELISA. 
The supernatant from an uninduced culture in XL medium (supplemented 
with 100|ig/ml ampicillin/1% (w/v) glucose) was used throughout as a 
negative control.
A hen egg white lysozyme solution at a concentration of 5.5 x 10‘5 M 
was used to coat the wells of an ELISA plate and the protocol described in 
Section 2.3.4 was performed. A primary polyclonal antibody serum specific
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for mouse IgG Fab fragments (rabbit anti-mouse IgG F(ab')2 fragment 
specific; Table 2.1) was used. Binding of this primary antibody was detected 
using a horseradish-peroxidase conjugated goat anti-rabbit IgG secondary 
antibody (Table 2.2).
6.3.3 Overexpression of scFv D1.3 and HEWL on the surface of the 
disrupted agglutinin mutants
The disrupted a-strain, CAY1 (Table 5.11), containing the overexpression 
vector, pYES2-SAGf-scFv D1.3 was induced with galactose for 24 hours 
(Section 4.3.3). The disrupted a-strain, CAY3 (Table 5.11), carrying pYES2- 
SAGf-HEWL was also treated with galactose and both sets of cells were 
employed as positive controls in all experiments concerning the expression 
of lysozyme and scFv D1.3 on the surface of the engineered cells.
6.3.4 Partial purification of a-factor (Betz et aL, 1977)
Phosphocellulose (10g) was resuspended in 400ml of water and allowed to 
swell. The water was decanted and 1 litre of 0.5M sodium hydroxide/sodium 
chloride was added for 5 minutes. This solution was decanted and the 
phosphocellulose was washed with 500ml of water using a Buchner funnel 
(Whatman No1 filter paper). The phosphocellulose was then resuspended in 
1 litre of 0.5M hydrochloric acid for 5 minutes. This solution was decanted 
and the washing step was repeated. The phosphocellulose was then 
resuspended in 75ml of 0.05M potassium phosphate buffer, pH 6.0 and 
allowed to settle. The unsettled particles were removed by decanting and 
this process was repeated several times. A 1ml column (1 by 10cm) of 
phosphocellulose was prepared and equilibrated with 50ml of 0.05M 
potassium phosphate buffer, pH 6.0.
The a-strain (D665-1A) was used to inoculate 50ml of minimal glucose 
medium (6.7g/l Bacto-yeast nitrogen base without amino acids, 20g/l 
glucose) and was shaken (250 r.p.m.) at 30°C for 24 hours. The cells were 
removed by centrifugation at 3000 r.p.m. (1500g) for 10 minutes using a 
Sorvall GLC-4 general laboratory centrifuge and the pH of the supernatant
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was checked (-pH 2.6). The cell-free supernatant was applied directly to 
the phosphocellulose column, washed with 1.5ml of 0.05M potassium 
phosphate buffer, pH 6.0 and eluted with 10ml of 0.5M potassium 
phosphate buffer, pH 6.0. Fractions (1ml) were collected, adjusted to pH 
5.0 and 10% (w/v) glycerol/1 mM EDTA was added. These fractions were 
then stored at -20°C until required.
The activity was analysed by dropping 10pl of each fraction onto 
BBMB plates that had been previously spread with 5 x 105 a-cells (FY10). 
[The BBMB plates were prepared by adding 0.03% (w/v) methylene blue 
and 0.1M phosphate-citrate buffer (pH4.5) to molten YPD/agar medium]. 
The BBMB plates were then incubated at room temperature for 2 days and 
analysed for the presence of halos (a-factor inhibits the growth of the a-cell 
lawn and therefore the appearance of halos can be used to measure a- 
factor activity). The lowest concentration of a-factor that gives a detectable 
halo is defined as 1 unit of pheromone/ml (Sprague, 1991). The 
concentration of pheromone present in different fractions was measured by 
performing dilutions (1 in 2, 1 in 5, 1 in 10) and applying 10^ 1 of these 
dilutions to a BBMB plate previously spread with a known amount (5 x 105 
cells) of a-cells.
6.3.5 Induction and detection of scFv D1.3 on the surface of 
engineered a-cells
The engineered a-strain containing the scFv D1.3 gene fused to the C- 
terminal end of the a-agglutinin gene (CAY2; MATa ura3-52 leu2A1 sagl- 
A976\\scFv D1.3) was grown to exponential phase (-1 x 107 cells/ml) in 
10ml of YPD at 30°C. The culture was divided into two parts. Two units of 
partially purified a-factor (Section 6.3.4) were added to one part of the 
culture (Betz et al., 1978), the other part was left untreated, and both were 
grown at 30°C for an additional 2 hours. A wild type a-strain (FY10) culture 
in exponential phase was also prepared for a negative control. The a- 
agglutinin null mutant, CAY1, carrying the scFv D1.3 overexpression vector 
was used as a positive control (MATa ura3-52 leu2A1 sag1-A976::kanMX4 
[pYES2-SA G1 -scFv D1.3]).
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After this time, approximately 2 x 107 cells from each culture were 
analysed for scFv D1.3 expression using an enzyme immunoassay 
(Section 2.3.5). The primary antibody, rabbit anti-mouse IgG F(ab' ) 2  
fragment specific (Table 2.1), followed by the secondary horseradish- 
peroxidase conjugated goat anti-rabbit IgG antibody (Table 2.2) were used 
for the detection of scFv D1.3. Cycloheximide at a concentration of 10|ig/ml 
was used in all solutions throughout the enzyme immunoassay to stop new 
protein synthesis.
6.3.6 Biotinylation of HEWL
A) Dialysis of lysozyme
The dialysis tubing was boiled for 10 minutes in 300ml of 2% (w/v) sodium 
bicarbonate/1 mM EDTA (pH 8.0) and rinsed thoroughly with distilled water. 
The tubing was then boiled for 10 minutes in 300ml of 1mM EDTA, pH 8.0 
and the rinsing step was repeated. The tubing was then washed with 0.1M 
sodium phosphate, pH 7.2 and 10ml of lysozyme solution (5.5 x 10"4 M) 
was placed inside the dialysis tubing. The lysozyme was dialysed in 250ml 
of 0.1 M sodium phosphate, pH 7.2 overnight on a magnetic stirrer, at 4°C.
B) Biotinylation of lysozyme
The dialysed lysozyme solution was biotinylated using the Immunoprobe™ 
biotinylation kit! A molar ratio of biotinamidocaproate-N-hydroxyl- 
sulfosuccinimide ester (BAC-SulfoNHS) to HEWL of 5:1 was prepared and 
the labelling reaction was performed according to the manufacturer’s 
instructions. Biotinylation of the HEWL was confirmed using an ELISA 
(Section 2.3.4). The wells of an ELISA plate were coated with the 
biotinylated HEWL at a concentration of 7nM and streptavidin-alkaline 
phosphatase, diluted (1:1000) in 0.5% (w/v) bovine serum albumin/PBS 
was used exclusively for detection. Bovine serum albumin (BSA) instead of 
non-fat dried milk (Marvel) was used as a blocking agent throughout. 
Alkaline phosphatase activity was analysed using 200fJ of FAST™ pNPP 
substrate in each reaction. The reactions were incubated in the dark at 
room temperature (for approximately 0.5-2hours) until a yellow colour
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developed. The reaction was then stopped with 50pl of 3M sodium 
hydroxide. The absorbances (at 405nm) were read using a Multiscan® 
MCC Labsystems ELISA plate reader. After verification, the biotinylated 
HEWL was lyophilised using a Lyoprep-300 freeze drier at less than 
0.05mbar overnight and stored at -20°C.
6.3.7 Functional identification of scFv D1.3 on the surface of 
engineered a-cells
The engineered a-strain containing scFv D1.3 DNA fused to the C-terminal 
end of a-agglutinin gene (CAY2; MATa ura3-52 leu2A1 sagl- 
2l976::scFvD1.3) was grown overnight in 10ml of YPD at 30°C. 
Approximately 2 x 107 cells were washed three times with PBS and 8nM of 
biotinylated lysozyme diluted in 0.5% (w/v) BSA/PBS was added. The cells 
were vortexed and incubated for 2-3 hours at room temperature on a 
vertically rotating platform. The cells were collected via centrifugation at 
13000 r.p.m. for 30 seconds. The cell pellets were washed three times with 
PBS/0.05% (w/v) Tween 20 and then three times with PBS. Streptavidin- 
alkaline phosphatase (1:1000) diluted in PBS/0.05% (w/v) BSA was added 
to each sample, vortexed and incubated at room temperature for 1 hour on 
the rotating platform. The washes were then repeated and 200pl of 
FAST™ pNPP substrate was added to each. The reactions were incubated 
at room temperature in the dark until a yellow colour developed and 
stopped with 50pl of 3M sodium hydroxide. The reaction mixtures were re- 
centrifuged and the supernatants were transferred to an ELISA plate. This 
protocol was also carried out with a negative control (FY10 only) and a 
positive control (MATa ura3-52 ieu2A1 sag1-A976\:kanMX4 [pYES2- 
SAG1-scFv D1.3]).
6.3.8 Induction and detection of HEWL on the surface of engineered 
a-cells
The engineered a-strain containing hen egg white lysozyme gene fused to 
the C-terminus of the a-agglutinin binding domain (CAY4; MATa ura3-52 
his3A200 aga2::HEWL) was grown to exponential phase (-1 x 107 cells/ml)
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in 10ml of YPD. a-Factor was added to 5ml of this culture to a final 
concentration of 5|iM (Sprague, 1991). The other 5ml of the culture was 
not treated with pheromone and both were left at 30°C for 1 hour at 250 
r.p.m. The parental a-strain (FY22) and disrupted a-strain, CAY3, 
containing the lysozyme overexpression vector (MATa ura3-52 his3A200 
aga2\\karMXA [pYES2-SAGf-HEWL]j were also grown to exponential 
phase and were used for negative and positive controls, respectively. 
Approximately 2 x 107 cells from each culture were analysed for lysozyme 
expression using an enzyme immunoassay (Section 2.3.5). The rabbit 
anti-HEWL primary antibody (Table 2.1) followed by the horseradish 
peroxidase conjugated goat anti-rabbit (Table 2.2) secondary antibody 
were used for detection of lysozyme on the surface of yeast. 
Cycloheximide at a concentration of 10ng/ml was used throughout the 
enzyme immunoassay protocol.
6.3.9 Functional identification of HEWL on the surface of 
engineered a-cells
The disrupted a-strain, CAY3, containing the lysozyme overexpression 
vector (MATa ura3-52 his3A200 aga2::kanMX4 [pYES2-SAG1-HEWL]) 
was patched onto two Synthetic Complete plates lacking uracil. These 
plates contained different carbon sources, either 2% (w/v) glucose or 2% 
(w/v) galactose, and were incubated for 3-4 days at 30°C. After this time, 
both plates were replica-plated onto one lysoplate and incubated at room 
temperature for several days. The plates were then observed for zones of 
clearing due to bacterial lysis. The size of the zones was proportional to the 
concentration of lysozyme (Osserman and Lawlor, 1966).
Lysoplates were prepared by resuspending M. lysodeikitus cells in a 
small amount (1-2ml) of 55mM potassium phosphate buffer, pH 6.2 
(Morsky, 1983) using a vertically rotating platform for 15 minutes. These 
cells were added to molten 1 % (w/v) low melting point agarose in 55mM 
potassium phosphate buffer, pH 6.2 to a final concentration of 0.5% (w/v) 
and the cell/agarose suspension was poured into 9cm petri dishes to a 
depth of 3-4mm (Osserman and Lawlor, 1966).
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The a-strain containing the hen egg white lysozyme gene fused to the 
3' terminus of the a-agglutinin binding domain (CAY4; MATa ura3-52 
his3A200 aga2;;HEWL) was also examined for functional lysozyme on its 
cell surfaces using the lysoplate method. This strain and the wild type a- 
strain (FY22) were patched onto the same YPD plate and incubated at 
30°C for 1-2 days. The plate was then replica plated onto a lysoplate, 
incubated for several days and analysed for zones of clearing around the 
replicated patches.
6.3.10 Agglutination assay (Lipke et al., 1989)
Three millilitres of YPD in 15ml centrifuge tubes were inoculated with 
approximately 107 cells of each of the mating types to be tested. The tubes 
were vortexed and incubated vertically overnight at room temperature on a 
rotating platform (120 r.p.m.). Agglutination should result in a lacy cell 
pellet that spreads out over the bottom of the tube, whereas non­
agglutinated mixtures should produce a compact cell pellet.
6.3.11 Solid mating assay (Lipke et al., 1989)
Approximately 2 x 107 mid-log phase cells of each mating type were mixed 
in a 1.5ml Eppendorf tube. The cells were collected on a filter paper 
(0.22pM GS) using a Buchner funnel and the filter was placed on a YPD 
plate for 6 hours at 30°C. The filter was then resuspended in 30ml of 1M 
sorbitol in a 50ml centrifuge tube and vortexed vigorously. The cells were 
diluted appropriately and plated onto both non-selective medium (YPD) 
and Selective Complete medium lacking leucine and histidine, which 
selected for diploids. These plates were incubated for 2 days at 30°C and 
the resulting colonies were counted on both the selective and non-selective 
plates. The mating frequencies were determined by dividing the number of 
colonies on selective medium (diploids) by the number of colonies on the 
non-selective medium (diploids and haploids).
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6.3.12 Liquid mating assay (Lipke et al.t 1989)
Approximately 2 x 107 mid-log phase cells of each mating type were mixed 
in 5ml of YPD medium in a 50ml conical flask and incubated at 30°C with 
rotation (300 r.p.m.) for 6 hours. The cells were vortexed vigorously, diluted 
and plated onto both non-selective medium (YPD) and Selective Complete 
medium lacking leucine and histidine. These plates were incubated for 2 
days at 30°C and the mating frequencies were calculated as described in 
Section 6.3.11.
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6.4 RESULTS
6.4.1 Functional expression of scFv D1.3 in E. coli
E. coli cells containing vector pl)C119His6mycXba-scFv D1.3 were shown 
to be expressing functional scFv D1.3 antibody fragments after an induction 
time of 24 hours. The supernatant of the uninduced culture displayed no 
lysozyme binding activity (Table 6.1).
Table 6.1 - ELISA results obtained from the supernatants of induced and uninduced 
cultures of TOP1 OF [pUC119His6mycXba-scFv D1.3].
Plasmid IPTG A b S 4 5 0 *
pUC119His6mycXba-scFv D1.3 + 0.50, 0.58, 0.53 (0.54)
M + 0.54, 0.55, 0.46 (0.52)
m
- 0.05, 0.02, 0.01 (0.03)
a Values in the brackets represent the mean of the three individual determinations.
6.4.2 Partial purification of a-factor
a-factor is not commercially available because it is difficult to synthesize due 
to its hydrophobic nature, structure and associated farnesyl group (Proteau 
et al., 1990). Therefore it was partially purified from the culture supernatant 
of a MATa strain (D665-1A) using ion-exchange chromatography. The 
chosen a-strain contained no auxotrophic mutations due to the fact 
unmanipulated strains are known to produce a large amount of pheromone 
(Betz et al., 1977). The fractions eluted from the phosphocellulose column 
were analysed for a-factor activity using BBMB plates. All a-factor activity 
was present in the first two millilitres of the eluted fractions and the amount 
of activity was determined semiquantitatively by analysing serial dilutions. A 
total of three units of pheromone was recovered which was comparable with 
results obtained for different a-strains (Betz et al.t 1977).
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6.4.3 Detection of scFv D1.3 on the surface of engineered a-cells
The engineered a-cells containing the scFv D1.3 gene integrated into the 
’N/C' junction of the a-agglutinin gene (strain CAY2) were analysed for cell 
surface expression of scFv D1.3 antibody fragment in the presence and 
absence of a-factor. Enzyme immunoassay results indicated that the 
Sag1p-scFv D1.3 fusion was detectable on the surface of a-factor treated 
cells but the surface expression of the untreated cells was not significantly 
above background (Table 6.2). The a-agglutinin null mutant, CAY1, 
carrying the scFv D1.3 expression vector was shown to be displaying a 
large amount of scFv D1.3 on its cell surface. Cycloheximide was used 
throughout the enzyme immunoassay to stop protein production. Hence, 
the agglutinin molecules that were analysed had become accessible at the 
cell surface directly after the pheromone treatment or galactose induction 
(Betz et al., 1978).
Table 6.2 - Enzyme immunoassay results for the detection of scFv D1.3 antibody 
fragments on the surface of pheromone-treated and untreated cells.
Strain3 a-factor A b S 4 5 0 °
CAY2 + 0.45, 0.47, 0.48 (0.47)
CAY2 - 0.33, 0.45, 0.49 (0.42)
CAY1 [pYES2-SAGf-scFv D1.3] - 1.41, 1.41,1.48 (1.43)
Wild type (FY10) - 0.32, 0.35, 0.39 (0.35)
a The genotypes of the strains used in this experiment are summarized in Table 5.11. 
b Values in the brackets represent the mean of the three individual determinations.
6.4.4 Functional identification of scFv D1.3 using biotinylated 
lysozyme
Lyzoyme was dialysed overnight and biotinylated using the 
Immunoprobe™ biotinylation kit. Biotinylation was confirmed by coating an 
ELISA plate with the biotinylated lysozyme and screening with streptavidin-
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alkaline phophatase. A mean absorbance (at 405nm) of 0.48 for three 
biotinylated samples compared to 0.05 for three non-biotinylated samples 
was obtained.
The engineered a-cells, CAY2, and a-agglutinin disrupted strain, 
CAY1, overexpressing scFv D1.3 were analysed for their ability to bind to 
lysozyme using the avidin-biotin system. Bound lysozyme was detected 
using streptavidin-alkaline phosphatase and absorbances obtained for both 
sets of cells were reproducibly above background (Table 6.3). 
Unfortunately, the ten-fold increase expected for the cells overexpressing 
the scFv D1.3 was not observed. These results indicated that there was 
some level of functional scFv D1.3 on the cell surfaces of the engineered 
a-strains.
Table 6.3 - Absorbance values obtained using the avidin-biotin system for the 
identification of functional scFv D1.3 on yeast cell surfaces.
Strain3 A b S 4 0 5 °
CAY2 0.13, 0.14, 0.14(0.14)
CAY1 [pYES2-SAG f-scFv D1.3] 0.17, 0.17, 0.17(0.17)
Wild type (FY10) 0.05, 0.07, 0.07 (0.06)
a The genotypes of the strains used in this experiment are summarized in Table 5.11. 
b Values in the brackets represent the mean of the three individual determinations.
6.4.5 Detection of HEWL on the surface of engineered a-cells
The engineered a-cells containing the hen egg white lysozyme gene fused 
to the 3’ end of the a-agglutinin binding domain (strain CAY4) were 
examined for the expression of lysozyme on their surfaces in the presence 
and absence of a-factor. Enzyme immunoassay results indicated that 
lysozyme was detectable on the surface of both pheromone-treated and 
untreated a-cells. The induced null a-agglutinin mutant, CAY3, containing 
the lysozyme expression vector was shown to be displaying a large
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amount of lysozyme on its cell surface compared to the engineered a-strain 
(Table 6.4).
Table 6.4 - Enzyme immunoassay results for detection of lysozyme on the surface of 
pheromone-treated and untreated cells.
Strain* a-factor AbS450&
CAY4 + 0.28, 0.32, 0.34 (0.31)
CAY4 - 0.25, 0.26, 0.26 (0.26)
CAY3 [pYES2-SAGf-HEWL] - 1.75,1.84, 2.61 (2.07)
Wild type (FY10) - 0.14,0.14,0.15(0.14)
a The genotypes of the strains used in this experiment are summarized in Table 5.11. 
b Values in the brackets represent the mean of the three individual determinations.
6.4.6 Verification of functional HEWL using M. lysodeikitus cells
The expressed lysozyme on the surface of the engineered a-cells (CAY4) 
was analysed for activity using M. lysodeikitus cells. No zones of clearing 
due to bacterial lysis were observed around the engineered a-cells after 
several days of incubation (Figure 6.1a). Therefore, it was presumed the 
expression level of lysozyme on the surface of the engineered a-cells was 
lower than the minimal amount detectable by the lysoplate method [of the 
order of pg/ml (Osserman and Lawlor, 1966)]. A zone of clearing was 
observed around the cells overexpresssing the lysozyme (Figure 6.1b) 
thereby demonstrating the lysozyme was active.
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Figure 6.1 - Lysoplate test for detection of lysozyme activity.
a) Wild type a-strain, FY22. 
(M A T a  u ra 3 -5 2  h is 3 A 2 0 0 )
Engineered a-strain, CAY4. 
(M A T a  u ra 3 -5 2  h is 3 A 2 0 0  aga2::HEWL)
b) Induced and uninduced patches of the a-agglutinin null mutant, CAY3, containing the 




Each cross described in Figure 6.2 was tested for agglutination. The 
parental strain cross (FY10 x FY22) produced the expected lacy cell pellet 
at the bottom of the tube (Lanes A and H). When both the a- and a- 
agglutinin disrupted mutants (CAY3 and CAY1, respectively) were mixed 
with the opposite parental mating type strains, no cell aggregates were 
detected. This confirmed the kanMX4 cassette had disturbed the agglutinin 
function at both loci.
Unfortunately, the crossing of the a-strain expressing the integrated 
scFv D1.3 (CAY2) with the a-strain expressing the integrated lysozyme
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(CAY4) did not produce the desired agglutination result (Lanes D and E). A 
compact cell pellet (no cell aggregates) was observed which indicated that 
the lysozyme-scFv D1.3 molecules on the surface of the relevant mating 
types were not interacting sufficiently to promote cell to cell contact.
Figure 6.2 - Agglutination test
A B C D E F  G H
Lanes Matinq tvoe crosses1
A and H FY10 x FY22
B and C CAY1 x FY22
D and E CAY2 x CAY4
F and G FY10 x CAY3
a = The genotypes of these strains are described in Table 5.11.
6.4.8 Mating results
When the mating experiments were performed on solid media, there was a 
slight reduction (four-fold) in the mating frequencies of the agglutinin- 
disrupted mutants compared to the parental strains. The same crosses were 
performed in liquid media and characteristically the mating frequencies for 
the null mutants were four orders of magnitude lower than for the wild type 
strains (Table 6.5).
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The engineered a- and a-cells expressing Aga2p-HEWL and Saglp- 
scFv D1.3 fusions on their cell surfaces, respectively, also were mated in 
both liquid and solid media. Unfortunately, the mating frequencies obtained 
for both the liquid and solid media were similar to the disrupted mutants. 
This result indicated that the surface lysozyme and scFv D1.3 molecules 
were not interacting sufficiently in courtship to promote the stable cell-to-cell 
contact required for diploid formation.
Table 6.5 - Mating frequenciesa obtained for the engineered and mutant a- and a-cells.
Cross0 Solid medium Liquid medium
FY10 x FY22 1,1 1,1
CAY1 X FY22 0.21,0.27 4.0x1 O'4, 4.9 x 10"4
FY10XCAY3 0.20, 0.25 2.5x1 O'4, 4 .0 x 1 0‘4
CAY2 X CAY4 0.21,0.25 3.2x1 O'4, 7.3 x10'5
* Relative to the wild-type frequency. Each cross was performed in duplicate. 
bThe genotypes of the strains used in this experiment are summarized in Table 5.11.
6.5 DISCUSSION
6.5.1 Expression levels
The scFv D1.3 antibody fragment was exported into the bacterial 
supernatant and was shown to be binding specifically to the antigen, 
lysozyme (Table 6.1).
The surface expression levels for both the Aga2p-HEWL and Saglp- 
scFv D1.3 fusions on the relevant engineered cells appeared to be very low. 
Firstly, the expression level for the Sag1p-scFvD1.3 fusion on the surface of 
the engineered a-strain was only detectable by an enzyme immunoassay 
after treatment with partially purified a-factor (Table 6.2). It was presumed 
that some level of Sag1p-scFv D1.3 expression would be identified on the
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surface of the untreated engineered a-cells due to the fact that 
approximately 5 x 104 agglutinin molecules are constitutively expressed 
(Wojciechowicz and Lipke, 1989). The a-strain (X2180-1B) used to calculate 
the number of surface agglutinin molecules is a relative of the a-strain 
(FY10) used in this project and therefore should have similar agglutinin 
expression levels. Wojciechowicz and Lipke (1989) also observed a 1.3 fold 
increase in the a-agglutinin expression level of a-factor treated a-cells 
(X2180-1B) using an enzyme immunoassay, which is comparable to the 1.7 
fold increase detected in these experiments.
Results obtained using the biotinylated lysozyme indicated that a low 
level of functional scFv D1.3 molecules was present on the surface of the 
engineered a-cells (Table 6.3). Surprisingly, the biotinylation results acquired 
for the cells overexpressing scFv D1.3 on their surfaces were not the 
expected order of magnitude higher. The limited amount of biotinylated 
lysozyme used in these experiments may have affected these results. 
Consequently, performing experiments with different amounts of biotinylated 
lysozyme may have been more definitive.
A 1.4 fold increase in the expression of the Aga2p-HEWL fusion on the 
surface of engineered a-cells was observed using an enzyme immunoassay 
after treatment with a-factor (Table 6.4). This is comparable to the 2-2.5 fold 
increase obtained for the native a-aggluitnin using the a-factor treated a- 
strain, X2180-1A (Terrance and Lipke, 1987). The level of lysozyme 
expression was too low to show functionality using the lysoplate method 
(Figure 6.1a) and a more sensitive method such as a turbidimetric assay 
(Kato et al., 1994b) could possibly be applied in future to calculate the 
amount of enzymatic activity on the surface of these cells. A preliminary 
turbidimetric assay was performed with the engineered a-cells but the results 
obtained were found to be unreproducible. Lysozyme overexpressed on the 
disrupted a-cells did cause bacterial lysis indicating that it was active on the 
cell surface (Figure 6.1b). Functional detection of the lysozyme in this 
experiment could have been assisted by the higher level of expression 
causing diffusion of some of the lysozyme molecules into the surrounding 
agar. Experiments analysing the expression of the scFv B7 antibody
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fragment on the surface of yeast cells indicated that a certain amount of the 
antibody fragment was secreted into the culture supernatant (Section 
4.4.4b).
With the limited information available, the expression levels for both the 
Aga2p-HEWL and Sag1p-scFvD1.3 fusions appear to be low. The reasons 
for these low expression levels could be numerous. Due to the fact that scFv 
D1.3 and lyzozyme are foreign to S. cerevisiae, elements such as codon 
usage adversely affecting the stability of the mRNA and fortuitous 
sequences causing pauses in transcription may lead to lower expression 
levels (Romanos et al. 1992). Furthermore, the loxP 511 sites in the middle 
of the protein fusions may be affecting expression either by being more 
susceptible to proteolytic cleavage (Alfthan et al., 1995) or by the incorrect 
initiation of transcription due to the two TATA sequences. Expression of the 
Sag1p-scFvD1.3 fusion could also have been hindered by the position of 
loxP 511 sequence between the promoter and initiation site affecting 
transcription. Additionally, palindromic sequences such as loxP sites have 
been reported to form secondary structures, which can drastically inhibit 
translation (Romanos et al., 1992).
Sequencing results from Chapter 5 showed that both the Aga2p-HEWL 
and Sag1p-scFv D1.3 fusions had the correct molecular information (i.e. 
signal sequences, GPI anchor attachment sequences, etc.) to be expressed 
through the secretory pathway and become incorporated on the cell surface 
(Figures 5.9 and 5.14). The Sag1p-scFvD1.3 protein fusion was shown to be 
functional on the surface of the engineered a-cells, therefore confirming the 
fusion was in the correct reading frame. Further experiments are required to 
show the Aga2p-HEWL fusion is active on the surface of the engineered a- 
cells. Additionally, experiments are required to prove that the agglutinin 
fusion proteins are covalently attached to the p-1,6-glucan component of the 
yeast cell wall.
6.5.2 Attempted mating
The unusual phenotype of a small decrease in the mating frequency on solid 
media and a three to five-fold reduction in liquid media is a characteristic of
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agglutinin mutants (Lipke et al., 1989; Roy et al., 1991). Both the 
constructed a- and a-agglutinin mutants, CAY1 and CAY3, displayed this 
phenotype (Table 6.5). Expression of aminoglycoside phosphotransferase, 
which is encoded by the kanMX4 cassette, does not affect mating frequency 
(Hadfield, 1990). Therefore, it can be presumed that the fusion of the 
kanMX4 cassette to the C-terminus of the a-agglutinin binding domain 
lf\GA2) and the replacement of the N-terminal binding domain of the a- 
agglutinin (,SAG1) with the kanMX4 cassette disrupted the agglutinin 
functions.
Theoretically, the replacement of the selectable marker, kanMX4, with 
the antigen and antibody DNA should mimic the a-/a-agglutinin interaction 
and promote the stable cell-to-cell contact necessary for mating. 
Unfortunately, the mating of the engineered a- and a-strains expressing the 
Sag1p-scFv D1.3 and Aga2p-HEWL fusions, respectively, did not produce 
the desired results. No cell aggregates were formed in the agglutination 
experiments (Figure 6.2) and no increase in mating frequencies compared to 
the agglutinin mutants was observed (Table 6.5). The agglutinability of the 
engineered and mutant strains was not quantified. Subtle differences 
between these cell types may have been detected by calculating an 
agglutination index for each mating cross (Terrance and Lipke, 1981). The 
agglutination index (Al) can be calculated by measuring the formation of cell 
aggregates in a mating reaction using a spectrophotometer [Al= 1 - (2 x Aa 
+a)/(Aa +Aa); where A is the mean optical density (at 600nm) obtained for the 
cell types or type indicated by the superscript]. The agglutination index 
varies from 0 to 1, with higher indices denoting a greater degree of 
agglutination.
The factors affecting the desired scFv D1.3-lysozyme interaction 
between the engineered a- and a-cells could be numerous. It can be 
presumed that the scFv D1.3 and lysozyme proteins were accessible on the 
exterior surface of the mating cells due to the fact the reagents used were 
able to detect them. The strength of the agglutination reaction in S. 
cerevisiae is affected more by the number of binding sites than by the 
binding constant (Terrance and Lipke, 1987). The expression results
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indicated that only low levels of scFv D1.3 and lysozyme were present on 
the surface of the engineered cells and consequently the number of binding 
sites available may have been the major limiting factor in promoting cell-to- 
cell contact. Hyperglycosylation of scFv D1.3 and/or HEWL proteins may 
also have inhibited their interaction (Romanos etal. 1992).
a- and a-cells have been shown to discriminate between different 
levels of pheromone and during courtship partners which are producing the 
highest level of pheromone are selected (Jackson and Hartwell, 1990). 
Lipke and Kurjan (1992) suggested the agglutinins might have a subsidiary 
role in increasing the local pheromone concentration at the shmoo tips of 
mating cells, especially in liquid media where pheromone concentration is 
affected by diffusion. Therefore, perhaps the scFv D1.3 and HEWL proteins 
were unable to increase the local pheromone concentration by this unknown 
mechanism which may also explain the observed mating defects of the 
engineered strains.
6.5.3 Future work
It is unknown whether the maximum level of expression was achieved for 
both the pheromone-treated a- and a-engineered cells, although the 
suggested amount of pheromone required to achieve maximum expression 
was used in both cases (Betz et al., 1978; Terrance and Lipke, 1981; 
Guthrie and Fink, 1991). Further experiments investigating pheromone 
induction time and concentration would help resolve this issue. A time 
course monitoring physiological changes such as shmoo formation or arrest 
in G1 phase might give the most favourable conditions. Replacing the scFv 
D1.3 or HEWL DNA with a reporter gene (i.e. p-galactosidase or green 
fluorescent protein) could be another way of estimating the maximum level 
of expression directly. In fact, green fluorescent protein (GFP) was 
integrated into the a-agglutinin locus using the Cr e-lox recombination system 
but initial expression experiments were unable to locate the GFP on the 
surface of the engineered a-cells (personal communication, Mark Redfern, 
this laboratory). Additionally, using a-cells which lack the barrier protease 
which degrades a-factor (barl mutants) may have increased the level of
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Aga2p-HEWL expression (Mackay et al., 1988). Although the expression of 
Sag1p-scFv D1.3 and Aga2p-HEWL on the surface of the pheromone- 
treated cells was not optimised in the individual detection experiments, the 
pheromone concentration presumably would have been optimal in the 
mating experiments.
Ideally, the number of molecules of scFv D1.3 and lysozyme on the 
surface of the engineered cells should have been calculated and compared 
to the display efficiency of the native agglutinins. Binding assays using 
variable amounts of labelled lysozyme or scFv D1.3 with a known amount of 
the appropriate engineered cells expressing scFv D1.3 or lysozyme on their 
cell surfaces would give the information required to calculate this (Terrance 
eta!., 1987). Additionally, two-colour flow cytometry, which has been used to 
estimate the display efficiency of the Aga2p-scFv fusion (under the control of 
a GAL1 promoter) on the surface of a-cells (Boder and Wittrup, 1997), may 
also have proved informative.
6.5.4 Conclusions
Both the a- and a-null mutants, CAY1 and CAY3, were shown to have their 
agglutinin functions disrupted by the selectable marker (kanMX4). 
Unfortunately, the strategy to mimic the germinal centre reaction by mating 
the engineered a- and a-strains, CAY2 and CAY4, was not achieved. The 
engineered a- and a-cells were shown to be expressing the antigen, 
lysozyme and the antibody, scFv D1.3 (analogous to follicular dendritic cells 
and B-cells), respectively. Crossing of these engineered strains did not 
increase the mating frequency compared to the agglutinin null mutants. 
These results indicate the scFv D1.3 and lysozyme were not interacting 





The overall aim of this project was to develop strategies for producing high 
affinity monoclonal human antibodies using the budding yeast, 
Saccharomyces cerevisiae.
In vivo, the germline antibody DNA is subjected to random mutation 
and antibodies with improved affinity for antigen are selected (a process 
known as affinity maturation). This stepwise process occurs in the germinal 
centre (Section 1.3.3) and the ultimate objective of this project was to 
generate high affinity human antibodies by copying this system. The current 
methods available such as hybridoma technology (Section 1.4.1), 
humanization (Section 1.4.2) and phage display (Section 1.4.4) are 
moderately slow at producing human monoclonal antibodies and are often 
unable to produce the quality required for therapy. At present, no antibody 
improvement scheme exists where both the mutation and antigen-selection 
processes can be controlled within a cell. Eventually, it was intended to 
create a fast and effective 'in-cell' mutational and antigen-selection yeast 
scheme. This scheme was devised to overcome all the extensive DNA 
manipulations that are required for present antibody improvement 
techniques. Although, this ultimate aim was not accomplished, the work 
described in this project has laid the foundations to achieve this goal.
7.1 Mimicking the genetic display package of B-cells
B-cells display antibodies on their cell surfaces and in this project an S. 
cerevisiae expression system was constructed which imitated this 
characteristic (Part I; Chapters 3 and 4). This system utilized the molecular 
information from the signal sequence and C-terminal anchorage domain of 
the a-agglutinin gene (Section 1.7) to target and covalently attach antibody 
fragments to the yeast cell wall. Single chain Fv antibody fragments were 
expressed on the surface of S. cerevisiae (Section 4.4.4c and 4.4.4e) and
Chapter 7- General discussion 231
shown to be fully functional (Section 4.4.4f). The utilization of the a-agglutinin 
cell wall protein to display antibodies on the cell surface is similar in certain 
respects to phage display technology (Section 1.4.4).
The minor and major phage coat proteins have been used extensively 
to display antibodies on the surface of phage. Although phage display 
libraries have been effectively employed to isolate a large number of different 
antibodies (reviewed in Winter et a/., 1994; Winter, 1998), unpredictable 
expression biases exist. Random sampling of a phage display library 
expressing scFv antibody fragments indicated that half the library sequences 
were undetectable in the culture supernatant (Vaughan et al., 1996). These 
expression biases are considered to be due to the fact that incorporation of 
the protein fusions into the phage particle depends upon the ability of E  coli 
to express them in a soluble form. E. coli is a prokaryotic microorganism, 
therefore lacks the endoplasmic reticulum-specific post-translational 
processing (i.e. disulphide bond formation, etc.) required for the efficient 
folding of eukaryotic proteins such as antibodies. Even closely related 
antibody sequences can demonstrate widely different expression 
characteristics in E. coli (Knappik and Pluckthun, 1995; Kipriyanov et al., 
1997; Nieba et al., 1997). S. cerevisiae is an unicellular eukaryote (Section 
1.5) and hence should alleviate the expression biases observed in 
prokaryotic expression systems.
Once surface expression of antibody fragments was established, the 
next part of this project was to develop a selection procedure that could 
isolate yeast cells expressing high affinity antibodies. The selection 
procedure would have to distinguish between cells that are expressing high 
affinity antibodies from cells displaying moderate affinity antibodies at higher 
expression levels. Part 1 of this project was designed with the intention of 
isolating high affinity antibodies directly using fluorescence-activating cell 
sorting (FACS). Before this work could be carried out, a two colour FACS 
method was reported to have successfully isolated yeast cells displaying high 
affinity antibodies from a small surface display antibody library (Boder and 
Wittrup, 1997; Kieke et al.,1997). Yeast cells which were highly fluorescent 
because of more efficient expression rather than higher affinity for the
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fluorescently labelled target were normalized using a second fluorophore 
which recognised a non-mutated part of the displayed antibody fragment 
such as an epitope tag. Since the FACS selection method had already been 
established, Part II of this project was designed for the purpose of selecting 
high affinity antibodies using a novel yeast mating strategy (discussed in 
Section 7.3).
7.2 Towards the construction of a mutant antibody library
For the yeast mating strategy to be successful it was deemed necessary to 
have constant expression levels on the surface of S. cerevisiae. Constant 
surface expression should overcome the selection problem of identifying 
yeast cells expressing high affinity antibodies from a population of cells 
displaying moderate affinity antibodies at higher expression levels. It was 
decided constant surface expression levels could be achieved by integrating 
the antibody (or antigen) DNA into the appropriate agglutinin loci (Schreuder 
et a/. ,1996).
To isolate high affinity antibody fragments on the surface of S. 
cerevisiae, a mutant antibody library was eventually to be created. With this 
intention, the Cre-/ox site-specific DNA recombination system from 
bacteriophage P1 (Section 5.1.1) was recruited to integrate the antibody (and 
antigen) DNA into the yeast genome. The single chain Fv was the chosen 
antibody format for this stage of the project, mainly due to the success of 
expressing the scFv on the surface of S. cerevisiae in Part I of this project. 
Additionally, all the genetic information for the scFv antibody fragment is 
contained within one 'gene' therefore it is easier to manipulate. For some 
therapeutic applications such as in vivo diagnostic imaging, the scFv is the 
antibody fragment of choice due to its ability to penetrate tumours owing to its 
small size (Huston etal., 1993).
The Cre-/ox system was successful at integrating the scFv antibody 
fragment DNA into the exact position at the a-agglutinin locus but 
unfortunately it was found that the frequency of undesirable recombination 
between the loxP and loxP 511 sites at the locus (or on the exchange vector) 
was quite high. In some clones, the selectable marker was removed from the
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genome without the replacement of the antibody DNA (Sections 5.6.5 and 
5.6.7). This undesirable recombination will limit the theoretical size of the 
antibody library. Hypothetically, the size of the library created using the Cre- 
lox system should only be limited by the efficiency of the transformation and 
a library of 106 clones (Schiestl et al., 1993) could be possible. With the 
results reported in this project, a potential library of approximately 104 clones 
is possible. A library of 104 clones is very small but is two orders of 
magnitude higher than attainable by standard integration methods. Future 
work investigating the cause of the illegitimate recombination problem would 
be extremely beneficial and hopefully lead to an increase in this potential 
library size.
It can be envisaged that a mutated scFv antibody library could be 
integrated into the a-agglutinin locus using the Cre-/ox system. Although the 
3D structure of the antigen-anti body (lysozyme-scFv D1.3; Figure 5.2) 
interaction was available for this project, often the exact structures of 
therapeutic 'lead' antibodies are unknown. Therefore, a random mutagenesis 
approach, analogous to the human immune system, is particularly favourable 
for antibody improvement.
The complementarity determining regions (CDRs) which form the 
antigen-combining site are normally the first area to be targeted by other 
mutatgenic approaches (Tsumoto et al., 1995; Yang et al., 1995; Li et al., 
1996). Often it is difficult to predict which residues in the CDRs should be 
targeted by site-specific mutagenesis and sometimes mutated amino acids 
not located at the antigen-antibody interface lead to an improved affinity 
(Foote and Winter, 1992; Hawkins et al., 1993). These 'framework' mutations 
can affect affinity indirectly by influencing the position of the side chain 
contacting the antigen, providing new contact residues or by replacing 
'repulsive' or low affinity contact residues with contact residues with more 
favourable energetics (Hoogenboom, 1997).
The random mutagenesis method recruited in this strategy must be 
carefully chosen for an appropriate mutation rate and its ability to generate 
single nucleotide substitutions. A mutation frequency that incorporates one 
mutation per antibody gene, similar to the mutation rate that is observed
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within the germinal centre (Section 1.3.4; Berek and Milstein, 1988), is well 
suited for the evolution of antibody fragments in a stepwise manner. Mutation 
frequencies should not be too high otherwise the combination of beneficial 
and deleterious mutations may result in the formation of an inefficient affinity 
maturation strategy (Kepler and Perelson, 1993; Oprea and Perelson, 1997). 
Additionally, mutation rates that are too low would cause a mutant library to 
be predominately wild type.
Successful phage display affinity maturation strategies using either 
error-prone PCR (Hawkins et al., 1993) or a bacterial mutator strain (Low et 
al., 1996) have been reported and these techniques could be used to create 
a mutant antibody library before integration into the yeast genome. 
Furthermore, a DNA shuffling method known as ’sexual' PCR (Stemmer, 
1994) which involves the random mutagenesis of several positively selected 
DNA molecules followed by DNA fragmentation and reassembly, could be a 
very fast way of evolving high affinity antibodies. However, all these methods 
involve extensive DNA manipulations outside of the cell before and in- 
between the antigen-selection process. Hopefully, the work described in this 
project will assist in the development of a total' in vivo ' mutational system, 
whereby mutation and antigen-selection can occur in a stepwise fashion, 
without any requirement for external DNA manipulations. Yeast mutator 
strains do exist which are deficient in DNA repair mechanisms (Vonborstel et 
al., 1993; Yang et al., 1996). Using a temperature sensitive strain, where the 
mutational activity can be controlled, could provide an extremely fast and 
effective affinity maturation strategy.
Once a clone expressing a high affinity antibody is isolated, it can be 
envisaged that the Cre-lox recombination system could also be used to 
obtain the advantageously mutated antibody DNA for further analysis. An 
exchange vector comprising of a marker gene flanked by loxP and loxP 511 
sites could be transformed into the yeast cells containing the desired mutated 
antibody DNA. Cre recombinase expression should catalyse the 
recombination event between the mutated antibody DNA in the genome and 
the exchange vector. Yeast cells acquiring the auxotrophic resistance 
encoded by the marker gene would represent the desired exchange event. 
Total genomic DNA from these yeast cells could then be transformed into E.
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coli and transformants conveying the same antibiotic resistance as the 
exchange vector would contain the cloned mutated antibody DNA. Using the 
Cre-/ox system in this way could bypass the need for extensive DNA 
manipulations that are required for recloning of the antibody DNA from the 
yeast genome.
The novel application of the Cre-lox system developed in this project 
demonstrates considerable potential for integrating any foreign DNA into a 
particular locus in the S. cerevisiae genome. This strategy does not use 
auxotrophic markers and therefore can be used in any yeast strain. The 
efficiency of integration using the Cre-lox system is two magnitudes higher 
than standard integration methods and therefore could be used in a number 
of applications such as functional genomic analysis studies or recombination- 
activated gene expression.
7.3 Attempting to copy the antigen-selection process of the germinal 
centre
During the germinal centre reaction (Section 1.3.3), B-lymphocytes 
(centrocytes) expressing advantageously mutated antibodies bind to antigen- 
presenting follicular dendritic cells for survival. In the second part of this 
project (Part II), the antigen-selection process of the germinal centre was 
copied by attempting to mate engineered a- and a-agglutinin haploid 
mutants. Agglutinins (Section 1.6.2) are essential for mating under conditions 
that do not promote stable cell to . cell contact (liquid media) and this 
characteristic was exploited in the antigen-selection mating strategy.
Firstly, the centrocytes and follicular dendritic cells of the germinal 
centre reaction were copied using the a- and a-haploid cells containing the 
appropriate antibody and antigen DNA in the relevant agglutinin loci, 
respectively. Unfortunately, expression of the antibody and antigen agglutinin 
fusions on the surface of the engineered cells was very low (Sections 6.4.3 
and 6.4.5). Upon mating of these individually engineered haploid cells, in 
conditions that did not promote cell-to cell-contact, the antibody and antigen 
proteins did not interact sufficiently to cause agglutination. Therefore, the 
mating frequency of the engineered haploid cells expressing the antigen and
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antibody DNA was comparable to the mating frequency of agglutinin 
disruption mutants (Section 6.4.8). The reasons why this antigen-selection 
mating strategy did not work could be numerous.
Presumably, the major limitation of this strategy was the low surface 
expression obtained for both the antigen and antibody agglutinin fusions. The 
agglutination reaction depends greatly on the number of agglutinin molecules 
on the yeast cell surface (Terrance and Lipke, 1987). Therefore, it would be 
beneficial to determine the number of agglutinin fusions on the surface of the 
engineered a- and a-haploid cells. If, as expected, the number of agglutinins 
is low, increasing the surface expression of the agglutinin fusions maybe 
worthwhile. The surface expression of the agglutinin fusions could be 
increased by integrating multiple copies of the relevant DNA into the genome 
(Schreuder et al., 1996) or placing a strong inducible promoter upstream from 
the fusions (Boder and Wittrup, 1997).
Another point of investigation could be to remove the lox sites from the 
promoter (for the scFv/a-agglutinin fusion) and terminator (for the antigen/a- 
agglutinin fusion) regions of the agglutinin loci. The genomic position of these 
lox sites could be affecting the transcription of the agglutinin fusions and 
hence the overall surface expression levels. The antibody or antigen genes 
could have been integrated into the relevant agglutinin loci using a two-step 
gene replacement method (Scherer and Davis, 1979) instead of the Cre-/ox 
recombination system. The two-step gene replacement method involves 
using a yeast integrating plasmid that contains a mutant copy of the allele of 
interest. Upon integration at the relevant locus duplication of the region will 
occur. The region of interest will then comprise of one wild type allele and 
one mutant allele separated by the plasmid sequence. Homologous 
crossovers between the mutant and wild type alleles result in excision of the 
plasmid and loss of one of the copies at the duplicated region. Depending on 
the exact location of the crossover, the copy left behind will be either the 
mutant or the wild type form of the gene. Southern hybridization, PCR 
screening and/or phenotype analysis are then required to distinguish 
between colonies containing either the wild type or mutant form of the gene. 
Although the efficiency of integration would have been lower using this two-
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step gene replacement method the absence of lox sites may have increased 
the surface expression of the antibody and antigen agglutinin fusions. 
Hopefully, increasing surface expression of the agglutinin fusions will 
promote stable cell-to-cell contact between the mating cells and produce a 
successful antigen-selection strategy.
Agglutinin molecules accumulate in the buds of shmooing cells 
(Watzele et al., 1988), therefore engineered yeast cells should be analysed 
by immunofluorescence to check if the agglutinin fusions are constantly 
expressed over the surface of the yeast cell. Accumulation of fusions in the 
buds of mating cells could affect the ability of the selection system to 
discriminate between cells expressing antibodies with slightly different 
affinities since the binding of antigen will be dictated by both affinity and 
avidity.
Once the problems of mating antigen-selection process are solved, 
the artificial yeast 'germinal centre' could be established. Using this strategy, 
the yeast cells that have formed diploids due to a positive antibody-antigen 
interaction could be sporulated under nutritional starvation conditions. The 
haploid a-cells containing the positively selected mutated antibody DNA 
could then undergo further rounds of mutation and selection without any 
requirement for extensive DNA manipulations. Finally, a yeast cell displaying 
a very high affinity antibody could be isolated which contains various 
advantageous point mutations within its antibody DNA.
7.4 General perspective of this project
A strategy that can harness all the aspects of the immune system should 
have the capability to create antibodies with a wide variety of affinities and 
specificities. The work described in this project provides the potential to 
eventually create a novel 'immune' system for the production of high affinity 
antibodies using the yeast, S. cerevisiae.
New therapeutic 'lead' antibodies could be isolated from a S. 
cerevisiae surface display library composed of human unrearranged variable 
light and heavy gene segments. Using unrearranged genes should avoid the 
biases created by in vivo tolerance mechanisms (Hoogenboom, 1997) and
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antibody fragments towards self-antigens such as tumour or disease 
associated epitopes could be isolated with great therapeutic value. This 
library would be analogous to a naive primary antibody repertoire of the 
human immune system without the self-bias.
Once a 'lead' antibody is isolated, its affinity to a particular therapeutic 
target could then be improved through a stepwise mutation and antigen- 
selection 'germinal centre' strategy as described in this project. Eventually, it 
is hoped that this strategy will produce therapeutic antibodies faster and 
more effectively than any system previously developed.
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